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Abstract

The major focus for the present study was to examine the effects of provider
stigmatization on the medical care of HIV+ patients, by using an experimental paradigm
and examining a conceptual framework to clarify the relationship between provider
stigmatization and negative treatment outcomes. Initial qualitative findings from focus
groups (n = 18) indicated that several key elements of stigmatizing treatment experiences
included judgmental and condescending language, patient avoidance, increased physical
distance between patient and provider during conversations and procedures, and use of
extra, unnecessary precautions (e.g. use of extra gloves, masks). These provider
behaviors were experimentally manipulated and incorporated into computerized vignettes
containing audio and visual stimuli depicting “typical” medical appointments. In the
experimental phase, participants (n = 90) were randomly assigned to view either a highly
stigmatizing or a non-stigmatizing treatment vignette and then subsequently rate their
willingness to engage in HIV care. Findings indicated that patients assigned to the highly
stigmatizing condition were the most unwilling to engage in HIV care as demonstrated in
lower intentions to remain in care, disclose sexual and substance use risk behaviors, and
discuss medication adherence difficulties. As hypothesized, the effect of the experimental
stigma condition on patients’ willingness to engage in care was mediated by patients’
feelings of comfort and their perceptions of stigma within the patient-provider
interaction. Findings from the present study may help to inform the development of
interventions to assist healthcare providers in creating more positive treatment
experiences for their HIV+ patients to improve implementation of self care and reduction
of risk behaviors.
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1
HIV-Related Stigmatization in Treatment Settings: Effects on Patient Comfort and
Treatment Decisions
Over one million people in the United States are currently infected with HIV and
global estimates indicate that 33 million are now living with HIV/AIDS worldwide
(UNAIDS, 2007). With the advent of highly active antiretroviral therapy (HAART),
many who are living with HIV can anticipate sustained viral suppression and much
improved life expectancy relative to patients living with HIV earlier in the epidemic.
Despite biomedical advances, HIV-infected individuals still face many challenges,
prominent among which is the widespread social stigma associated with HIV disease.
Stigmatization broadly refers to viewing a person, or a group of persons, as devalued,
spoiled or flawed in the eyes of society, resulting in stereotyping, prejudice, status and
power loss, social isolation, and discrimination (Crocker, Major, & Steele, 1998).
Although negative attitudes toward HIV+ individuals have decreased somewhat in recent
years, HIV-related stigmatization remains prevalent both in the United States and
globally (Mahajan et al., 2008). Studies suggest that the persistence of HIV-related
stigmatization is the result of a complex relationship of several interacting factors,
including misconceptions about HIV being transmitted through casual contact, the
symbolic association of HIV to homosexuality and drug use, and the belief that HIV+
persons are to blame for becoming infected (Pryor, Reeder, & Landau, 1999; Pryor,
Reeder, Yeadon, & Hesson-McInnis, 2004).
HIV+ individuals are cognizant of this stigmatization. In a recent clinic-based
study of 221 HIV+ men and women, 42% indicated that others behaved negatively
towards them because of their HIV status and 29% reported that people avoid being
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around them because they are HIV+ (Vanable, Carey, Blair & Littlewood, 2006). Indeed,
the effects of HIV-related stigma on persons living with HIV are significant and wide
ranging. A significant proportion of HIV+ persons report experiencing physical violence,
decreased social support, and job-related difficulties as a result of disclosing their HIV
status (Berger, Ferrans, & Lashley, 2001; Rothenberg, Paskey, Reuland, Zimmerman, &
North, 1995; Vara-Diaz, Serrano-Garcia, & Toro-Alfonso, 2005; Zierler et al., 2000).
Stigma-related experiences also contribute to stress and adjustment difficulties in HIV+
individuals (Clark, Lindner, Armistead, & Austin, 2003; Lee, Kochman, & Sikkema,
2002). In addition, research indicates that stigma interferes with disease management,
inhibits disclosure of HIV status to sexual partners, and undermines HIV prevention
efforts among at-risk populations (Chesney & Smith, 1999; Lindau et al., 2006; Vanable
et al., 2006).
Provider Stigmatization: A Focus on Patient Self Care and Transmission Risk
Reduction
The experience of stigmatization in health care settings may be particularly
detrimental to the health and well being of persons living with HIV. Treatment advances
and the advent of HAART have allowed many HIV+ individuals to live longer and
healthier lives (Wood et al., 2003), but successful management of HIV requires strict
adherence to demanding medication regimens, careful attention to diet and health
behaviors, and vigilant efforts to control infections that can harm the immune system
(Agne, Thompson, & Cusella, 2000; Bodenlos et al., 2007). Healthcare providers,
including physicians, nurses, and medical students, play a critically important role in
overseeing care for persons living with HIV. In so far as instances of negativity and
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discomfort among providers likely contribute to poor patient-provider communication,
provider stigma may reduce patients’ willingness to attend appointments, reduce
serostatus disclosure to healthcare providers, and interfere with patient comprehension of
important medical instructions (Bodenlos et al., 2007; Catz, Kelly, Bogart, Benotsch, &
Mcauliffe, 2000; Heckman, Catz, Heckman, Miller, & Kalichman, 2004). Indeed,
provider stigmatization may greatly impact the care received by HIV+ individuals,
though few studies have examined this assertion. As such, the present study aims to fill
this gap by examining the impact of provider stigmatization on several aspects of HIV
medical care related to communication, patients’ psychological comfort, and the
disclosure of behaviors that may compromise HIV+ patients’ health.
Provider Stigmatization in the Context of Patient-Provider Interactions
Existing research suggests that the development and maintenance of positive
patient-provider relationship plays an especially important role in predicting which
patients will remain in care and openly discuss their risk behaviors and medication
adherence difficulties (Mallinson, Rajabiun, & Coleman, 2007). For persons living with
HIV, initial interactions with medical providers serve as a critical opportunity to develop
positive patient-provider relationships. Instances of provider stigmatization, expressed
through specific behaviors and overall demeanor, can presumably create barriers to the
process of gaining the trust necessary for a strong working relationship between HIV+
individuals and their treatment providers. Qualitative reports from HIV+ individuals
indicate that stigmatizing experiences at the time of disclosure can lead to decreased trust
in current providers and also deter serostatus disclosures with future healthcare providers
(Agne, Thompson, & Cusella, 2000). Indeed, unsatisfactory treatment experiences (in
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general) have been found to negatively influence patients’ perceptions and expectations
of their providers, with reduced trust in one’s provider predicting decreased adherence to
HIV clinic appointments (Whetten, et al., 2006).
The CDC reports that 75% of HIV+ persons are aware of their diagnosis, and of
those, approximately one third are not receiving HIV care (Glynn & Rhodes, 2005).
Although attributable to a variety of causes, this statistic demonstrates that despite being
aware of one’s HIV status, barriers exist which deter some HIV+ individuals from
enrolling or remaining in HIV care. Demonstration of stigmatizing behaviors from a
healthcare provider may be one of these barriers, with HIV+ persons’ decisions to enroll
in treatment potentially being deterred by previous experiences with stigmatizing
demeanor or actions of providers. The failure to enroll in HIV care not only poses a
substantial health risk to HIV+ persons, but has also been found to contribute to increased
HIV transmission, as HIV+ persons who forgo treatment often have been found to have
higher viral loads and therefore pose a greater risk for infection to their sexual partners
(Kalichman, Rompa, Luke, & Austin, 2002). Studies are needed which examine possible
deterrents to enrollment in HIV care.
Open communication within a patient-provider relationship has perhaps become
an even more important issue in recent years, as CDC guidelines now recommend that
HIV care providers deliver HIV-prevention services to identify and reduce patients’
transmission related risk behaviors at routine medical visits (Grodensky, Golin, Boland,
Patel, Quinlivan, & Price, 2008). Effective interventions necessitate the honest and
accurate disclosure of one’s transmission related risk behaviors, which in turn requires a
certain level of trust within the patient-provider relationship. These prevention efforts not
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only serve to protect the health of HIV+ individuals’ sexual partners and the larger
population, but also have the potential to protect HIV+ patients themselves in terms of
becoming infected with other sexually transmitted diseases which may compromise their
health further.
Positive patient-provider relationships are also a critical element in interventions
with substance using HIV+ patients. HIV+ patients who perceive stronger relationships
with their provider are more likely to discuss their substance use at medical visits
(Metsch, et al., 2008). Subsequently, engaging in discussions of substance use with HIV+
care providers is associated with increased likelihood of entering into substance abuse
treatment (Korthuis, et al., 2008). In this context, stigmatizing experiences may decrease
HIV+ patients’ willingness to disclose risky substance use behaviors, thereby precluding
any chances to effectively intervene with the patient.
Similar concerns pertain to sexual risk behaviors and medication adherence, such
that providers demonstrating stigmatizing behaviors may decrease the chance of their
patients being forthright about sexual risk-taking and adherence difficulties. Indeed,
research points to an association between poor patient-provider relationships and reduced
adherence to highly active antiretroviral therapies (HAART) regimens (Johnson, et al.,
2006; Schneider, Kaplan, Greenfield, Li, & Wilson, 2004). Without a strong sense of
trust in their providers, patients may be less able to effectively manage the side-effects of
HAART, the complexity of dosing schedules, and the special dietary instructions that
make it difficult to maintain the level of adherence required to ensure complete viral
suppression (Bangsberg, et al., 2001; Chesney, 2003; Trotta, et al., 2002). Thus,
stigmatization among providers may serve as a significant barrier to high quality patient
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care by way of its effects to the patient-provider relationship in general, and more
specifically its effects to the areas of communication regarding disclosure of risk
behavior and subsequent patient receptivity to risk reduction messages from providers.
With provider-based intervention initiatives garnering more attention and support in HIV
research, it is critical to undertake studies that increase our understanding of the
mechanisms through which provider stigmatization may interfere with provider based
efforts to promote sexual risk reduction, medication adherence, and related health
behavior changes.
As medical providers continue to play a critical role in promoting the health and
well-being of HIV+ individuals, it is important to understand if certain behaviors within
the treatment settings may be perceived as stigmatizing by patients and hence detract
from this process. Thus, the major focus for the present study was to examine the effects
of provider stigmatization on several important aspects of HIV treatment. More
specifically, the study uses both qualitative focus groups and an experimental paradigm
to (1) identify key characteristics of stigmatizing treatment experiences and (2)
characterize the association of HIV-related stigmatization to patients’ decisions to enroll
in care, disclose risky sexual and substance use behaviors, discuss medication adherence
difficulties, and their willingness to engage in conversations related to risk reduction and
promotion of self care. The present study tests the hypothesis that the presence of
stigmatization in patient provider interactions will decrease the willingness of HIV+
patients to engage in the above mentioned elements of HIV treatment related to intentions
to enroll in care, intentions to openly communicate with their providers, and decisions to
disclose sensitive health information related to sexual risk, substance use, and medication
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adherence difficulties. By utilizing an experimental paradigm that assesses HIV+
patients’ reactions to hypothetical vignettes of stigmatizing and non-stigmatizing patientprovider interactions and then their subsequent decisions to engage in various aspects of
HIV care, the present study extends the limited field of research evaluating the impact of
provider stigmatization.
HIV-related Stigmatization within Treatment Settings
An important basis for conducting the present study lies in the fact that
stigmatization within healthcare settings remains prevalent even today. Nearly 30 years
into the epidemic, available data provides evidence to suggest that a significant subset of
healthcare providers still harbor stigmatizing beliefs about HIV+ individuals and
demonstrate behaviors detrimental to their medical care including patient avoidance,
inadequate care, differential treatment, and to a lesser extent, refusal of treatment
(Anderson, Vojir, & Johnson, 1997; Buseh & Stevens, 2006; Carter, Lantos, & Hughes,
1996; Ladany, Stern, & Inman, 1998; McCann, 1999; McDaniel & Carlson, 1995).
However, although recent literature has provided much description about the experience
of HIV-related stigmatization in treatment settings, few studies have examined the impact
that provider stigmatization may have on the medical care of HIV+ patients. To inform
the present research examining the impact of provider stigmatization on HIV patients’
willingness to engage in care and communicate openly with their providers, it is
important to first review the general literature surrounding provider specific, HIV-related
stigmatization. Reviewed qualitative and quantitative findings describe the widespread
nature of provider stigmatization as experienced by HIV+ patients, examining
frequencies of specific provider behaviors and providing detailed accounts of
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stigmatizing treatment experiences and the ways in which HIV+ patients’ perceive
provider behaviors and demeanor. Studies examining the effects of provider stigma
receive a more detailed examination. The review reports on studies occurring since 1995,
as a thorough review of earlier studies was completed by Eldridge and St. Lawrence
(1995). Broadly, earlier findings indicated a high occurrence of stigmatizing attitudes and
behaviors from providers including blaming HIV+ individuals for their infection,
unfounded fear of contagion, and frequent treatment refusals. For the current review, an
emphasis was placed on identifying gaps and limitations in existing research, hence
providing a basis for the importance of conducting the present study.
Provider behaviors indicative of stigmatization were categorized as those
pertaining to (1) subtle indicators related to provider demeanor and (2) more overt
indicators tied to specific aspects of provider care. Behaviors demonstrating a negative
demeanor are those which are often perceived by a patient as stigmatizing, but the intent
behind such behaviors is largely unknown (Rintamaki et al., 2007). They include
nonverbal and verbal communication of negative affect, such as irritations or anger,
nervousness, or fear at having to work with HIV+ individuals. In contrast, stigmatizing
behaviors in the form of care provision are more overt and may directly compromise
treatment (Rintamaki et al., 2007). As shown in Table 1, a total of 14 studies provide
qualitative or quantitative data on stigmatizing behaviors of healthcare providers as
reported by HIV+ patients. The table specifies each study’s sample size, participant
characteristics, design, objectives, and major findings, while also summarizing the
study’s limitations and method in which provider stigma was operationalized and
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assessed. Table 2 provides a summary of the stigmatizing behaviors examined by each
study.
Stigmatizing Behavior Related to Demeanor
As the experimental paradigm of the present study utilizes vignettes incorporating
both visual and audio elements to depict patient-provider interactions, the success of the
study design relies heavily on the accurate depiction of both stigmatizing and nonstigmatizing provider behaviors and treatment experiences. As such, it is important to
understand precisely which behaviors HIV+ patients note as indicative of a stigmatizing
treatment experience in terms of both subtle cues of a provider’s demeanor and attitude,
as well as more overt behaviors. This first section of the review examines findings from
studies that report data on negative demeanor among providers, as reported by HIV+
patients. Behaviors demonstrating a negative demeanor are those that are often perceived
by a patient as stigmatizing, but the intent behind such behaviors is largely unknown
including judgmental language, nonverbal behaviors, expression of discomfort, and
negative affect. Though these demeanor-related actions may not have as obvious a
detrimental impact as a refusal of treatment, they remain some of the most reported
negative experiences of HIV+ patients, especially in more recent years.
Judgmental or deficient communication. Seven qualitative studies reported data
on negative experiences within the realm of provider communication (see Table 2). Some
of the most frequently reported negative experiences of HIV+ patients involved
providers’ use of judgmental language. Language of this nature often pertains to making
attributions about a patient’s acquisition of HIV, blaming the patient for their infection,
and judging patients negatively based on their HIV+ status. Another complaint noted in
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this literature pertained to the general lack of communication between the patient and
provider as related to the HIV+ individuals’ health, medication, prevention, or other
treatment details. In two studies focusing on the experiences of HIV+ mothers (Lindau et
al., 2006; Marcenko & Samost, 1999), a subset of participants reported experiences in
which nurses and physicians spoke to them in ways that indicated moral disapproval of
their decision to become pregnant while HIV+. In Blake et al. (2008), a qualitative study
focusing on HIV testing and care experiences, many of the HIV+ women in the sample
(n=64) noted deficits in providers’ willingness to communicate with them about
prevention strategies and treatment elements.
In three other qualitative studies (Buseh & Stevens, 2006; Rintamaki et al., 2007;
Surlis & Hyde, 2001), patients described experiences in which providers made negative
attributions about the route in which they became infected. For example, in a study
conducted by Buseh and Stevens (2006), an African American woman reported that her
physician assumed she became infected through intravenous drug use because of her
ethnicity. More overt accounts of victim blaming were noted in Rintamaki et al.’s (2007)
study of HIV+ veterans, with one participant reporting pain during a blood draw, upon
which the nurse replied, “If you hadn’t done this to yourself, we wouldn’t have to be
going through this!” (pp. 963). Similar accounts of blaming were noted by intravenous
drug users in Surlis and Hyde’s (2001) qualitative study of HIV+ individuals receiving
nursing care in a hospital setting. Thus, findings regarding judgmental communication
appear to demonstrate a high frequency of patient blaming and negative judgment of
HIV+ individuals.
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Nonverbal behaviors related to proximity, eye contact, and extra
precautions. Three studies reported provider stigmatization as experienced through
inadequate eye contact, increased distance between the patient and provider, or the use of
seemingly unnecessary precautions during health visits (Blake et al., 2008; Lindau et al.,
2006; Rintamaki et al., 2007). All of these studies were qualitative in nature, with patients
providing firsthand accounts of their treatment experiences. HIV+ patients reported
“being stared at and watched” by providers (Blake et al., 2008), as well as receiving “the
sort of looks” that denoted negative judgment (Lindau et al., 2006). HIV+ veterans
(Rintamaki et al., 2007) reported perceiving stigma when providers demonstrated less
than adequate amounts of eye contact and distanced themselves during treatment visits.
Among veteran participants (N=50), some recounted experiences in which physicians
placed themselves across the room, behind another patient’s bed, and even out in the
hallway to discuss treatment or other AIDS-related issues (Rintamaki et al., 2007). Such
behaviors not only risk injuring the patient emotionally, but also threaten their rights to
confidentiality. In both Blake et al.’s (2008) qualitative study of HIV+ women and
Rinktamaki et al.’s (2007) qualitative study of HIV+ veterans, patients reported the use of
extra gloves in situations in which one pair of gloves was likely adequate. An additional
account noted surgeons wearing protective suits and face shields during a discussion
taking place well in advance of a patient’s surgery (Rintamaki et al., 2007). Patients
reported a heightened sensitivity to the precautions taken by providers, as they had
witnessed incidents in which the precautions taken with them were noticeably different
than those taken with other patients. Although limited to only three qualitative studies,
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these studies nonetheless provide narrative accounts of the way in which nonverbal
behaviors of providers can be perceived as stigmatizing among HIV+ patients.
Expression of discomfort or negative affect. Four studies (1 qualitative and 3
quantitative) reported stigmatizing experiences related to provider discomfort or
expression of negative affect (see Table 2). HIV+ veteran patients in Rintamaki et al.
(2007) reported many instances in which their providers were overtly nervous or fearful
during treatment, as well as experiences where providers demonstrated hostility,
irritation, and anger through their facial expressions, vocal tones, or other non-verbal
mannerisms. Most apparent examples of such behavior occur when providers shifted their
demeanor immediately after discovering the patient’s HIV+ status. For example, Kinsler
et al. (2007) reported that 20% of the HIV+ participants they surveyed (N=223) reported
that a healthcare provider had been uncomfortable with them since learning of their HIV
diagnosis. Similarly in the quantitative study by Schuster et al. (2005), 20% of surveyed
participants from a nationally representative sample of HIV+ individuals (N= 2466)
reported the experience of being seen by a physician who appeared to be uncomfortable
around them after learning that they were HIV+. Discomfort and negative affect were
also assessed in a final quantitative study (Thrasher et al., 2008) that examined the
relationship between discriminatory healthcare experiences and adherence to HAART.
Though statistics for individual items were not listed, 41% of the HIV+ participants
(N=1886) reported experiencing at least one of the six discriminatory healthcare
experiences, two of which were associated with provider affect and discomfort. Thus
findings across the four studies assessing provider discomfort suggest that a small but
significant proportion of HIV+ patients perceive their providers to be uncomfortable
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around them and note affective displays of negativity in the form of irritability,
nervousness, or anger.
Stigmatizing Behavior Related to Provision of Care
In contrast to above findings related to provider demeanor, stigmatizing behaviors
in the form of care provision can be considered more overt stigma encounters which
compromise the medical treatment of HIV+ individuals including patient avoidance,
delayed treatment, lack of touch, differential or inadequate care, and treatment refusal.
Though stigmatization of this nature occurs at a lessened frequency than compared to the
start of the epidemic, HIV+ patients nonetheless continue to report experiencing these
provider behaviors. As such, they are relevant to the present study and will inform the
content of both the qualitative focus groups and the treatment vignettes of the
experimental phase of the study. Stigmatization findings related to the provision of care
are reviewed below.
Patient avoidance or delayed treatment. Eight studies (5 qualitative and 3
quantitative) provided reports of experiences in which treatment was delayed or patients
were avoided by their providers presumably because of their HIV status (see Table 2). In
four qualitative studies, patients reported incidents in which their appointments were
delayed for extended periods (Blake et al., 2008; Marcenko & Samost, 1999), staff would
not bring them their food (Buseh & Stevens, 2006), and physicians would not
acknowledge their presence in the room (Rintamaki et al., 2007). Indeed, quantitative
survey data from Schuster et al. (2005) and Kinsler et al. (2007) indicated that between
18% and 19% of HIV+ participants reported perceiving that some healthcare provider
preferred to avoid them. As both Schuster et al. (2005) and Kinsler et al. (2007) utilized
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the same item, “Since you have had HIV, has any health care provider preferred to avoid
you?”, it is unclear what specific act of avoidance the participants might be reporting on
(e.g. canceling appointments, avoiding touch, etc.). In the qualitative study by Surlis and
Hyde (2001), hospital patients who had become infected with HIV through intravenous
(IV) drug use were more likely to report that nurses ignored them as compared to those
infected through homosexual activity. They believed they were avoided even more so
because of the combination of their HIV status and their IV drug use. In sum, both
qualitative and quantitative studies suggest that a significant minority of HIV+ patients
report experiences in which they were avoided or felt ignored by their providers.
Lack of touch during treatment. A majority of health visits require providers to
physically touch their patients to perform assessments (blood pressure, physicals) and
procedures (dressing wounds, surgeries). As such, when providers decrease their level of
touch, or refuse to do so altogether, treatment quality may decline. In two of the reviewed
qualitative studies (Blake et al., 2008; Lindau et al., 2006), patients reported incidents in
which their providers refused to touch them and perform physical examinations. In both
studies focusing on HIV+ women, participants reported feeling subsequent shame (Blake
et al., 2008) and threats to their safety, with one woman reporting that she had even been
transported to another hospital by taxi because no one wanted to touch her (Lindau et al.,
2006). Though literature is limited, available qualitative reports denote that providers’
unwillingness or aversion to touching HIV+ individuals remains an important issue and
concern for some patients.
Inadequate or differential treatment. Six studies (3 qualitative and 3
quantitative) reported data concerning the question of whether HIV+ patients perceived
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that they received differential or inadequate treatment based on their serostatus (see Table
2). For example, veteran patients in Rintamaki et al.’s (2007) qualitative study reported
that health providers sometimes spent inadequate time on their needs, leaving them to
experience unnecessary pain during procedures. Irish hospital patients from another
qualitative study (Surlis & Hyde, 2001) indicated that providers treated them
differentially based on their mode of infection, with patients infected through IV drug use
believing they received the poorest care.
Two quantitative studies also reported findings related to inadequate or
differential treatment due to HIV status. In a survey study by Elford et al. (2008), 14% of
HIV+ patients recruited from HIV outpatient clinics in London (N=1385) reported that
they had been treated differently or unfairly by a healthcare provider because of their
HIV status. Differential or unfair treatment was reported to occur most often from
dentists (25%), followed by general practitioners (17%), with 5% noting unsatisfactory
treatment by healthcare providers at HIV specialty clinics. In contrast, participants in
Bodenlos et al.’s (2007) study of patients’ attitudes towards their healthcare providers in
an HIV clinic setting reported high levels of satisfaction in terms of their providers’
treatment efforts and overall quality of care. Thus, findings regarding the quality of care
HIV+ patients perceive they are receiving appear to be mixed, with two studies noting a
high frequency of poor or differential care (Elford et al., 2008; Rintamaki et al., 2007)
and another reporting high ratings of healthcare quality (Bodenlos et al., 2007).
Treatment refusal. Treatment refusal based on a person’s HIV status is the most
overt form of stigmatization. Such experiences were noted in six of the reviewed studies
of patient reports of provider stigmatization (see Table 2). Approximately 4% of African
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American females sampled (N=366) in Wingwood et al.’s (2007) qualitative study
reported being denied medical care as a result of being HIV+. Higher incidence of
treatment refusals were noted in quantitative, survey-based studies by Schuster et al.
(2005) and Kinsler et al. (2007), with 8% and 19% of patients reporting this experience
respectively. In addition to an outright denial of care, treatment refusals can take the form
of refusal to perform certain procedures or being referred to other providers. For
example, in qualitative studies focusing on the treatment experiences of HIV+ veterans
(Rintamaki et al., 2007) and HIV+ mothers (Lindau et al., 2006), participants provided
accounts of nurses refusing to draw blood, dentists refusing to pull teeth, and incidents in
which they presented with emergency needs and were transferred to other hospitals after
providers learned of their serostatus. In sum, recent findings denote that a subset of HIV+
individuals still encounter refusals for medical treatment, though at a decreased frequency
relative to studies carried out earlier in the epidemic (Weinberger, Conover, Samsa, &
Greenberg, 1992).
Summary
The reviewed studies of provider stigmatization provide information on the extent
to which HIV+ patients continue to have stigmatizing experiences within medical care
settings and validate the need for conducting the present study. Indeed, as provider
stigma remains a concern for a subset of HIV+ patients, studies examining its impact are
needed. Although differences in study methodologies and sampling strategies preclude
definitive prevalence estimates, both qualitative and quantitative data from the review
suggest that a significant minority of HIV+ patients continue to experience stigmatization
in healthcare settings. Findings suggest that some HIV+ patients experience negativity
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from health care providers, including judgmental communication, increased distance
during treatment, lessened eye contact, the use of unnecessary precautions, and the
expression of discomfort or negative affect. While stigmatization related to the direct
markers of HIV care provisions (e.g., inadequate care, refusal of treatment) was noted to
occur less frequently, such behaviors were nonetheless experienced by a subset of HIV+
patients sampled across studies. Indeed, patients reported multiple instances where
providers (1) avoided, delayed, or refused treatment, (2) were uncomfortable with or
avoided direct physical contact with patients, and (3) instances where treatment was
inadequate or differential because of a patient’s HIV status. The reviewed literature
describing experiences of provider stigmatization in the form of both negative demeanor
and altered provision of care informs the design of the present study in terms of the
content of the qualitative focus group interview guide as well as the development of the
hypothetical treatment vignettes used in the experimental phase of the study. Although
existing studies provide a foundation for understanding which provider behaviors are
perceived to be stigmatizing by HIV+ patients, qualitative focus groups will be helpful in
informing on more recent experiences of provider stigmatization, as well as provider
behaviors that have occurred most often specifically among the present study’s sample
population.
Impact of Provider Stigmatization on HIV Care
The studies reviewed thus far focus on providing descriptive data to characterize
stigmatization as perceived by HIV+ patients. Several quantitative studies focus more
broadly on the question of whether provider stigmatization is associated with markers of
treatment access and self care, including appointment attendance, HAART adherence,
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access to care, and perceived quality of care. A review of this literature provides a
foundation for the present study, as the included studies are the few examples of
correlational research examining the impact of provider stigmatization on HIV care.
Although the present study focuses specifically on the impact of provider stigmatization
on HIV+ patients’ decisions to engage in care and willingness to discuss sensitive topics
like sexual and substance use risk behaviors and medication adherence, reviewed findings
nonetheless offer initial data on the impact of stigmatization on aspects of HIV self care
and patients’ perceptions of the care they receive.
Appointment attendance. Regular appointment attendance is integral to the
successful management of HIV. During routine clinic visits, providers monitor disease
status and immune functioning, make treatment adjustments, provide support for
medication adherence, and strive to control infections that can harm immune systems. In
Bodenlos et al. (2007), findings indicated that HIV clinic patients (N=109) who perceived
less provider stigmatization reported better appointment attendance. Indeed, low
stigmatization and a positive provider relationship, combined with having a large social
support network and being on a HAART medication regimen accounted for 27% of the
model’s variance in predicting appointment attendance. This finding is particularly
relevant to the present study, as one of the outcomes of interest pertains to HIV+ patients’
intentions to remain in care following a stigmatizing treatment experience. Findings from
Bodenlos et al. (2007), suggest that the experience of provider stigmatization does indeed
play a role in predicting which patients are more likely to actively engage in care, as
defined by consistent appointment attendance.
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Quality and access to care. Two studies examined the association between
provider stigmatization and access to care, defined in terms of affordability, availability,
convenience, and specialist accessibility. First, in Kinsler et al. (2007), 26% of a sample
of HIV+ men and women recruited from medical centers, outreach programs, case
management services, and HIV clinics in the Los Angeles area (N=223) endorsed at least
one item indicating experiences of provider stigmatization (See Table 1). Fifty-eight
percent of the sample also endorsed at least one of six items related to low access of care,
with bivariate and multivariate analyses indicating that higher perceptions of provider
stigmatization at baseline assessment were associated with lower access to care at the six
month follow-up assessment (Kinsler et al., 2007). Second, Schuster et al. (2005)
confirmed their hypothesis that higher perceptions of provider stigmatization would be
related to lower access to care among their nationally representative sample of 2466
HIV+ individuals, using the same measures utilized by Kinsler et al. (2007). The authors
(Schuster et al., 2005) also found that patients reporting higher levels of stigmatization
were more likely to report receiving a lower quality of medical and hospital care. Taken
together, findings from these two studies denote that patients perceiving higher levels of
stigmatization from their providers are more likely to report lower access to care and
lower quality of care received. As two of the stigma items utilized in Kinsler et al. (2007)
and Schuster et al. (2005) related to patient avoidance and treatment refusal, these
findings suggest provider stigmatization may affect an HIV+ individual’s access to care
by limiting the amount of available treatment centers they are able receive care at. In
addition, after experiencing negative interactions with providers, patients may be
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reluctant to return follow up appointments or seek out other treatment even when in great
need (Kinsler et al., 2007).
HAART adherence. A study conducted by Thrasher et al., (2008) examined the
association of healthcare discrimination and provider distrust to HAART adherence, with
an emphasis on explaining potential disparities in adherence based on racial/ethnic
differences. Discriminatory experiences directed towards HIV+ patients did not emerge
as a predictor of adherence difficulties. Further, a hypothesized mediating path between
ethnicity, provider stigmatization, and adherence was not supported. However, findings
did indicate that discriminatory experiences were associated with provider distrust and
weakened belief in the effectiveness of HAART, variables which subsequently predicted
adherence difficulties. Thrasher et al.’s (2008) findings speak to importance of
considering indirect pathways in understanding the effect of stigmatization on health and
treatment outcomes by way of stigma’s effects to the patients’ perceptions of their
providers. Drawing from this research, the present study has also considered patients’
perceptions of the provider and feelings within the treatment interaction as relevant
factors to explaining the effect of stigmatization on HIV+ patients’ decisions to engage in
care.
Summary
Three studies provide data on the relationship of provider stigmatization to
treatment outcomes of HIV+ patients. Taken together, they provide initial data on the
impact of perceived stigmatization from healthcare providers on HIV care, both in terms
of the treatments provided by healthcare workers and also in patients’ efforts regarding
self care. These reviewed correlational studies provide initial evidence for a link between

21
provider stigmatization and detrimental effects to treatment in terms of lower perceived
quality of care, lower access to care, decreased appointment attendance, and to a lesser
extent, lower HAART adherence. Although additional research is needed to address
methodological limitations, reviewed findings provide preliminary evidence to suggest
that provider stigmatization negatively impacts the medical care of HIV+ individuals.
Findings provide a strong basis for conducting the present study, which will contribute to
the small literature that has examined the impact of provider stigmatization on aspects of
HIV treatment and self care. The present study will also extend the literature by
providing the first experimental examination of this area of study.
Limitations of Existing Studies
The reviewed literature documents the existence of HIV-related stigmatization
among healthcare providers and its potential effects to the medical treatment and self care
of HIV+ patients. However, several inconsistencies and gaps in our understanding of
provider stigmatization exist due to methodological limitations within the literature.
Limitations of the present literature include a general lack of studies examining the
impact of provider stigma, a lack of quality and consistency in the measures used to
assess provider stigma, and a lack of studies utilizing experimental designs to examine
the experience of provider stigmatization and its impact on various aspects of HIV care
and HIV+ patients’ perceptions of their treatment experiences. Such limitations are
discussed, with attention paid to how the present study addresses them through both its
focus and design.
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Lack of Studies Examining the Impact of Provider Stigma
Broadly, there is a need for studies that specifically aim to examine the effects of
provider stigmatization on the medical care of HIV+ individuals. Although several
qualitative studies provide anecdotal evidence for the link between provider
stigmatization and poor treatment outcomes, there are relatively few empirically-based
studies that examine such questions. Those that do exist are correlational in nature. A
growing number of well-designed, theoretically informed studies have begun examining
the impact of societal stigma on HIV+ individuals’ emotional and physical health.
Indeed, experiencing HIV-related stigmatization (not provider-specific) negatively
impacts mental health (Berger et al., 2001; Clark et al., 2003), as well as contributes to
delays in entering into care, lapses in medication adherence, and fewer status disclosures
to physicians (Chesney & Smith, 1999; Vanable et al., 2006). Research on providerspecific stigmatization would benefit from a greater focus on empirically-based studies
that seek to document the impact of stigma on the medical treatment of HIV+ individuals
including engagement in care, patient-provider communication, and issues related to risk
behavior and medication adherence. The present study helps to fill this gap in the
literature, clarifying how provider stigmatization can affect the above mentioned HIV
treatment and self care variables.
Lack of Quality in the Conceptualization and Measurement of Provider-specific
HIV Stigmatization
In stigmatization research, the operationalization and assessment of HIV-related
stigmatization varies widely across studies. This lack of consistency in stigma
measurement creates difficulties when trying to generalize and compare findings across

23
studies and over time (Eldridge & St. Lawrence, 1995; Mahajan et al., 2008; Nyblade,
2006). For empirically-oriented studies involving patient self-report, measures are often
restricted to small item sets and narrowly focused on extreme behavioral markers of
stigmatization such as treatment refusal. Recent qualitative studies provide a richer
understanding of the stigma experiences of HIV+ individuals within treatment settings,
and future research would benefit from incorporating this information into the
development of better tools to assess perceptions of provider stigma. The present study
addresses this limitation, as its operationalization of provider stigma is multifaceted in
nature. The study incorporates findings from previous literature and information gathered
from qualitative focus groups to create detailed representations of provider stigma in
vignettes depicting a range of provider behaviors related to both demeanor and the
provision of care.
Reviewed studies also lacked time-sensitive language in their measures, often
assessing instances of stigma since the time of diagnosis. This approach not only lacks
the specificity required to capture current trends related to stigmatization in treatment
settings, but is also prone to error associated with memory recall difficulties. Needed are
studies that capture more in-the-moment measures of patient perceptions of provider
treatment behaviors. The present study’s design addresses this limitation as well,
requiring HIV+ patients to rate their level of psychological comfort (e.g. level of worry,
nervousness, etc.) and beliefs about the patient-provider relationship immediately
following the presentation of (potentially) stigmatizing behaviors in a hypothetical care
visit via a computer program. This design indeed allows for time-sensitive assessments of
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reactions to provider stigma and lessens the possibility of recall errors often found in
traditional survey based studies.
Lack of Experimental Study Designs
In the few existing studies that examine the impact of HIV+ patients’ perceptions
of provider stigma, none have utilized an experimental design to examine stigma’s
association with negative treatment outcomes. Indeed, past research has relied solely on
self report measures of perceptions of provider stigma within the treatment setting and
has been correlational in nature. A major limitation of these studies pertains to the
potential risk of attributional biases. Indeed, all of the patient-based studies
operationalized provider stigma as behaviors perceived by HIV+ patients to be
stigmatizing, with no outside validation of the providers’ actual behaviors. Given the
historically negative treatment of HIV+ individuals within our culture, HIV+ patients
may be especially prone to perceiving threat or injustice in situations that may actually be
benign (Chapman, 2002; Frable, Blackstone, & Scherbaum, 1990). As such, HIV+
persons may be more alert to potential threats, hyperaware of people’s treatment toward
them, and potentially more likely to label neutral behavior as stigmatizing.
The use of an experimental paradigm, as utilized in the present study, has the
potential to address these limitations and advance stigmatization research in several ways.
First, relative to correlational studies, experimental designs allow for an examination of
the causal effects of stigmatizing provider behaviors to HIV+ patients’ perceptions of
treatment experiences and their decisions to engage in HIV care in terms of treatment
enrollment, disclosure, and receptivity to risk reduction messages. Secondly, an
experimental design allows for the level of stigmatizing behaviors demonstrated by
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providers to be controlled and manipulated across HIV+ patient subjects, thereby limiting
the effects of attributional biases in the examination of stigma’s impact on HIV care. The
vignette design of the present study allows for an examination of the potentially
differential effects of having a highly stigmatizing treatment experience as compared to a
treatment experience characterized by more neutral or positive provider behaviors while
controlling for the exact stimuli being perceived by the patients (via the creation of the
standardized vignettes). In this design, the patients’ perceptions of the provider behaviors
are directly assessed through their self report, while the exact provider behaviors that are
being experienced by the HIV+ patients are controlled in the standardized vignettes.
Indeed, it is yet unknown which of the two, the behaviors or the perceptions of the
behaviors, is more closely linked (if either) with treatment outcomes of HIV+ patients.
In sum, the existing literature pertaining to HIV-related, provider stigmatization
informs the focus, content, and design of the present study. Limitations of previous
research leave a gap in our understanding of the impact of provider stigmatization on the
lives of HIV+ individuals. The present study begins to address these limitations and
advances the current state of provider stigmatization research.
Theoretical Considerations of the Present Study
The theoretical framework of the present study integrates findings from the
provider stigmatization literature with the broader literature on patient-provider
relationships to help explain the ways in which negative provider interactions may
influence patients’ decisions to engage in medical care. The Interaction model of Client
Health Behavior (IMCHB; Cox, 1982), described below, informs the mediational model
utilized in the present study. The mediational model of the present study is described in
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detail, drawing reference from the IMCHB model while also elaborating on its own
unique focus on the effects of provider stigmatization on HIV+ patients’ feelings of
psychological comfort (e.g. level of worry, nervousness, etc.), intentions to enroll in care,
intentions to openly communicate with the provider, and their disclosure of sensitive
health information related to sexual risk behaviors, substance use, and lapses in
medication adherence.
The Interaction Model of Client Health Behavior
Although not specific to HIV care literature, the Interaction Model of Client
Health Behavior (Cox, 1982) provides a useful framework for considering the role of
patient-provider interactions in determining health outcomes. Indeed, this model captures
the dynamic relationship between patient background characteristics, cognition, affect,
and patient-provider interactions in predicting patient health outcomes, and has been used
in its entirety or in parts as the guiding framework in studies predicting a range of health
outcomes, including the use of prenatal care (Cox & Roghmann, 1984), engagement in
self breast exams (Cox, Montgomery, Rai, McLaughlin, Steen, & Hudson, 2008), weight
control behaviors (Troumbley & Lenz, 1992), children’s physical activity and diet
(Robinson & Thomas, 2004), and satisfaction with medical care (Benkert, Hollie,
Nordstrom, Wickson, & Bins-Emerick, 2009). The Interaction Model of Client Health
Behavior (IMCHB) is multidimensional and dynamic, as illustrated in Figure 1. Of
relevance to the present study, the IMCHB describes (1) individual patient characteristics
(client singularity) and (2) patient-provider interactions as the elements of care most
predictive of health outcomes.
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Individual patient characteristics. Individual patient characteristics include
demographic background, availability of social supports, environmental constraints,
previous experiences in healthcare, as well as their level of motivation to engage in
healthcare. In addition, the IMCHB model also posits that each patient will differ from
other patients in their cognitive appraisal of and affective response to their medical
condition and treatment process. The model dictates that these aspects of client
singularity have important effects on the subsequent patient behavior and treatment
outcomes, such that the characteristics, cognitions, and emotions of an individual will
first affect how they behave in patient-provider interaction, which will then affect health
outcomes. Findings from Cox et al. (2008) and Troumbley and Lenz (1992) provide
support for the importance of considering patient characteristics when predicting patient
behavior and treatment outcomes. In both studies, participant background characteristics
were found to be predictive of health behaviors, with findings from Troumbley and Lenz
also demonstrating that patients with psychological distress are more likely to engage in
risky health behaviors and have poorer health outcomes (e.g. risky driving, high blood
pressure, experience illness, etc.).
Patient-provider relationship. According to Cox’s (1982) model, positive
patient-provider interactions are defined in large part by the provider’s ability to
demonstrate their competency, provide affective support, give the patient control in
decisions, and provide health information in the proper amounts as based on the highly
individualized needs of the patient. Failure of providers to correctly assess and
subsequently meet the patient’s needs within the patient-provider interaction may
negatively affect the patient health care decisions, behaviors, and treatment outcomes by
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lowering the patient’s level of motivation and self confidence and skewing their appraisal
of their health status, treatment needs, and quality of care received (Cox, 1982). For
example, in Benkert et al.’s (2009) examination of the IMCHB model, findings
demonstrated that the complex relationship between patients’ racial identity and their
perceptions of the client-professional relationship had significant effects on patients’
satisfaction with primary care. The patient-provider interaction element included in the
present study is more narrowly focused than that originally described in the IMCHB
(Cox, 1982), using standardized vignettes to portray specific aspects of patient-provider
relationships related to provider stigmatization.
Model of the Present study
The present study adapts several aspects of the IMCHB model to examine the
impact of provider stigmatization on HIV+ patients’ engagement in treatment. Both
patient characteristics and treatment interactions were incorporated into the present
study’s conceptualization of how provider stigmatization effects patients’ decisions to
engage in treatment. Patient characteristics are operationalized as participant
demographics and previous experiences with stigmatization in healthcare settings.
Characteristics related to cognitive appraisal and affective response are operationalized in
the present study as perceptions of stigmatization and their psychological comfort (level
of worry, nervousness, etc.) within the patient-provider interaction respectively. For the
present study, engagement in treatment is operationalized in terms of patients’ intentions
to enroll in care, intentions to openly communicate with their provider, and the disclosure
of sensitive health information related to sexual risk behaviors, substance use, and lapses
in medication adherence. Specifically, the model posits that HIV+ patients’ perceptions
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of stigmatization for a hypothetical patient-provider interaction and their feelings of
psychological comfort with the provider will mediate the relationship between the
experimental manipulation of provider stigmatization and HIV+ patients’ decisions to
engage in treatment (See Figure 2). It is proposed that when providers engage in
stigmatizing behaviors, HIV+ patients’ (1) perceive the devaluing nature of these
behaviors, (2) their perceptions of the patient-provider relationship are harmed, and (3)
their level of psychological comfort (e.g. level of worry, nervousness, etc.) within the
treatment setting will decrease. A patient’s lowered sense of comfort, perceptions of
stigmatization, and negative perceptions of the patient-provider relationship would then
negatively influence their decisions to remain in care, disclose sensitive health
information, and engage in discussions related to sexual risk behaviors, substance use,
and medication adherence difficulties.
The role of motivational biases. In focusing specifically on outcome variables
related to the disclosure of sensitive health information, the present study also considers
the potential role of motivational biases in our conceptualization of the effects of provider
stigmatization of patients’ disclosure of socially sensitive health behaviors. In particular,
it is believed that patients who experience stigmatization and negativity during a medical
visit may be motivated to under-report socially sensitive behaviors because of concern
about the possibility of experiencing further stigmatization from the provider.
The literature on self-report accuracy for socially sensitive behaviors suggests that
impression management and social desirability biases can lead to underreporting of
behaviors that are seen as socially unacceptable (see e.g., Schroder, Carey, and Vanable,
2003). Thus, research suggests that patients disclose higher rates of sexual risk behavior
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when they are assured of anonymity relative to when they are asked about their past
behaviors in a face to face interview (e.g., Des Jarlais, 1999; Metzger et al., 2000).
Likewise, individuals are more likely to under-report substance use behaviors as the level
of privacy afforded in the mode of assessment decreases (Moskowitz, 2004; Wright,
Aquilino, Supple, 1998). Patients also vary in their degree of concern about impression
management, and such differences help to explain under-reporting of substance use
behaviors (e.g., Davis, Thake, and Vilhena, 2010).
Within the present study’s framework, motivational biases to under-report
sensitive health behaviors are considered to be of potential relevance to the proposed
mediational model. Put simply, when a HIV+ patient perceives that their provider is
behaving in disrespectful or uncaring manner because of their HIV status, they may
experience discomfort with the idea of communicating openly with the provider. In turn,
patients may be reluctant to disclose socially sensitive behaviors because of fear that such
disclosures will elicit increased negativity and judgment from the provider. That is,
patients will likely underreport risky behaviors related to sexual behavior, substance use,
and medication lapses in an effort to avoid further feelings of shame and to present
oneself in a more positive light (e.g. “the good patient”). As such, the model posits that
participants’ who engaged in the stigmatizing treatment interaction (vs. the nonstigmatizing vignette) would be less likely to disclose accurate (and potentially
embarrassing) information regarding their risk behaviors, as a function of their decreased
feelings of comfort with the provider and their perceptions of being devalued by the
provider because of their HIV status.
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Summary of the Mediational Model
The present study tests the hypothesis that provider stigmatization within a
medical visit will negatively impact HIV+ patients’ decisions to engage in treatment and
openly communicate with the provider. It was predicted that patients’ perceptions of this
stigmatization and discomfort with the hypothetical provider would mediate the
relationship between the experimental manipulation of provider stigmatization and HIV+
patients’ decisions to engage in treatment. The mediational model of the present study
draws upon several elements of the IMCHB (Cox, 1982) by incorporating both client
characteristics (e.g. participant demographics, past stigma experiences, psychological
comfort, and perceptions of stigma) and treatment interactions in its conceptualization of
how provider stigmatization effects patients’ decision to openly communicate with
providers and disclose sensitive information. The model also draws upon the literature
on self-report biases to support the hypothesized effects of stigmatization on disclosure of
sensitive self-report data. Indeed, the basic tenets of the IMCHB (i.e. client singularity
and patient-provider interactions) are relevant in examining the effects of provider
stigmatization on the health and treatment outcomes of HIV patients, in so much as
negative provider attitudes and behaviors may be detrimental to the formation of the
patient-provider relationship, impair a provider’s ability to provide needed emotional
support, detract from the provision of health and treatment messages, decrease patients’
feelings of psychological comfort, and negatively affect patients’ perceptions of the care
they receive. Within the framework of the present study, provider stigmatization was
hypothesized to negatively impact health outcomes via its impact on patient-provider
interactions and subsequent negative changes to patients’ level of motivation to engage in
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care, their need to present themselves in a socially desirable fashion, and their trust in
their provider. The present study examines this model, hypothesizing that the relationship
between provider stigmatization and HIV+ patients’ decisions to engage in treatment (i.e.
intentions to enroll in care, intentions to openly communicate with provider, disclosure of
sensitive health information) would be mediated by HIV+ patients’ perceptions of
stigmatization within the hypothetical patient-provider interaction and their comfort with
the provider.
Overview of the Present Study
The major focus for the present study was to examine the effects of provider
stigmatization on several important aspects of HIV treatment related to patients’
decisions to engage in care, including intentions to enroll in HIV care, intentions to
engage in discussions related to risk behaviors, adherence challenges, and risk -reduction
strategies, and the actual disclosure of sexual risk behavior, substance use, and lapses in
medication adherence. Although many recent studies have documented the existence of
stigmatization in medical treatment settings, few have examined the impact of provider
stigmatization on HIV+ patients’ decisions to engage in various aspects of HIV care, and
none have utilized experimental designs to address limitations inherent in survey based
studies. The small existing literature supports an association between provider
stigmatization and lower appointment attendance, lower access to care, and to a lesser
extent, reduced HAART adherence, among HIV+ patients. However, conclusions are
limited by the correlational nature of the findings. The present study addresses these
limitations by not only exploring the extent to which HIV+ patients perceive
stigmatization within the treatment setting, but also examining the effects these

33
perceptions of stigma have on their decisions to engage in important aspects of HIV care
including issues related to disclosure, patients’ psychological comfort, and willingness to
participate in risk reduction conversations.
In using an experimental design, the present study utilizes a standardized and
behaviorally oriented approach to assessing patient’s reactions to stigmatization in health
care settings. In so doing, the present study advances a conceptual framework to clarify
the relationship between provider stigmatization, patients’ feelings of psychological
comfort and perceptions of stigma in the patient-provider interaction, and aspects of HIV
care pertaining to HIV+ patients’ willingness to disclose risk behaviors, engage in risk
reduction discussions, and enroll in care. Outcome variables as a whole are referred to as
“engagement in care.” Specifically the model of the present study posits that the
relationship between provider stigmatization and HIV+ patients’ engagement in care will
be mediated by HIV+ patients’ perceptions of stigmatization within the hypothetical
patient-provider interaction and their sense of psychological comfort (with regard to the
provider in general and specifically in relation to engaging in conversations related to
sexual risk behavior, substance use, and medication adherence).
The present study also examines demographic characteristics and previous
experiences of provider stigmatization as possible covariates or moderators for the
proposed model. For example, the study explores whether differences in a participant’s
degree of previous experiences with provider stigmatization alter the strength of the
hypothesized causal relationship between the experimental stigmatization manipulation
and participant’s subsequent decisions to engage in care. In the study’s experimental
paradigm, HIV+ patients were randomized to provide ratings of either a highly
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stigmatizing or a non-stigmatizing hypothetical treatment encounter with a physician
described as very competent in treating HIV+ patients. Patients provided several ratings
of general feelings of psychological comfort (e.g. level of worry, nervousness, etc.) with
the provider while viewing the hypothetical treatment vignette and provided ratings
regarding their comfort discussing risk behaviors with the provider, perceptions of
stigmatization within the hypothetical patient-provider interaction, and their subsequent
decisions to engage in various aspects of HIV care (e.g. intentions to enroll in care,
disclose of sexual and substance use risk behaviors, and intentions to participate in
medication adherence and risk reduction conversations) after the presentation of the
vignette.
By using an experimental paradigm and characterizing the mechanisms through
which provider stigmatization affects HIV+ patients’ decisions to engage in care, the
present research fills an important gap in the literature. An understanding of the
mechanisms underlying the patients’ decisions to engage in care and openly
communicate with their providers will help to highlight areas where changes to provider
demeanor, language, or behaviors may be especially helpful. As such, the current
research may inform the development of interventions to assist healthcare providers in
creating more positive treatment experiences for their HIV+ patients to improve
implementation of self care and reduction of risk behaviors. Qualitative focus groups
informed the development of the hypothetical treatment vignettes of the experimental
phase of the present study. Hypotheses for this between-subjects study were tested using
an experimental paradigm assessing HIV+ patients’ reactions to medical treatment
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scenarios that vary in their degree of provider stigmatization, as depicted using visual
representations and audio recordings of the hypothetical patient/provider interactions.
Aims and Hypotheses of the Present Study
Utilizing both qualitative focus groups and an experimental paradigm, the present
study aims to: (1) identify key characteristics of stigmatizing treatment experiences
among men and women receiving HIV treatment, (2) validate vignettes depicting
stigmatizing and non-stigmatizing treatment interactions, and (3) characterize the
association of HIV-related stigmatization to patients’ decisions to enroll in care, disclose
risky sexual and substance use behaviors, discuss medication adherence difficulties, and
their willingness to engage in conversations related to risk reduction and promotion of
self care. The present study utilizes a between-subjects experimental design, randomizing
participants into “stigma” and “non-stigma” vignette conditions. Vignette conditions
depicting hypothetical patient-provider interactions varied based on the visual stimuli and
audio recordings presented to the HIV+ participants using a computer program developed
with MediaLab software (Jarvis, 2006). HIV+ participants were asked to imagine that
they were the patient depicted in the hypothetical treatment vignette and then rated their
feelings of psychological comfort, perceptions stigmatization within the patient-provider
relationship, and decisions to engage in various aspects of HIV care.
The randomized stigma vignette condition serves as the study’s independent
variable of interest. The mediational variables of the present study include HIV+ patients’
perceptions of stigmatization within the hypothetical patient-provider interaction and
ratings of the patients’ psychological comfort with the provider (generally and in relation
to discussing sensitive sexual, substance use, and adherence-related information) assessed
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after individual, potentially stigmatizing provider behaviors are displayed. The dependent
variables include several treatment outcomes pertaining to HIV+ patients’ decisions to
engage in care. Specifically, the present study focuses on patient’s intentions to remain in
care, intentions to discuss risk behaviors and risk reduction strategies, and actual
disclosure of sexual risk behaviors, substance use, and lapses in medication adherence to
the provider described in the hypothetical vignettes. What follows is a summary of the
aims and the major study hypotheses.
Aim 1: To conduct qualitative research that will help to identify key
characteristics of stigmatizing treatment experiences. The first aim of the present
study was achieved through the use of three qualitative focus groups, totaling 18 HIV+
men and women, with the aim of determining what elements of patient-provider
interactions were perceived to be most stigmatizing. These responses informed the
development of vignettes to be used during the validation and experimental phases of the
present study.
Aim 2: Validate vignettes depicting stigmatizing and non-stigmatizing
treatment interactions. The second aim of the present study was achieved by
conducting a small pilot study to examine the validity of the vignettes as depictions of
stigmatizing and non-stigmatizing treatment interactions. HIV+ patients (n = 20) viewed
both of the computerized vignettes, rated their level of psychological comfort (e.g. level
of worry, nervousness, etc.) with the featured providers, rated their perceptions of the
stigmatizing nature of the vignettes, and also provided verbal feedback to the research
assistant about suggestions for improving the vignettes. Revisions to the vignettes would
have been based on a lack of statistical differences in psychological comfort and
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stigmatization ratings provided for the two vignette conditions, though such revisions
were not necessary.
Aim 3: To characterize the association of HIV-related stigmatization to
patients’ decisions to engage in medical care. A major goal of the present study was to
determine whether stigmatization within medical treatment settings affects HIV+
patients’ decisions to enroll in HIV care, intentions to communicate openly with their
providers about risk and self-care behaviors, and the self-reported disclosure of risky
sexual behavior, substance use, and lapses in medication adherence. This aim was
achieved by assessing HIV+ patients’ reactions to medical treatment vignettes depicting
either high levels of provider stigmatization or no stigmatization and their subsequent
decisions to engage in various aspects of HIV care. Reactions to the vignette were
operationalized as participants’ perceptions of stigmatization within the hypothetical
patient-provider interaction and their ratings of psychological comfort with the
hypothetical provider (generally and in relation to disclosure of sensitive sexual,
substance use, and adherence-related information) following the presentation of the
patient-provider interaction. Following the presentation of the vignette, participants rated
their intentions to enroll in care, and their intentions to engage in conversations related to
risk behaviors and self care. Participants were also asked to disclose personal risk
behaviors related to sexuality, substance use, and lapses in medication adherence. The
vignette and all study measures were administered via a computer program designed
using MediaLab software (Jarvis, 2006).
Hypothesis 1: Impact of provider stigmatization on patient comfort and
perceptions of stigmatization within the patient-provider interaction. It was
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hypothesized that the presence of provider stigma would lead to lower ratings of patient
psychological comfort and higher perceptions of stigmatization within the patientprovider interaction. Specifically, it was hypothesized that patients assigned to the
“stigma” treatment vignette would report lower levels of comfort with the provider and
increased perceptions of stigmatization within the patient-provider interaction following
exposure to stimuli demonstrating various provider behaviors (e.g. eye contact, level of
touch, etc.) as compared to those in “non-stigma” condition.
Hypothesis 2: Effects of provider stigmatization on patient engagement in
care. It was hypothesized that the presence of provider stigma would lead to lower
engagement in HIV medical care. Specifically, it was hypothesized that patients assigned
to the “stigma” treatment vignette would report lower intentions to engage in care as
compared to those in “non-stigma” conditions. This would be demonstrated by lower
intentions to enroll in care and lower intentions to engage in conversations related to
risky sexual behaviors, substance use, and medication adherence difficulties. In addition,
it was predicted that participants in the “stigma” group would report lower rates of
disclosure of actual sexual risk behavior, substance use, and lapses in medication
adherence.
Hypothesis 3: Mediating effects of patient comfort and perceptions of
stigmatization on engagement in care. It was hypothesized that lower ratings of
psychological comfort and higher perceptions of stigma within the patient-provider
interaction would lead to lower engagement in HIV medical care. In particular, it was
hypothesized that patients reporting lower levels of comfort and higher perceptions of
stigma within the patient-provider interaction featured in the vignette would also report
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lower willingness to enroll in care, engage in conversations related to risky sexual and
substance-related behaviors, discuss medication adherence difficulties, and disclose
personal risk behaviors to the provider from their vignettes. Further, it was hypothesized
that participants’ feelings of comfort and perceptions of stigmatization within the patientprovider interaction would mediate the effect of stigmatization (as operationalized as
“stigma” and “non-stigma” randomized conditions) on patients’ decisions to engage in
care.
Exploratory Aim 1: Examine the impact of previous experiences of provider
stigmatization on participants’ feelings of psychological comfort, their perceptions
of stigmatization within the treatment vignettes, and their decisions to engage in
care. An exploratory aim of the study was to test whether participants’ previous
experiences with provider stigmatization influenced the strength of the relationship
between provider stigmatization and participants’ subsequent decisions to engage in care.
In particular, the present study seeks to clarify whether past negative experiences impact
patients’ psychological comfort in a treatment setting (as tested using the vignette
methodology), their perceptions of patient-provider interactions, and their future
decisions to engage in care.
Orientation to Methods, Results, and Discussion Sections
The presentation of the methodology, results, and discussion sections of the
present study are organized according to the three phases of the protocol: qualitative
focus groups, validation sub-study, and the experimental phase. Hence, descriptions of
the major aims, participants, measures, procedures, analytic strategy, results, and
discussion are first presented for Phase 1, followed by separate methodology and
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results/discussion sections for Phase 2, and finally those for Phase 3. Detailed recruiting
procedures are noted in the description of Phase 1.
Phase 1: Qualitative Focus Groups
The major aim of Phase 1 was to conduct qualitative research that would help to
identify key characteristics of stigmatizing treatment experiences. Participant responses
would inform the development of vignettes to be used during the validation and
experimental phases of the present study.
Methods
Participants. Eighteen HIV+ male and female adults were recruited during
outpatient medical visits at the University Hospital Outpatient Infectious Disease (ID)
Clinic, a teaching hospital affiliated with State University of New York (SUNY) Upstate
Medical University. University Hospital is a Designated AIDS Care center providing
outpatient and inpatient medical care for HIV infected people from the 15 county Central
New York area, with an active outpatient population of approximately 785 HIV+
patients. Women and individuals from minority groups were included in this study. One
third of the sample (n=6) was comprised of women, 61% were African American, 22%
were Caucasian, and among men, 66% identified as men who have sex with men (MSM).
Three focus groups (6 participants each) were conducted.
Measures.
Background characteristics and health history. Demographic and medical
history data were collected to characterize the sample (See Appendix A). Demographic
questions were assessed using standard questions developed in previous research with the
population. Because health-related factors may relate to participants’ willingness to
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engage in HIV care, patients also reported on several health indicator variables including
viral load and CD4+ counts at last clinic visit, presence of AIDS diagnosis, time since
HIV infection, and current medications.
Qualitative interview. A qualitative interview guide was utilized to facilitate
discussion for three focus groups. Each focus group lasted approximately two hours.
Focus group content pertained to participants’ experiences of HIV-related stigmatization
within healthcare settings, positive experiences with providers, and suggestions for
improving HIV-related healthcare experiences. Further details of the interview process
are included in the procedures section.
Procedures.
Recruitment. For all phases of the study, the principal investigator (PI) worked in
collaboration with staff at the Infectious Disease Clinic to recruit HIV+ patients during
routine visits. A designated health care provider (e.g., triage nurse) informed patients
about the opportunity to participate in the study and obtained verbal assent from patients
regarding their willingness to be introduced to the PI. Patients who provided oral assent
(to meet with the research staff) were then introduced to the PI or research assistant who
provided a description of the study. The study description stated that the purpose of the
research was to identify what medical provider behaviors are perceived as stigmatizing
by HIV+ patients and to gain a better understanding of how providers’ behaviors can
affect the care of HIV+ patients. Eligibility for the all phases of the study was limited to
those who were HIV+, at least 18 years of age, English-speaking, and physically and
psychologically capable of providing informed consent as determined by treatment
providers.
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Study protocol. After the initial meeting with the PI, qualitative focus group
participants were informed of the time, date, and location of the focus groups and
scheduled accordingly. Upon arriving for the focus group, participants were again given a
thorough description of the requirements, risks, benefits, and confidentiality protections
of the study, as outlined in the qualitative interview protocol (See Appendix C).
Participants were then asked to sign consent forms (See Appendix D), complete a brief
demographics sheet (See Appendix A), and participate in a two-hour discussion group.
After the completion of the group, participants were compensated $20 for their time, and
signed a receipt (Appendix E) before leaving the lab.
Data collection. At the time of the focus group, the facilitator first provided an
overview of the focus group procedures and provided an overview of the consent form.
After participants provided informed consent, they completed a brief demographics
survey. Then, the focus group began with initial introductions of group members and the
facilitators (PI and additional graduate student assistant).
Next, the facilitator initiated the focus group by asking a series of questions
designed to prompt a discussion about both stigmatizing experiences in medical treatment
settings, as well as and positive experiences interactions with medical providers (See
Appendix B). Participants were first asked about any negative experiences they have had
in medical care, with respect to the providers’ behaviors, the participant’s subsequent
feelings, and their perceptions about why they were treated poorly. After this introduction
to negative treatment experiences, participants were asked more specifically about
experiences of provider stigmatization. They were questioned about what they perceive
stigmatization to be and also given a definition consistent with how it has been previously
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defined in research to help direct discussions. Initial questions were open-ended, asking
participants to report on treatment experiences (early and more recent) they found to be
stigmatizing. Facilitators asked follow-up questions to clarify (1) what aspects of the
provider interaction were stigmatizing and (2) how the participant came to attribute the
negative behaviors to HIV-related stigmatization (vs. racial stigma, poor social skills,
poor medical skills, etc.). Following the open discussion of stigmatizing and positive
provider interactions, facilitators inquired about provider behaviors reported by HIV+
individuals in previous studies but not yet mentioned by the present study’s participants
(e.g. eye contact, distance, etc.). Subsequent questions prompted discussions surrounding
HIV+ participants’ perceptions of the emotional, social, and treatment-related effects of
experiencing stigmatization from a healthcare provider. Closing discussions explored
participants’ ideas for improved interactions with medical providers and obtain feedback
about their participation in the focus group.
Qualitative data synthesis. Each focus group was audio-taped and reviewed
several times by the principal investigator, with extensive notes taken upon each review.
The process of data synthesis entailed the PI completing an open-coding of the detailed
notes to capture maximum detail and complexity in the data. The focus group interview
guide topics served as the initial framework upon which the coding classification scheme
was derived, with additional topics pertinent to stigmatizing treatment experiences that
emerged during the focus groups being added to the classification scheme. Coding was
structured to differentiate stigmatizing treatment experiences related to provider’s overt
behaviors, treatment practices, demeanor, and language, as well as document the
commonality of patient experiences and the relative frequency of which they occurred.
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Results and Discussion
Focus group participants reported a variety of stigmatizing experiences, including
those related to provider demeanor, as well as more serious instances of stigmatization
related to provision of care. As shown in Table 3, the most frequently reported
experiences of provider stigmatization were related to judgmental language and
avoidance and distancing within the exam room, with 56% and 44% of focus group
participants (n = 18) reporting such instances respectively. In one instance, a female
participant who had sought treatment for chest pain reported that upon disclosure of her
HIV status to a hospital nurse, “Her demeanor changed. She was less friendly and
ignored me. I was left hooked up to an EKG machine for three hours. My boyfriend had
to search the hospital to get someone to help me.” Participants frequently reported being
blamed for their HIV infection, with providers also making assumptions about the way
they became infected and speaking to them in condescending manners. One female
participant noted that when she disclosed her status, a nurse responded, “Well, you
shouldn’t be out on the street messing around.” Many participants also reported instances
in which their providers stood far away from them in the exam room and also tried to
touch them as little as possible during examination procedures like taking blood pressure,
using a stethoscope, and taking their temperature. Approximately one-third of
participants (28%) also reported that their providers demonstrated awkward,
uncomfortable, or nervous body language while treating them or upon finding out that
they were HIV+. For example, one participant noted that upon disclosing his status, his
provider appeared “more cold and standoffish,” adding that “he couldn’t maintain eye
contact with me.”
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Though noted less frequently, participants also reported instances in which
providers took unnecessary precautions while treating them (22%), provided a lower
standard of care because of the participants’ HIV status (22%), ignored the patients’
symptoms because they were HIV+ (22%), and demonstrated a lack of knowledge in
HIV-related treatment issues (22%). For example, several participants reported providers
wearing masks in the exam room during routine check-ups, with one participant reporting
that his physician put on two pairs of gloves to examine him when he presented with leg
pain. Two participants reported instances of being denied care entirely.
Based on these qualitative data, salient and commonly occurring stigmatizing
behaviors of providers were identified to inform the development of the treatment
vignette content utilized in the validity and experimental phases of the protocol. Audio
and visual stimuli were created based on these identified experiences with consideration
for the frequency of such occurrences and the capabilities of reproducing such
experiences via the audio and visual design of the study’s experimental manipulation.
Phase 2: Validation Sub-study
The major goal of this small validity sub-study was to validate the present study’s
treatment vignettes depicting stigmatizing and non-stigmatizing patient provider
interactions. This goal was accomplished by first creating the vignettes and then
completing a small pilot study to confirm whether they were believable and adequately
depicted stigmatizing and non-stigmatizing treatment experiences.
A second goal of the validity sub-study was to examine the feasibility and utility
of using a “short-form” vs. a “long-form” version of the computerized questionnaire. In
the “short- form” version, the four segments (audio and associated pictures) of the
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treatment vignettes were presented together, with each segment being presented
immediately following the preceding segment. Measures of patient comfort and
perceptions of stigma were presented once following the presentation of the final vignette
segment. In the “long-form” version, the four segments of the treatment segments were
presented individually (one at a time), with measures of patient comfort and perceptions
of stigma being presented after each vignette segment for a total of four presentations of
such items. Statistical analyses were conducted to determine whether there were
significant differences in comfort and stigma ratings between short and long form
versions. If no differences emerged, this would provide justification for using the timeefficient “short-form” presentation.
Methods
Participants. Twenty HIV+ male and female adults were recruited during
outpatient medical visits at the University Hospital Outpatient Infectious Disease (ID)
Clinic for the validity sub-study phase of the present research. Seventy percent of the
sample was male, 55% identified as Caucasian, 35% identified as African American,
70% were unemployed, 30% had an AIDS diagnosis, and 85% were on a HAART
medication regimen.
Measures.
Background characteristics and health history. Demographic and medical
history data were collected in order to characterize our sample (See Appendix A).
Demographic questions were assessed using standard questions developed in previous
research with the population. Because health-related factors may relate to participants’
willingness to engage in HIV care, patients also reported on several health indicator
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variables including viral load and CD4+ counts at last clinic visit, presence of AIDS
diagnosis, time since HIV infection, and current medications.
Patient comfort. HIV+ patients’ level of psychological comfort within the
hypothetical treatment interaction was assessed by a brief measure of psychological
patient comfort developed by Spake et al. (2003). This eight item measure has good
internal consistency and has previously been used to predict patients’ intentions to remain
in care with their physicians (Spake & Bishop, 2009). Alpha in the current sample was
approximately .95 across the experimental “stigma” and “non-stigma” vignettes and short
and long form versions of the validity study questionnaire program. Participants were
asked to rate their feelings within the patient-provider relationship depicted in the
vignette along eight related dimensions, including discomfort-comfort, uneasiness-at
ease, tense-relaxed, worried-worry free. Although the original measure was rated on a 10point dimensional scale, the present study utilized a 7-point dimensional scale to be
consistent with other study measures (See Appendix F). In addition, a more specific
assessment of comfort related to engaging in conversations about sexual risk behaviors,
substance use, and adherence difficulties was completed at the close of the vignette
presentation (See Appendix F). Participants were asked (via ACASI) to imagine
themselves as the patient depicted in the vignette and respond to the psychological
comfort items. For example: “Please imagine that you are the patient portrayed in this
vignette. Now rate how you feel interacting with this provider in terms of feeling
comfortable. Now rate how you feel interacting with this provider in terms of feeling
worried.”

48
Responses were rated using a 7-point Likert scale ranging from 1 (extremely
uncomfortable, extremely worried) to 7 (extremely comfortable, extremely worry free).
These items were presented to participants completing the “long-form” version four
times, immediately following the presentation of each of the four segments of the
hypothetical medical visit. Participants completing the “short-form” version completed
this measure once following the presentation of the final vignette segment. Each segment
of the treatment vignette featured one or two provider behaviors being manipulated
across the two stigma conditions (e.g. eye contact, lack of touch, judgmental language).
After the vignette presentation, participants completing both the short and long form
version responded to three additional comfort items pertaining specifically to comfort in
engaging in conversations with the vignette provider about (1) sexual risk behaviors, (2)
substance use, and (3) medication adherence-related issues. For the purposes of the
present validation study, summed psychological comfort ratings (Spake et al., 2003) and
ratings on individual conversation-related comfort items were treated as separate
dependent variables.
Perceptions of provider devaluation. HIV+ patients’ perceptions of the
stigmatizing and devaluing nature of the hypothetical treatment interaction were assessed
following their ratings of psychological comfort (See Appendix F). These items were
presented to the participants completing the “long-form” version four times, immediately
following the presentation of each of the four segments of the hypothetical medical visit.
Participants completing the “short-form” version completed this measure once following
the presentation of the final vignette segment. Nine items were created by the PI to reflect
reactions to and perceptions of the treatment interaction as related to the experience of
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being devalued (a defining characteristic of stigmatization). As defined by Crocker,
Major, and Steele (1998), a stigmatized person is one whose social identity calls into
question their humanity, such that the person is devalued, spoiled or flawed in the eyes of
society. In essence, people who are stigmatized are no longer viewed as individuals, but
as mere representatives of a particular socially identified and devalued group, and,
consequently, are assumed to possess many or all of the characteristics associated with
that group. Items created by the PI reflect these concepts.
Participants were asked to imagine that they were the patient in the vignette and
respond via ACASI to such items as: “I felt devalued by this provider,” “I believe this
provider made negative judgments about me,” and “I believe this provider was
comfortable treating me.” Scale ratings reflect a 7-point Likert scale ranging from 1
(strongly disagree) to 7 (strongly agree). For the purposes of the validation study, the sum
score of devaluation ratings were treated as the dependent variables of interest. The
psychometric properties of this measure were examined in terms of its internal
consistency, with the measure having an alpha of approximately .75 across the
experimental “stigma” and “non-stigma” vignettes and short and long form versions of
the validity study questionnaire program.
Procedures.
Recruitment. Recruitment procedures are described in Phase 1 methodology.
Experimental manipulation of provider stigmatization: Patient-provider
interaction vignettes. A description of the present study’s vignettes depicting
stigmatizing and non-stigmatizing patient-provider interaction is outlined in the following
subsections, detailing the technology utilized to present the vignettes, the content of the
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vignettes, and the format of the vignettes in terms of how they were presented to the
participants.
Technology utilized. MediaLab software (Jarvis, 2006) was used to create a
computer program that (1) presented the visual and audio elements of the patient-provider
interaction vignettes, as well as (2) provided a computerized assessment of the study’s
independent and outcome measures of interest. MediaLab offers a flexible programming
framework for integrating assessments and experimental content from a variety of media
formats (e.g., video, audio, PowerPoint, questionnaires). The PI is experienced in
MediaLab software (Jarvis, 2006) programming, having completed prior research
utilizing a computerized, hypothetical vignette design (Heath & Vanable, 2009).
Vignette content. Creation of the treatment vignettes for the validation and
experimental phase of the study was informed by the qualitative focus groups that were
tasked with identifying key elements of provider behaviors that have been experienced by
HIV+ patients and were considered to be stigmatizing. Based on these findings, and a
thorough review of prior qualitative and quantitative provider stigmatization research,
medical visit vignettes incorporated varying levels of the provider’s use of judgmental
language, spatial proximity, eye contact, negative affect and discomfort, lack of touch,
respect for confidentiality, and avoidance. The PI also consulted with providers (mostly
nurse practitioners) at the Infectious Disease Clinic for additional input regarding the
structure and content of typical, first-time medical appointments (e.g. questions asked,
procedures completed, length of interactions, etc.).
Prior to the presentation of the vignettes, participants were instructed (via audio
recordings presented on the computer) to imagine that they were the patient depicted in
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the interaction on the screen. They were asked to take in their surroundings, imagine
themselves sitting on the exam table, and focus on the thoughts and feelings that they
might be having. They were informed of the premise of the medical appointment, which
was described as involving a first time appointment following a move to a new city. They
were told that although the doctor has the patient’s previous treatment records, he or she
plans to discuss some of the information for verification and clarification of certain
details. They were informed that the doctor was very competent in treating HIV+ patients
and had been practicing at the clinic for several years. After this preliminary information
was presented to the participants, the presentation of the vignette began.
The basic elements of the medical appointment scenario proceeded as follows: (1)
provider enters room and greets patient, (2) provider chooses a location in the room to sit,
(3) provider asks about general health and well-being, (4) provider refers to patient’s
chart and asks about information related to means of transmission (e.g. male-to-male
sexual contact, male-to-female sexual contact, IV drug use, etc.), recent illnesses and
procedures, and HIV status indicators (CD4 count, viral load), (5) patient and provider
discuss medication options, (6) provider does brief physical exam on patient (checks
heart beat and breathing, examines ears and throat, etc.), (7) provider discusses recent
headache symptoms with patient, (8) provider summarizes findings to patient and
outlines treatment plan, (9) provider exits room and returns with headache medications,
(10) provider returns and alerts patient that they will be asked several questions related to
sexual risk behaviors and substance use.
Throughout the hypothetical treatment visit, specific elements related to provider
demeanor and behaviors were manipulated, so as to be presented in either stigmatizing or
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non-stigmatizing ways. This was accomplished through modifying the provider’s use of
judgmental language, spatial proximity, eye contact, negative affect and discomfort, lack
of touch, respect for confidentiality, and avoidance. In order to maintain a high level of
experimental control, the vignettes were standardized so that (1) the credentials of the
provider described in the vignette were the same (i.e. highly competent), (2) the same
actors were portrayed in all visual depictions, (3) the same actor’s voice was used to
portray the provider across conditions, and (4) the flow and content of the treatment visits
(e.g. greeting, conversations, procedures) was consistent across conditions. The
presentation of the vignette took approximately ten minutes.
Vignette format. Vignettes incorporated photographs of a hypothetical medical
provider and audio voice recordings to demonstrate varying levels of stigmatization
within the treatment visit. Photographs and audio recordings for stigmatizing and nonstigmatizing treatment vignettes differed in terms of the provider’s use of judgmental
language, spatial proximity, eye contact, negative affect and discomfort, lack of touch,
respect for confidentiality, and avoidance. Audio recordings were also used to narrate the
hypothetical patient-provider interactions, providing step-by-step descriptions of the
providers’ behaviors throughout the medical visit. Additional audio recordings were used
to simulate patient-provider discussions, with actors portraying the voices of the patient
and the provider. Voices for the narrator were provided by the PI, with voices for the
patient and provider provided by several student actors chosen based on their
appropriateness for the roles. Both male and female patient versions were created to
increase participants’ ability to identify with hypothetical patient. Photographs of the
manipulated provider behaviors were taken by the PI using a high quality digital camera.
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Photos of an older student actor (age 30 or older) were used for the vignettes.
Photos depicted a hypothetical provider engaging in various aspects of the outlined
vignette scenario in an actual medical examination room to increase believability of the
interactions. Photographs were presented simultaneously with the corresponding audio
description of the treatment visit to provide visual representations of the potentially
stigmatizing provider actions.
The treatment vignettes of the patient-provider interactions within the medical
care visit were presented in four segments, with each segment presenting one or two
provider behaviors such as eye contact (or lack thereof), judgmental language regarding
HIV status (or more non-judgmental statements), and placing oneself across the room
from the patient (as compared to choosing the seat nearest them). Figures 3, 4, 5, and 6
provide illustrative examples of how the “stigma” and “non-stigma” vignette segments
were arranged in the long and short form versions of the program. Though these figures
are not meant to be exact representations of the visual or audio content of the actual study
vignettes, they provide an example of the intended general layout and nature of the
treatment vignettes. The “stigma” condition featured stigmatizing behaviors in all four
segments and the “non-stigma” condition featured no stigmatizing behaviors in all of the
segments.
Study protocol. After the initial meeting with the PI, validity phase participants
either followed the investigator to the assigned lab space and immediately completed the
study protocol (after clinic visit) or were informed of available times and dates and
scheduled accordingly. Upon arriving for the validity phase of the study, participants
were greeted by the PI who followed protocol procedures (See Appendix G) and
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provided a thorough description of the study via the informed consent procedures (See
Appendix H). The validity phase stimuli and questionnaire battery were administered
using audio computer-assisted self-interviewing (ACASI) on a desktop computer. Before
beginning, the PI introduced the computerized study protocol and described how the
computer program works. The PI answered questions the participant had and confirmed
the participant’s ability to successfully interact with the computer program. For
participants with limited computer exposure, the PI provided additional instruction on the
use of the mouse and keyboard as necessary. Participants were also instructed that if they
had any difficulties with the computer program to ring a bell on the desk and the PI
would assist them.
After completing consent procedures and filling out a brief demographics
questionnaire (see Appendix A), participants viewed both the “stigma” and “non-stigma”
vignettes on a computer. The ordering of the vignettes was randomized. Participants in
the “long form” version of the survey rated their level of comfort (e.g. level of worry,
nervousness, etc.) with the provider and how stigmatizing they perceived the vignette
interaction to be after each of the four segments of a vignette, via a questionnaire
presented on the computer (See Appendix F). Participants completing the “short-form”
version provided ratings for comfort and perceptions of stigmatization once, immediately
following the presentation of the fourth vignette segment. Following the presentation of
both vignettes, participants engaged in a brief discussion with the PI regarding their
reactions to the vignettes. The discussion assessed whether the “stigma” vignette
segments were perceived to be adequately stigmatizing by the participant and if they
were distinguishable enough from the “non-stigma” vignette segments. Suggestions for
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improving the vignettes were elicited from the participants. After completing this
protocol, participants were compensated $10.
Analytic strategy. Analyses for the validity sub-study consisted of both betweensubjects and within-subjects t-tests to evaluate differences between ratings for the
“stigma” and “non-stigma” vignettes. Between-subjects t-tests evaluated potential
differences in psychological comfort and stigmatization ratings between persons viewing
the “stigma” vignette first and persons viewing the “non-stigma” vignette first. Withinsubjects t-tests evaluated participants’ ratings of comfort and perceptions of
stigmatization on the “stigma” vignette as compared to their ratings on the “non-stigma”
vignette. The potential effect of presentation order of the vignettes was also examined.
All analyses were performed on averaged comfort and stigmatization ratings, with “longform” responses averaged across vignette segments to compare with “short-form”
responses. There was an expectation of significant differences in psychological comfort
and stigmatization ratings between the stigmatizing and non-stigmatizing manipulations.
It was also expected that there would not be any statistical differences between comfort
and stigma scores between short and long form versions.
Results and Discussion
Significant differences in perceptions of stigmatization and comfort ratings were
found when comparing participant responses to the “stigma” and “non-stigma” vignettes
when using both the short and long form survey formats (see Table 3). Results from ttests also indicated no significant order effects of the presentation of the vignettes, nor
any significant differences between stigma and comfort ratings when comparing long and
short form versions of the survey (see Table 3). These latter results provide support for
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the use of the more time-efficient and participant-favored (via verbal feedback) “short
form” survey protocol in the experimental phase of this study. Overall, findings support
the use of the vignettes as a valid experimental manipulation of HIV-related
stigmatization within a medical treatment setting, as the provider in the “stigma” vignette
was rated as more stigmatizing/devaluing of his patients and found to induce lower
feelings of comfort within the treatment setting. As such, no changes were made to the
content of the vignettes for the experimental phase of the study.
Phase 3: Experimental Study
The major goal of the experimental phase of the present study was to determine
whether stigmatization within medical treatment settings affects HIV+ patients’ decisions
to engage in HIV care and communicate openly with their providers about risk and selfcare behaviors such as unprotected sex, drug use, and medication adherence. This goal
was achieved by assessing HIV+ patients’ reactions to medical treatment vignettes
depicting either high levels of provider stigmatization or no stigmatization and their
subsequent decisions to engage in various aspects of HIV care.
Methods
Participants. Ninety HIV+ male and female adults were recruited during
outpatient medical visits at the University Hospital Outpatient Infectious Disease (ID)
Clinic for the experimental phase of the present research. Cell sizes between conditions
were equal, with 45 participants randomized to the “stigma” condition (29 males, 16
females) and 45 participants randomized to the “non-stigma” condition (29 males, 16
females). Of the experimental phase participants, 34.4% were female, 69% of males
identified as MSM, 52% were African American, 71% were unemployed, 22.2% held an
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AIDS diagnosis, and 83.3% were on a HAART medication regimen. The complete
demographic characteristics of the experimental sample can be found in Table 5.
Measures.
Background characteristics and health history. Demographic questions were
assessed using standard questions developed in previous research with the population
(See Appendix A). Because health-related factors may relate to participants’ willingness
to engage in HIV care, patients also reported on several health indicator variables,
including viral load and CD4+ counts at last clinic visit, presence of AIDS diagnosis,
time since HIV infection, and current medications.
Previous HIV-related stigmatization experiences. Past research suggests that
HIV+ persons may be more alert to potential threats, hyperaware of people’s treatment
toward them, and potentially more likely to label neutral behavior as stigmatizing
(Chapman, 2002; Frable, Blackstone, & Scherbaum, 1990). It stands to reason that the
risk of these appraisals may be heightened if an HIV+ individual has experienced
previous instances of stigmatization in a healthcare setting. As such, an original measure
assessing previous experiences with provider HIV-related stigmatization was included in
the present study to include as a possible covariate or moderator in the model (See
Appendix I). Fifteen items assessed the number of times the participant had experienced
various types of stigmatizing experiences while in a healthcare treatment setting. The
measure contains items related to more demeanor-based aspects of HIV-related
stigmatization (e.g. lessened eye contact, judgmental language, discomfort), as well as
stigmatizing behaviors related to the provision of care (e.g. avoidance, differential care,
refusal of treatment). This measure was presented at the end of the study, and participants
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reported how many times they have experienced each stigma item as based on a five
point rating scale ranging from 0 (never) to 4 (more than 10 times). The measure was
created following a review of the relevant qualitative and quantitative provider
stigmatization literature and was evaluated in terms of internal consistency (Chronbach’s
alpha), individual item performance, and factor structure (via exploratory factor analyses)
following data collection. Factor analyses indicated that the scale performed well as a
single factor measure, with the model accounting for 57% of the variance explained. This
measure also demonstrated strong internal consistency with an alpha of .91.
Patient comfort. HIV+ patients’ level of psychological comfort was assessed
following the presentation of the vignette by a measure of psychological patient comfort
developed by Spake et al. (2003). Further detail about this eight item measure is provided
in the validity phase methodology. Participants were asked (via ACASI) to imagine
themselves as the patient depicted in the vignette and respond to the comfort items. These
items were presented to the participants once, immediately following the presentation of
the final segment of the hypothetical medical visit. Factor analyses indicated that the
scale performed well as a single factor measure, with the model accounting for 89% of
the variance explained. This measure also demonstrated strong internal consistency with
an alpha of .95. In addition, a more specific assessment of comfort related to engaging in
conversations about sexual risk behaviors, substance use, and adherence difficulties was
also completed at the close of the vignette presentation. For the purposes of the
experimental study, both a composite score of comfort ratings (Spake et al., 2003) and
individual conversation-related (sexual behavior, substance use, adherence difficulties)
comfort items were examined as mediator variables of interest.
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Perceptions of stigmatization within the patient-provider interaction.
Perceptions of stigmatization within the hypothetical treatment interaction were assessed
in two ways (See Appendix K). First, the measure of devaluation that was developed for
the validity phase of the present study was used (see validity phase methodology for
detailed description). As described earlier, this subscale consists of nine items (rated on
7-point Likert scale) created to reflect reactions to and perceptions of the treatment
interaction as related to the specific experience of being devalued (a defining
characteristic of stigmatization). Participants were asked to imagine that they are the
patient in the vignette and respond to the items via ACASI.
The second way that perceptions of stigmatization was assessed was through an
adaptation of the 13-item Engagement with Health Care Providers scale (Bakken, et al.,
2000), with modifications to accommodate the experimental nature of the present study.
Items from this subscale focus on participants’ perceptions of the patient-provider
relationship. The original scale has strong internal consistency and has been successfully
used with HIV+ patient populations (Bakken, et al., 2000; Metsch, et al., 2008). Items
were modified to assess participants’ beliefs about the future actions of the hypothetical
providers and nature of the patient-provider relationship presented in the vignettes (e.g. “I
believe this provider would involve me in treatment decisions.”), rather than assess the
current nature of their patient-provider interactions (e.g. “My provider involves me in
treatment decisions.”) as indicated in the original scale. Examples of additional items
include: “I believe this provider would respect me,” “I believe this provider would care
about me,” and “I believe this provider would see me when I ask.” Scale ratings reflect a
7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree).
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The psychometric properties of the entire perceptions of stigmatization measure
were examined in terms of its internal consistency (e.g. Chronbach’s alpha) and factor
structure via exploratory factor analyses. The factor structure of the entire perceptions of
stigmatization measure was examined to determine whether the measure in its entirety or
its potential subscales should be treated as mediator variables in the planned analyses.
Contrary to original expectations, factor analyses indicated that the scale performed well
as a single factor measure, with the model accounting for 77% of the variance explained.
This measure also demonstrated strong internal consistency with an alpha of .96.
Engagement in care. HIV+ patients’ engagement in care was assessed using
several brief measures created specifically for this study (See Appendix L). Engagement
in care measures served as the primary dependent variables of interest and were assessed
using two types of items: (1) those that assessed a participant’s intentions to engage in
various aspects of care, and items that assessed (2) participants’ disclosure of actual risk
behaviors. Participants’ intentions to engage in care were operationalized as participants’
intentions to (1) remain in care with the provider portrayed in the vignette, (2) discuss
sexual risk behaviors with the provider, (3) discuss substance use with the provider, and
(4) discuss medication adherence difficulties with the provider. These items were worded
to assess the likelihood of participants engaging in these various treatment activities and
will be rated on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7
(extremely likely). Assessment of actual patient disclosure included nine items pertaining
to (1) sexual risk behavior, (2) substance use, and (3) lapses in medication adherence.
Items required participants to report the frequency in which they have actually engaged in
various risk behaviors.
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An assessment approach based on patients’ intentions to engage in care and
openly communicate with their providers about risky behaviors was utilized to allow for
a larger pool of responses from the sample. As some participants may not engage in the
various risk behaviors assessed in the present study, items were worded in terms of their
intentions to disclose in the hypothetical event that these behaviors had occurred (e.g. “In
the event that you happened to engage in X, how likely is it that you would disclose this
to the provider?). Although the more direct assessment of disclosure (e.g. having the
participant choose whether to actually disclose their own risky behavior to the
hypothetical provider) has greater external validity, such an approach could potentially be
limited by the number of participants in the sample who had actually engaged in the
behavior of interest. As such, it was deemed important to include both an intentionsbased measure of disclosure and a more direct assessment of patient disclosure following
a potentially stigmatizing treatment experience. The psychometric properties of all
engagement in care measures were examined to assure their internal consistency (e.g.
Chronbach’s alpha).
Intentions to remain in care. Participants’ intentions to remain in care with the
provider shown in the vignette was assessed with the single item, “How likely is it that
you would remain in care with this provider?” and measured on a 7-point Likert scale.
Intentions to discuss sexual risk behaviors. Intentions to discuss sexual risk
behaviors included items related to disclosing unprotected anal/vaginal sex with a steady
partner of HIV- or unknown serostatus (historically vs. occurrences within the past three
months), disclosing unprotected anal/vaginal sex with a casual partner of HIV- or
unknown serostatus (historically vs. occurrences within the past three months), and also
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initiating a conversation about difficulties achieving and maintaining safer sex practices.
The decision to use the three month point as the cut off for “recent” sexual experiences is
based on several findings supporting the reliability of self reports of sexual risk behaviors
measured at this time frame (Carey et al., 2001; Jaccard et al., 2002; Kauth, St. Lawrence,
& Kelly, 1991). As actual sexual risk behaviors were assessed later in the study, items
assessing intentions to disclose sexual behaviors were also based on the three month time
frame for the purpose of item consistency. Items were worded in terms of their
willingness to disclose as based on the hypothetical event that these behaviors had
occurred (e.g. “In the event that you happened to have unprotected anal sex, how likely is
it that you would disclose this to the provider?). These items were rated on a 7-point
Likert scale ranging from 1 (extremely unlikely) to 7 (extremely likely). This measure
demonstrated strong internal consistency with an alpha of .95.
Intentions to discuss substance use risk behaviors. Intentions to discuss substance
use risk behaviors included items related to disclosing substance abuse and dependence
(historical vs. recent, alcohol vs. other drugs), disclosing needle sharing, and initiating
conversations about seeking substance use treatment. Similar to the sexual risk items,
intentions to disclose substance use were based on a three month time frame to
distinguish intentions to disclose “recent” vs. “historical” occurrences of risk behavior.
As some participants may not have engaged in these substance use risk behaviors, items
were worded in terms of their intentions to disclose based on the hypothetical event that
these behaviors had occurred (e.g. “In the event that you happened to have shared needles
during drug use, how likely is it that you would disclose this to the provider?). These
items will be rated on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7
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(extremely likely). This measure demonstrated strong internal consistency with an alpha
of .97.
Intentions to discuss medication adherence difficulties. Intentions to discuss
medication adherence difficulties included items related to disclosure of unintentional
non-adherence to HAART (e.g. forgetting, misplacing medications, sleeping through
doses), disclosure of intentional non-adherence to HAART (e.g. purposely skipping
doses, medication vacations, taking meds not as prescribed), and initiating conversations
related to difficulties with medication adherence. Similar to the other risk items,
intentions to disclose adherence difficulties were based on a three month time frame to
distinguish willingness to disclose “recent” vs. “historical” lapses in medication
adherence. Items were worded in terms of their intentions to disclose, presuming that
these behaviors had occurred (e.g. “In the event that you happened to skip taking your
medications, how likely is it that you would disclose this to the provider?). These items
will be rated on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7
(extremely likely). This measure demonstrated strong internal consistency with an alpha
of .96.
Disclosure of health risk behaviors. In contrast to the aforementioned outcome
variables, items assessing disclosure of health risk behavior assessed the participants’
willingness to disclose their actual sexual and substance use related risk behaviors, as
well as lapses in medication adherence. This measurement domain included nine items
that assessed the participants’ history of risk behaviors and was designed to closely
represent the types of risk assessment questions that a provider typically asks during a
routine medical treatment visit in terms of content, specificity, and quantity (See
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Appendix L). Items were read to the participants in the voice of the provider (neutral
tone) in order to mimic as closely as possible what it would be like to disclose sensitive
information to the provider they viewed in the treatment vignette.
Three items assessed history of sexual risk behavior, including number of lifetime
sexual partners, number of partners in past three months, and percentage of time in which
condoms were used in the past three months.
Four items assessed history of substance use, including two alcohol use items
assessing quantity and frequency of use in past three months (Quantity Frequency
method), one item providing a basic assessment of lifetime drug use, and one item
assessing frequency of drug use in the past three months.
Two items were used to assess lapses in HIV medication adherence, with one
item assessing how long ago a dose of medication was purposely skipped, and another
item assessing the total percentage of HAART doses taken in the previous week.
Other than items related to sexual partner history, disclosure items provided
participants with categorical, ordered response choices to identify frequency of condom
use, alcoholic consumption, and missed medication doses, typically on a five point scale.
The rationale for using a categorical response format was to control for participant error
in item interpretation, subsequent errors when entering responses, and to eliminate the
need to handle extreme outlier responses in data analyses. As some items assessed for
typical behaviors across a time period, categorical responses allow participants to report
ranges of behaviors, that may be more accurate representations of their activities (vs.
having to choose one number). Although participants will not see the assigned score of
their response (e.g. 3-4 alcoholic drinks in one week = 2, more than 6 drinks in one week
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= 4), these scores were used to describe a basic, relative level of risk present in their
behaviors. Sexual behavior items related to lifetime and recent number of sexual partners
were presented in open-response format to allow for the large range of sexual partner
experiences expected in the clinical participant population, rather than estimate and
determine meaningful cutoffs for categorical responses.
Responses to personal disclosure items were examined individually rather than
via composite variables after discovering the poor internal consistency of the potential
subscales. Higher scores on all items were conceptualized to represent increased
willingness to disclose risk behaviors, rather than actual differences in risk behaviors
between the stigma and non-stigma experimental groups. This conceptualization was
based on the assumption that randomization would control for behavioral differences
between the experimental groups, thus allowing any significant differences in the
quantity or frequency of reported risk behaviors between groups to be attributed to the
effects of stigmatization on participants’ willingness to disclose sensitive information. All
measures assessing HIV+ patients’ decisions to engage in care were presented via
ACASI, following the complete presentation of the treatment vignettes and the measures
of patient psychological comfort and perceptions of the patient-provider relationship.
Procedures.
Recruitment. Recruitment procedures are described in Phase 1 methodology.
Experimental manipulation of provider stigmatization. Provider stigmatization
was operationalized as varying levels of stigmatizing demeanor and treatment behaviors
presented to HIV+ participants through the use of hypothetical vignettes. Vignettes of
hypothetical HIV medical care visits incorporated visual and audio stimuli and were
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presented to participants via a computer screen (for further description of vignettes, refer
to validity sub-study methodology). Patient-provider interactions in the vignettes were
manipulated to portray two experimental conditions: “stigma” and “no stigma.” As noted
previously, the vignettes used in the experimental phase of the present study were
reviewed by HIV+ patients in the validity sub-study and found to accurately depict
stigmatizing and non-stigmatizing patient-provider interactions. Scripts for these
vignettes can be found in Appendix M. As a between-subjects study, participants in the
experimental phase were randomized to a condition and viewed only one treatment
vignette. To maintain a high level of experimental control, the vignettes (stigma and no
stigma conditions) were standardized so that (1) the credentials of the provider described
in the vignette were the same (i.e. highly competent), (2) the same actor was portrayed in
all visual depictions, (3) the same actor’s voice was used to portray the provider across
conditions, and (4) the flow and content of the treatment visits (e.g. greeting,
conversations, procedures) was consistent across conditions. The “stigma” condition
featured stigmatizing behaviors in all four segments and the “non-stigma” condition
featured zero stigmatizing behaviors in all of the segments. For further illustration of the
presentation of the vignette segments, see Figures 3, 4, 5 and 6.
Study protocol. After the initial meeting with the PI, experimental phase
participants either followed the investigator to the assigned lab space and immediately
complete the study protocol (after clinic visit) or were informed of available times and
dates and scheduled accordingly. Upon arrival, participants were greeted by the PI who
followed protocol procedures (See Appendix N) and provided a thorough description of
the study via the informed consent procedures (See Appendix O). The experimental
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stimuli and questionnaire battery were administered using audio computer-assisted selfinterviewing (ACASI) on a desktop computer. Because ACASI affords greater privacy
over traditional paper and pencil questionnaires and interviewer administered surveys,
ACASI may have enhanced participants’ willingness to disclose sensitive information
(Schroder, Carey, & Vanable, 2003). Similar to the validity sub-study, the PI first
introduced the computerized study protocol, described how the computer program works,
answered any questions the participant had, and ensured the participant’s ability to
successfully interact with the computer program. For participants with limited computer
exposure, the PI provided additional instruction on the use of the mouse and keyboard as
necessary. Participants were also instructed that if they had any difficulties with the
computer program to ring a bell on the desk and the PI would assist them. Participants
then completed the small battery of self-report assessments (e.g. demographics, healthrelated variables) and responded to one treatment vignette as depicted on the computer
through visual and audio components. The ordering of the protocol was as follows: (1)
reporting of background and health information, (2) presentation of the treatment vignette
with, (3) ratings of psychological comfort, (4) ratings of perceptions of stigmatization
within the hypothetical patient-provider interaction, (5) ratings on measures assessing
decisions to engage in care, and (6) ratings on the Experiences of HIV-related
Stigmatization in Healthcare Settings measure. After completing this protocol,
participants were compensated $20 for approximately 45 minutes to one hour of their
time and signed a receipt.
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Experimental phase analyses.
Descriptive and preliminary analyses. The full sample was described using
summary statistics (frequency, mean, standard deviation) obtained from self-reported
demographic information, health status variables (i.e., AIDS diagnosis, HIV-related
hospitalizations), medical history variables (initiation of HAART, time elapsed since
diagnosis), and past experiences of HIV-related stigmatization in healthcare settings.
Summary statistics were also generated for the proposed mediating and outcome
variables of interest (i.e., perceptions of patient-provider relationship, psychological
comfort, intentions to enroll in care, intentions to disclose sexual and substance use risk
behaviors, intentions to discuss medication adherence difficulties, and actual disclosure
of personal risk behaviors). Finally, analyses pertaining to measure reliability and factor
structure were performed to ensure strong internal consistency of the proposed mediators
and dependent variables, with particular attention paid to the newly created measures.
Equivalency between study conditions. To assess for equivalence between the
“stigma” and “non-stigma” vignette conditions, separate ANOVA and Chi-square
analyses were performed on demographic variables, health status variables, and the
measure of past stigmatizing experiences reported during the experimental phase
protocol. Non-significant findings would indicate that the randomization procedure was
successful. Any significant differences in demographic, health status, or past stigma
characteristics between the conditions would be considered as additional covariates in
analyses examining primary study hypotheses.
Analyses for aim 3: To characterize the association of HIV-related
stigmatization to patients’ decisions to engage in medical care. First, bivariate analyses
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were conducted to identify the association between mediators (perceptions of patientprovider relationship and level of comfort), dependent variables (treatment engagement
measures), and relevant demographic, health status, past stigma experiences, and medical
history variables to identify potential covariates and moderators for the mediational
model. To examine study hypotheses, regression equations were conducted using an
SPSS macro designed to examine multiple mediator models (Preacher & Hayes, 2008)
using the product-of-coefficients mediation approach and bootstrapping statistical
methods. This macro also allows for the statistical control of covariates and comparisons
between indirect effects in mediation analyses. Separate regression analyses were
performed for the intentions and disclosure outcome variables representing engagement
in care: (1) intentions to remain in care, (2) intentions to discuss sexual risk behaviors, (3)
intentions to discuss substance use, (4) intentions to discuss medication adherence
difficulties, and (5) disclosure of personal risk behaviors (nine items examined in
separate regression equations). Stigma condition (stigma vs. no stigma) served as the
models’ independent variable of interest, with patients’ perceptions of stigmatization
within the hypothetical patient-provider interaction and levels of psychological comfort
within the treatment setting serving as the models’ proposed mediators.
Support for study hypotheses would be provided by significant unstandardized
regression coefficients for the direct effect of stigma level on engagement in care
outcome variables reaching significance at the conventional .05 level. This was similarly
expected for the regression paths between stigma level and the mediating variables
regarding perceptions of stigmatization within the patient-provider interaction and
psychological comfort. Finally, in examining the mediation hypothesis, it was expected
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that Sobel’s test of the models’ total indirect effects would be significant, demonstrating
that the effects of stigma on engagement of care are either partially or fully mediated by
the effects of patient perceptions of stigmatization within the patient-provider interaction
and patients’ psychological comfort.
Results
Equivalency between study conditions. T-test and Chi-square analyses revealed
few differences between participants randomized to the “stigma” and “non-stigma”
conditions on demographic variables, health status variables, and the measure of past
stigmatizing experiences reported during the experimental phase protocol. As noted in
Table 5, the only significant difference noted was for paid work hours, with participants
in the “stigma” condition reporting significantly more work hours than those in the “nonstigma” condition, t(23) = -2.07, p = .05. However, as only 24 participants were included
in this analyses (due to high rates of unemployment among participants) and work hours
was not significantly related to study outcome measures, it was not selected as a covariate
in subsequent analyses. These largely non-significant findings indicate that the
randomization procedure was successful.
Descriptive findings. In performing initial descriptive analyses, all mediating and
“intentions-based” outcome variables were found to have normal distributions, with no
signs of significant skew or kurtosis. In contrast, seven of the nine disclosure-based
outcome variables presented with non-normal distributions as a function of significant
skew, and in some cases, the presence of extreme outliers (lifetime and recent sexual
behavior items). Such outcome variables were transformed using log transformations to
correct for skew, with extreme outliers also truncated to three standard deviations away
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from the mean. All analyses were performed using both original and transformed
versions of variables, with no significant differences in outcome noted. Statistics
presented within the text and associated tables and figures report findings from analyses
performed with the transformed variables.
As shown in Table 6.1, significant correlations were noted between the mediating
variables of the present study (perceptions of stigma, general comfort, and specific
disclosure comfort measures), between the intention-based outcome variables, and finally
between the mediators and the intentional outcome variables. Correlations were in the
expected direction, with perceptions of stigma being significantly (negatively) correlated
with comfort measures (other mediating variables) and intention-based outcome
measures assessing intentions to a) remain in care, b) disclose sexual risk behavior, c)
disclose substance-related risk behavior, and d) disclosure medication adherence
difficulties. In contrast, comfort-based mediating variables were positively correlated
with intention-based outcome variables, such that higher levels of comfort were
associated with greater likelihood to remain in care and disclose risk activities.
Only two significant associations were noted for mediators and disclosure-based
outcome variables. As noted in Table 6.2, the only significant correlations were found
between general patient comfort and report of number of sexual partners in the past three
months (r = -.22, p < .05) and also between comfort related to discussion of sexual risk
and report of lifetime number of sexual partners (r = -.23, p < .05). Contrary to study
hypotheses, both of these significant negative correlations suggest that increased patient
comfort was associated with decreased reporting of sexual risk. Perceptions of stigma and
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patient comfort were not related to participants’ reports of any of the other sexual,
substance-related, and medication adherence risk behaviors.
Bivariate examination of effects of stigma condition on engagement in care.
Summary statistics in Table 7 present mean values for mediating and outcome variables
for both experimental conditions, with significant differences reported via t-test statistics.
As noted, participants in the “non-stigma” condition reported significantly lower
perceptions of stigma, higher levels of comfort (general and disclosure related), and
greater intentions to remain in care and to disclose risk behaviors than those in the
“stigma” condition (see Table 7).
Two trends (p < .10) were noted among disclosure-based outcome variables (see
Table 7). First, participants in the “non-stigma” condition reported missing doses of their
HAART medications more recently than did participants in the “stigma” condition.
Second, participants in the “non-stigma” condition reported using condoms less
frequently than participants in the “stigma” condition. No differences between the
groups were found for number of lifetime and recent sexual partners, alcohol
consumption, or lifetime and recent drug use variables. Such outcomes may suggest
greater disclosure of risk behaviors from participants in the “non-stigma” condition.
Exploratory Aim: Impact of previous experiences of provider stigmatization.
Correlational analyses were used to examine the relevance of previous experiences of
provider stigmatization as a covariate or moderator of the proposed mediational model.
As no significant associations were noted between previous experiences of stigmatization
and the mediating and outcome measures of the present study (see Tables 6.1 and 6.2), it
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was not selected as a covariate in subsequent analyses regarding primary study
hypotheses.
Primary study hypotheses: Mediational model of the association of HIVrelated stigmatization to patients’ decisions to engage in medical care. Regression
equations predicting intention-based and disclosure-based outcomes were conducted
using an SPSS macro designed to test multiple mediator models (Preacher & Hayes,
2008). The macro relies upon the product-of-coefficients mediation approach and
bootstrapping statistical methods. Results are first described in terms of the overall fit of
the mediational models (see Table 8), indicating the extent to which provider
stigmatization accounted for a significant percentage of the variance in the engagement in
care outcome measures. Results are secondarily described using illustrative figures of
separate a (IV to mediator), b (mediator to DV), c (full direct effect of IV on DV), and c'
(remaining direct effect of IV on DV after accounting for indirect effects via mediators)
paths. Although Sobel’s test and bootstrapping procedures do not rely on examining the
statistical significance of separate a and b paths (e.g. Baron and Kenny’s causal steps
mediation approach), these figures provide useful information about the relationships
between the individual variables in the model. Lastly, results are described in terms of the
significance of their unstandardized coefficients from Sobel’s test of the indirect effects
of provider stigmatization (experimental IV) on engagement in care via the mediating
pathways (ab paths) of the model. Confidence intervals (CI) pertaining to the coefficients
were created via bootstrapping resampling procedures and are also provided in Tables
9.1-9.4 and Tables 10.1-10.9.
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Intention-based mediation models. In focusing on the intention-based mediation
models, it was hypothesized that participants’ feelings of comfort and perceptions of
stigmatization within the patient-provider interaction would mediate the effect of
stigmatization (as operationalized as “stigma” and “non-stigma” randomized conditions)
on participants’ decisions to engage in care and openly engage in conversations about
risk behaviors regarding sexuality, substance use, and medication non-adherence. Results
described below outline the performance of the proposed mediator models, noting overall
model fit, as well as providing information about the specific individual associations
(model paths) between all of the included variables in the models (e.g. IVs, mediators,
DVs).
Mediational model fit. Findings related to overall model fit provided support for
the present study’s primary mediational hypotheses, such that the negative effects of
provider stigmatization (experimental manipulation) on engagement in care were
significant and these effects were mediated through the IV’s negative effects to
participants’ perceptions of stigmatization and feelings of comfort. As shown in Tables
9.1 to 9.4, the total direct and indirect effects of provider stigmatization accounted for a
significant proportion of the variance in participants’ intentions to remain in care, F(3, 86)
= 122.90, p < .001, R2 = .80, disclose risky sexual behavior, F(4, 85) = 26.69, p < .001, R2 =
.54, disclose substance-related behaviors, F(4, 85) = 23.69, p < .001, R2 = .51, and disclose

medication adherence difficulties, F(4, 85) = 10.90, p < .001, R2 = .31.
Individual a and b pathways. Pathways from the IV to the mediating variables
(a1-a3) were all significant with unstandardized path coefficients ranging from -3.67 to
3.23 (all ps < .001), demonstrating the negative effects of provider stigmatization
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(experimental manipulation) on participants’ perceptions of stigmatization and feelings of
comfort. Differences were noted among intention-based outcome models with regards to
the significance of b paths from mediating variables to DVs, such that perceptions of
stigma, general patient comfort, and specific comfort measures related to disclosure did
not yield significant regression paths to every intentions outcome measure. These
findings suggest that participants’ perceptions of stigmatization and feelings of comfort
did not consistently predict participants’ intentions to remain in care and open engage in
conversations related to risk behaviors, such that the performance of each mediator was
unique to the outcome variable examined. As noted in Figures 7.1-7.4, perceptions of
stigma yielded a significant b path in models predicting intentions to remain in care (B =
-.57, p < .001), intentions to disclose sexual risk behaviors (B = -.44, p < .01), and
intentions to disclose medication adherence difficulties (B = -.41, p < .05), with a trend
noted for intentions to disclose substance-related risk behavior (B = -.30, p < .1). The
path coefficients for general patient comfort were only significant for models predicting
intentions to remain in care (B = .55, p < .001) and intentions to disclose sexual risk
behavior (B = .47, p < .05), with specific disclosure-related comfort measures being
significantly associated only with intentions to disclose substance-related risk behavior
(B = .37, p < .1).
Direct c and c' pathways. As noted in Figures 7.1-7.4, direct effects, as indicated
in c pathways from the IV to the DV, were all significant with unstandardized path
coefficients ranging from -1.61 to -3.40 (all ps < .001), indicating that the experimental
stigma condition was predictive of participants’ intentions to remain in care, disclose
sexual risk behavior, disclosure substance-related risk behaviors, and disclosure
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medication adherence difficulties. When indirect effects of the IV via the mediating
variables were accounted for, remaining direct effects (c' path coefficients) of the
experimental stigma condition (IV) on intentions-based outcome variables were found to
be non-significant, indicating the presence of mediation (see Figures 7.1-7.4). The latter
finding supports the hypothesis that the negative effects of provider stigmatization on
patients’ intentions to engage in care are mediated by HIV+ patients’ ability to perceive
the stigmatization within the patient-provider relationship and also their experience of
lower levels of comfort.
Sobel’s test of indirect effects and bootstrapping resampling analyses. Results
from Sobel’s test of indirect effects and additional bootstrapping analytical procedures of
the macro (Preacher & Hayes, 2008) provide a final source of support for the present
study’s primary mediational hypotheses regarding the effects of provider stigmatization
(experimental manipulation) on engagement in care being mediated through the IV’s
effects to participants’ perceptions of stigmatization and feelings of comfort. Indeed,
findings from Sobel’s tests and bootstrapping procedures supported all intentions-based
mediation models, such that the total indirect effects of the experimental stigma condition
(IV) on the intent-based DVs (remain in care, disclose risk behaviors) via participants’
perceptions of stigma and reports of comfort were significant at the p < .001 level for
each model (see Tables 9.1-9.4). Similarly, percentile based and bias corrected and
accelerated 95% CI ranges did not include a value of zero for any of the models,
providing further support for the significance of the models’ total indirect effects, as
obtained through bootstrapping resampling procedures. As shown in Tables 9.1-9.4, there
were differences among the “intentions-based” models with regard to the significance of
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individual mediating ab paths, such that all mediating pathways (e.g. perceptions of
stigma, general comfort, disclosure specific comfort) were not significant in every model.
These findings suggest that although all individual mediating paths (e.g. stigma
comfort  intent to disclose substance-related risk behaviors) did not significantly
predict every outcome variable, the composite of all the mediational paths of the model
(i.e. stigma  perceptions of stigma, comfort, disclosure comfort  intentions outcome)
were successful in predicting HIV+ participants intentions to remain in care and disclose
risk behavior related to sexual activity, substance use, and medication non-adherence.
Significant mediating pathways for the “intent to remain in care” model included
perceptions of stigma (B = -1.86, p < .001) and general patient comfort (B = -1.71, p <
.001). The “intentions to disclose sexual risk behavior” model included the same
mediating pathways, with the perceptions of stigma (B = -1.86, p < .001) and general
patient comfort (B = -1.71, p < .001) paths both having significant path coefficients,
while the path for the sexual disclosure comfort measure did not reach significance. The
comfort measure concerning substance-related disclosure was the only significant
mediating pathway (B = -1.11, p = .007) for the “intent to disclose substance-related risk
behavior” model, with a trend noted for the perceptions of stigma path (B = -.98, p = .08).
Finally, for the “intent to disclose HAART non-adherence” model, Sobel’s test of indirect
effects indicated that perceptions of stigma was a significant mediating pathway (B = 1.31, p = .04). However, confidence interval ranges obtained through bootstrapping
resampling procedures contained a value of zero for both percentile and bias corrected
and accelerated CIs, suggesting that mediating pathway coefficient may not statistically
differ from zero.
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Disclosure-based mediation models. In focusing on the disclosure-based
mediation models, it was hypothesized that participants’ feelings of comfort and
perceptions of stigmatization within the patient-provider interaction would mediate the
effect of stigmatization (as operationalized as “stigma” and “non-stigma” randomized
conditions) on participants’ decisions to disclose sensitive information about their actual
sexual behavior, substance use, and medication adherence practices. Results described
below outline the performance of the proposed mediator models, noting overall model fit,
as well as providing information about the specific individual associations (model paths)
between all of the included variables in the models (e.g. IVs, mediators, DVs).
Mediational model fit. Findings related to overall model fit failed to provide
support for the present study’s primary mediational hypotheses, such that the effects of
provider stigmatization (experimental manipulation) on disclosure were non-significant
and these effects were not mediated through participants’ perceptions of stigmatization
and feelings of comfort. As shown in Table 8, the total direct and indirect effects of
provider stigmatization did not account for a significant proportion of the variance in any
of the disclosure-based outcome models. This is largely expected given that no
significant differences between the groups were found during bivariate analysis (t-tests)
on any of the disclosure-based outcome variables, leaving very little between group
variance to be explained. The few significant findings from mediational analyses are
reported with the understanding that groups did not significantly differ from each other.
A trend was noted for the “disclosure of lifetime sexual partners” model, with the
manipulation of provider stigmatization accounting for 7% of the variance in the number
of lifetime sexual partners reported by participants, F(4, 72) = 2.46, p < .10, R2 = .07. The
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direction of this effect was unexpected, as the presence of stigma was associated with
disclosure of greater number of lifetime sexual partners. Further discussion of results for
the disclosure-based outcomes is completed with consideration of the poor fit of the
mediational models.
Individual a and b pathways. As with “intentions-based” outcomes, pathways
from the IV to the mediating variables (a1-a3) were all significant with unstandardized
path coefficients ranging from -3.67 to 3.23 (all ps < .001), demonstrating the negative
effects of provider stigmatization (experimental manipulation) on participants’
perceptions of stigmatization and feelings of comfort. Few significant findings were
noted among disclosure-based outcome models with regards to the significance of b paths
from mediating variables to DVs, such that perceptions of stigma, general patient
comfort, and specific comfort measures related to disclosure did not yield significant
regression paths for many of the disclosure outcome measures. Such findings suggest that
participants’ perceptions of stigmatization and feelings of comfort were largely not
associated with participants’ decisions to disclose risky behaviors. As noted in Figures
8.1-8.9, perceptions of stigma did not yield any significant b path in the disclosure-based
models. The b path coefficients for general patient comfort were only significant for
models predicting disclosure of lifetime drug use (B = -.32, p < .05), frequency of drug
use in past three months (B = -.06, p < .05), with specific disclosure-related comfort
measures being significantly associated with disclosure of lifetime sexual partners (B = .23, p < .01).
Direct c and c' pathways. In examining the direct relationship between
stigmatization and patients’ disclosure of risk behavior, findings largely failed to provide
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support for the present study’s primary hypotheses. As noted in Figures 8.1-8.9, direct
effects, as indicated in c pathways from the IV to the DV, were non-significant for seven
of the nine disclosure-based models, indicating that the experimental stigma condition
was largely not predictive of participants’ actual disclosure of sexual risk behavior,
substance use, and HAART non-adherence. Trends were noted for the direct path for
recent condom use and recency of missed HAART doses (see Figures 8.3 & 8.8), such
that the presence of provider stigmatization (experimental manipulation) was associated
with lower disclosure of failure to use condoms and missing recent doses of HAART.
When indirect effects of the IV via the mediating variables were accounted for, remaining
direct effects (c' path coefficients) of the experimental stigma condition (IV) on condom
use remained at a trend level, while effects to recency of missed HAART doses were
found to be non-significant, providing initial support for the presence of mediation in this
model.
Sobel’s test of indirect effects and bootstrapping resampling analyses. Results
from Sobel’s test of indirect effects and additional bootstrapping analytical procedures of
the macro (Preacher & Hayes, 2008) failed to provide strong support for any of the
proposed disclosure-based mediation models. Indeed, the total indirect effects of the
experimental stigma condition (IV) on the disclosure based DVs (disclosure of risk
behaviors) via participants’ perceptions of stigma and reports of comfort were nonsignificant for all the disclosure-based models (see Tables 10.1-10.9). Similarly,
percentile based and bias corrected and accelerated 95% CI ranges included values of
zero for all of the models, providing further support for the non-significance of the
models’ total indirect effects, as obtained through bootstrapping resampling procedures.
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Additionally, as shown in Tables 10.1-10.9, very few models possessed any individually
significant mediating pathways (e.g. perceptions of stigma, general comfort, disclosure
specific comfort).
Perceptions of stigma did not account for significant mediating pathways in any
of the disclosure-based models. Sobel’s test of indirect effects indicated that generalized
patient comfort provided a significant mediating pathway for disclosure of recent drug
use (B = .20, p < .05) and disclosure of lifetime drug use (B = 1.00, p < .05). However,
confidence interval ranges pertaining to disclosure of lifetime drug use contained a value
of zero for bias corrected and accelerated CIs, suggesting that mediating pathway
coefficient may not statistically differ from zero. The mediating pathway through
disclosure specific comfort measures was found to be significant for only the “disclosure
of lifetime sexual partners model” (B = .70, p < .01). Based on these findings, alternative
single mediator models were examined. These post hoc analyses revealed that stigma
condition accounted for a significant amount of variance in the disclosure of lifetime
sexual partners when disclosure-specific comfort was entered as the sole mediating
pathway (see Tables 11.1 & 11.2). No significant improvements were noted in overall
model fits for lifetime and recent drug use models (see Tables 11.1, 11.3, 11.4).

82
Discussion
Summary of major findings. HIV remains a highly stigmatized illness and is
associated with a number of adverse consequences among HIV+ individuals (Lee,
Kochman, & Sikkema, 2002; Vanable et al., 2006).The experience of stigmatization in
health care settings may be particularly detrimental to the health and well being of
persons living with HIV. Although many recent studies have documented the existence of
stigmatization in medical treatment settings, few have examined the impact of provider
stigmatization on HIV+ patients’ decisions to engage in various aspects of HIV care. The
present study used an experimental design and a behaviorally oriented approach to assess
patients’ reactions to medical treatment scenarios in order to examine the impact of
stigmatization on health care engagement. It was hypothesized that participants’
perceptions of stigmatization and feelings of comfort within the patient-provider
relationship would mediate the effects of provider stigmatization (experimentally
manipulated) on participants’ intentions to remain in care and openly engage in risk
reduction conversations, as well as their decisions to disclose actual risk behaviors.
Hypotheses were tested using an experimental design that randomized participants into
“stigma” and “non-stigma” vignette conditions in which HIV+ participants were
presented with visual stimuli and audio recordings depicting hypothetical patientprovider interactions. Stigmatizing and non-stigmatizing vignettes differed in terms of
distancing, avoidance, use of extra precautions, negative demeanor, and judgmental
language. Primary study analyses were conducted within the framework of multiple
mediator models based on the product-of-coefficients approach and bootstrapping
analytical techniques.
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Two important findings emerged from the study. The first major finding pertains
to the negative impact provider stigmatization can have on HIV+ patients’ sense of
comfort, their perceptions of the patient provider relationship, and ultimately their
decisions related to care and sharing sensitive, health-related information with their
healthcare providers. Findings from bivariate and mediational analyses confirmed that
when the provider behaved in stigmatizing ways, HIV+ participants reported higher
perceptions of stigmatization, more discomfort, and lower intentions to engage in care.
Thus, participants were impacted in terms of their cognitive appraisal of the interaction,
their emotional responses, and subsequent intentions to engage openly with the provider.
Indeed, exposure to the “stigmatizing” provider lead to greater feelings of being
devalued, more negative perceptions of the patient-provider relationship, and greater
discomfort. Additionally, participants randomized to the “stigma” condition also reported
having significantly lower intentions to remain in care and disclose sensitive health
information regarding sexual risk activity, substance use, and medication non-adherence
to the provider viewed in the vignette.
In contrast to the “intentions-based” findings, no significant differences were
noted for outcomes that focused on actual disclosure of risky sexual, substance, and nonadherence related behaviors, with the presence of provider stigmatization having little
effect on participants’ willingness to disclose sensitive information on the computerized
survey. Indeed, participants randomized to the “stigma” and “non-stigma” conditions
reported similar numbers of sexual partners, alcohol and drug use habits and histories,
and medication adherence behaviors. Trend-level differences were noted for reports of
condom use and disclosure of the recency of missed HAART doses, with participants
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exposed to the “non-stigmatizing” provider being more likely to report instances of
unprotected sex and lapses in medication adherence. These trend-level differences
suggest that provider stigmatization may influence HIV+ patients’ decisions to be
forthcoming about potentially risky sexual behaviors and less-than-perfect medication
adherence. Additional research is warranted to explore these intriguing, yet inconclusive,
trends in the data.
The second major finding of this study pertains to the mediating pathways
through which provider stigmatization negatively impacted patients’ intentions to openly
communicate with their providers and effectively engage in their care. As hypothesized,
findings from mediational analyses demonstrated that the effects of provider
stigmatization (e.g. the experimental manipulation) on intention-based outcome measures
were mediated by patients’ perceptions of stigmatization within the patient provider
interaction and their feelings of comfort. Indeed, models containing stigma condition
(IV), patient perceptions of stigmatization (mediator), general patient comfort (mediator),
and measures of disclosure-specific comfort (mediator) performed very well in predicting
participants’ intentions to remain in care and disclose risky sexual, substance use, and
medication non-adherence behaviors with models explaining 30-80% of the variance in
these intention-based outcome measures. For all of these models, the direct effect of
stigma condition became non-significant after accounting for the total indirect effects of
the mediating pathways, an indication of the presence of mediation. To elaborate on these
findings, when the provider engaged in stigmatizing behaviors, HIV+ patients’ (1)
perceived the devaluing nature of these behaviors, (2) their perceptions of the patientprovider relationship were harmed, and (3) their level of psychological comfort within
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the treatment interaction decreased. Subsequently, these negative cognitive appraisals and
affective responses to the stigmatizing interaction influenced their decisions to decline
future treatment with the provider and lessened their willingness to disclose sensitive
information about their health behaviors and engage in discussions related to sexual risk
behaviors, substance use, and medication adherence difficulties.
As noted, provider stigmatization (as experimentally manipulated) was not
associated with significant differences in actual disclosure of risk behaviors among study
participants in the “stigma” and “non-stigma” groups. Largely due to this lack of
significant group differences and associated lack of between group variance, mediational
models aimed at explaining the effect of stigma on patient disclosure performed poorly.
Additionally, seven of the nine disclosure-based outcome variables required
transformations due to non-normal distributions (e.g. extreme outliers regarding sexual
partner numbers, skew due to low frequency use of drugs and alcohol) with several of the
variables still not adhering to what could be considered preferred standards of skew and
kurtosis even after the transformations were performed (though they were greatly
improved). Indeed, variance explained through these mediational models ranged from
.3% to 7% (a trend level effect for prediction of lifetime sexual partners). Examination of
mediating paths suggests that even though participants exposed to stigmatizing provider
behaviors reported perceiving more stigmatization and feeling less comfortable with the
provider (IV to mediator paths), these perceptions and feelings did not influence the
degree to which patients disclosed sensitive personal information on the computerized
survey (mediator to DV paths).

86
Study strengths, limitations, and future directions. This present study is the
first to utilize an experimental design to examine the detrimental effects of provider
stigmatization on HIV+ patients’ treatment decisions and intentions to disclose sensitive
health information. The strength of this design is that it provides evidence of a causal
relationship between provider stigmatization and patient response.
A second strength of the present study concerns the use of a multidimensional
operationalization of HIV-related provider stigmatization. Stigma measures from
previous empirical studies involving patient self-report are often restricted to small item
sets that focus on extreme behavioral markers of stigmatization such as treatment refusal.
The present study addressed this limitation by carefully constructing detailed
representations of provider stigma in vignettes depicting a range of provider behaviors
related to both demeanor and the provision of care. In addition, the present study allowed
for time-sensitive assessments of immediate reactions to provider stigma, thereby
lessening the possibility of recall errors. Finally, use of a computerized design likely
increased patients’ perceptions of confidentiality, thus decreasing the chances of socially
desirable responding often found in traditional survey based studies.
One limitation of the present study concerns the use of a dichotomized
experimental manipulation of stigma, with one condition being highly stigmatizing and
the other containing no elements of a stigmatizing interaction. In focusing on the highly
stigmatizing interaction, the vignette was created to contain numerous examples of
stigmatizing behaviors to characterize what a “stigmatizing provider” might look like. In
reality, it may be unlikely that a provider would demonstrate this entire spectrum of
stigmatizing behaviors, and if they did, such behaviors would probably not take place in
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the span of a single treatment visit. Given that this study was the first of its kind to
experimentally examine the impact of provider stigma on medical care decisions, it was
deemed important to first get a clear picture of the effects of HIV-stigmatization in a very
apparent form. Future experimental research should examine the effects of stigmatization
as operationalized on a continuum, either in the level of extremity, the quantity, or the
types (e.g. verbal, non-verbal) of stigmatizing behaviors patients are exposed to.
A second limitation of the present study concerns the use of hypothetical
vignettes. Vignettes were developed to provide a realistic depiction of stigmatizing and
non-stigmatizing medical appointments. Further, participants were encouraged to imagine
themselves in the situation that was depicted in the vignette, “as if they were the patient.”
By participant report, these efforts were largely successful. HIV+ patients in the validity
study indicated that the behavior of the provider in the stigmatizing vignette was indeed
stigmatizing and realistic, offering validity to the content of the vignettes. However, even
the most carefully constructed vignettes are only modest approximations of what patients
experience during an actual provider visit. The lack of significant findings for disclosure
of actual sexual behavior, substance use, and adherence difficulties may be due to
inherent design limitations associated with using vignettes as a mode of delivery for an
experimental manipulation of an interaction. Though these items were read to the
participants in the voice of the provider to mimic as closely as possible what it would be
like to disclose sensitive information to the provider, this approximation may not have
been a powerful enough mode of delivery to influence participants’ comfort with
disclosing health behavior lapses. In sum, although the content of the vignettes may have
been powerful in eliciting reactions from participants, the mode of delivery may have
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been too weak of an approximation to affect participants’ actual disclosure of risk
behaviors.
A final limitation of the present study is the presence of high overlap between
variables as indicated by the high correlations among the study’s mediating variables.
Although the multiple mediator statistical design of the present study allowed for
correlations between the included mediator variables, future studies would benefit from
conceptualizing and/or operationalizing patients’ reports of comfort and perceptions of
stigma in ways that better allow for more distinct comparisons of the effects of these
variables. In addition, to further extend the findings from the present study, future
experimental designs should include participant randomization to realistic stigmatizing
and non-stigmatizing healthcare care experiences taking place within real medical
facilities and portrayed by live “actors.” In so doing, research could provide additional
insight into the impact of provider stigmatization on patient behavior. Ultimately, studies
that utilize experimental manipulations of stigmatization will help to provide a more
comprehensive understanding of the ways in which provider stigma effects HIV+
patients’ decisions to communicate openly with their provider and effectively engage in
their care. This is important within the context of healthcare not just within the United
States, but globally as well. In looking to future research, the present study provides a
step-by-step research framework (qualitative interviews, vignette development and
testing, experimental procedures) for identifying the content of stigmatizing behavior
within treatment settings and understanding its impact on HIV+ patients. The portability
of this protocol allows for the examination of provider stigmatization across many
cultures and treatment settings. With future research and intervention efforts, it is the
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hope that provider stigmatization will eventually be examined, understood, and decreased
on a global scale.
Implications for the IMCHB model and practical applications. Findings from
the present study provide support to Cox’s (1982) IMCHB model, emphasizing the
impact of patient-provider relationships on treatment decisions and patient behaviors. As
discussed, findings demonstrated that the effects of provider stigmatization were
mediated by patients’ feelings of comfort within the treatment interaction, patients’
abilities to perceive the presence of devaluing nature of the stigmatizing behaviors, and
their negative views of the quality of the patient-provider relationship (with the latter two
comprising the study’s perceptions of stigma measure). As dictated in Cox’s (1982)
IMCHB model, positive patient-provider interactions are defined in large part by the
provider’s ability to demonstrate their competency, provide affective support, give the
patient control in treatment decisions, and provide health information in the proper
amounts as based on the highly individualized needs of the patient. Provider
stigmatization likely inhibits the development of positive patient-provider relationship, as
patients are left feeling devalued, disrespected, emotionally unsupported, uncomfortable,
and vulnerable due to the behaviors of the persons responsible for their medical care. As
a function of stigmatization, providers may fail to form positive working relationships
with their HIV+ patients. In failing to achieve a sense of comfort and trust with their
providers, patients’ may be less willing to disclose important information about their
health and health behaviors in fear of further negative judgment and emotional pain.
Without such patient honesty, physicians are not able to obtain a complete picture of their
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patients’ lives and health conditions and, consequently, are limited in their ability to
provide high quality health care.
In focusing on practical implications, findings from the present study suggest that
instances of provider stigmatization, expressed through specific behaviors and overall
demeanor, play an important role in predicting which patients will likely remain in care
and openly discuss their risk behaviors and medication adherence difficulties. As
demonstrated in the present study, the process of evaluating the quality of the patientprovider relationship and making decisions about disclosure can begin as early as the first
appointment with the provider. Thus, it is important for medical care providers to
understand how certain protocols (e.g. use of gloves, frequent assessments of sexual
behavior, etc.), language, and behaviors within the treatment settings may be perceived as
stigmatizing by patients and hence detract from this process.
Routine training programs for health care providers would benefit from focusing
on practical steps to prevent HIV-related stigmatization within treatment settings. Such
trainings should aim to help professionals in the health care field gain an awareness of
how even the subtlest of their behaviors may be interpreted by the HIV+ patients they
treat. A first step in developing such trainings would be to undertake future research to
pinpoint the “hot-button” provider behaviors noticed most frequently by HIV+ patients
and found to cause the most damage to the patient-provider relationship. Identifying a
few key areas for behavioral intervention would allow for the fairly quick training of a
large number of providers, with a chance for maximum recall and dissemination of
learned skills. It is also suggested that providers be exposed to HIV care settings and to
HIV+ patients multiple times throughout their medical training to increase their skill,
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confidence, and comfort in developing working relationships with this patient population.
By teaching providers to focus on and potentially reshape certain aspects of their
demeanors, language, and nonverbal behaviors, it is the hope that positive patientprovider relationships can be formed and the overall quality of patient experiences within
HIV care could be increased.
Conclusions
In summary, the present study provided initial evidence regarding the negative
effects of provider stigma on HIV+ patients’ willingness to openly communicate about
risk behaviors and make decisions about the future of their care. Compared to patients
who were not exposed to provider stigmatization, patients exposed to stigmatizing
language and behaviors from the healthcare provider were less willing to remain in care
and less willing to disclose sexual and substance use related risk behaviors and
medication adherence difficulties. These effects were mediated by patients’ perceptions
of the degree of stigmatization present within the patient provider relationship and their
feelings of comfort throughout the medical appointment. Future explorations of the
impact of provider stigmatization on HIV+ patient’s healthcare decisions and health
outcomes are needed in order to inform the development of stigma reduction
interventions and ultimately improve the medical treatment of HIV+ individuals.

Table 1. Patient Reports of Provider Stigmatization
First
Author
Agne
(2000)

Study
Design

Study
Objectives

qualitative
(pilot):
interviews

1. describe
predictors
of
serostatus
disclosures
to
healthcare
providers

quantitative
(primary):
self-report
survey

Sample

Pilot:
HIV+ (N=7)
- gender: 5 men
-age range: 25-35
-health status:
many experienced
multiple health
problems
Primary:
HIV+ (N=107)
-gender: 89% male
-sex. or: 75%
homosexual
-race: not provided
-M age: not
provided

Stigma
Variable/Meas
ure
Pilot:
interviews
regarding
healthcare
experiences and
disclosure

Pilot:
-all reported that they
disclosed to their
providers
-many noted that they
would not disclose in
the future because of
negative experiences
with stigma at time of
disclosure
-stigma experiences:
avoidance and delay
of treatment,
disrespectful
treatment, inadequate
care
Primary:
-despite feeling
stigmatized, most
patients still disclosed
-provider relational
factors important to
disclosure decision

Limitations

Pilot:
-very small
sample size
Primary:
-poor stigma
measure: not
“provider
specific” and only
1 item
-patient reports
perceived stigma
only, with no
observable
measures of
provider stigma

92

Primary:
Perceived
Stigma
- one Likert
item
- general
perceptions of
HIV as
stigmatizing
disease
- items from
Medical
Interview
Satisfaction
Scale
- ratings of
provider
communication
and care quality

Findings

Blake
(2008)

Bodenlos
(2007)

qualitative:
focus
groups

quantitative:
self-report
survey

1. describe
experiences
of women
receiving
HIV testing
and care

Interviews
about HIV
testing and
health care
experiences

HIV+ (N=109)
-gender: 59% male
-sex. or: not
provided
-race: 85% Black
-M age: 38

Attitudes
Toward HIV
Health Care
Providers
Scale:
- 19 Likert
items
- newly created
Professionalism
and Emotional
Support
subscales

-HIV stigma as a
barrier to testing for
at-risk HIV- women
-HIV+ women noted
that having a caring
provider was critical
to a positive provider
relationship and their
decision to stay in
care

-patient reports of
perceived stigma
only, with no
observable
measures of
provider stigma

- positive relationship
with healthcare
provider team
predictor of better
appt. attendance

-stigma not
overtly measured
in scale which
focuses more on
provider
relationships

-study more
tightly focused on
providerrelationships
rather than
provider based
stigma

-appt attendance
measured
retroactively so
cause and effect
relationship not
able to be stated
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1. assess
how
attitudes
towards
healthcare
providers
impact
appointmen
t
attendance
among
HIV+
patients

HIV+ women
(N=23)
and HIV- at risk
women (N=41)
-gender: 100%
female
-sex. or: not
provided
-race: 59% Black
-M age: 32

Buseh
(2006)

Elford
(2008)

qualitative:
longitudinal
individual
interviews

quantitative:
self-report
survey

1. examine
HIV+
African
American
women’s
life
experiences
and
responses
to stigma

HIV+ women
(N=29)
-gender: 100%
women
-sex. or.: not
provided
-race: 100% black
-M age: 40

-interviews
about life
experiences and
HIV, including
stigma
experiences

1. assess
the extent
to which
HIV+
persons
experience
discrimination
because of
their
serostatus

HIV+ (N=1385)
-black, hetero.
women (n=448)
-black, hetero. men
(n=210)
-gay or bisexual
men: (n=727)
(85% white)
-M age: mid to late
30s

Discrimination
due to HIV
status:
- one item
(have you been
treated unfairly
because of
status)
- followed by
list of persons
to check for
presence of
perceived
discrimination

-stigma (general)
caused multiple
constraints: damaged
self esteem, loss of
hope, rejection, social
restrictions

-patient reports of
perceived stigma
only, with no
observable
measures of
provider stigma

-stigma from
-small sample
providers caused
women to perceive the
providers as lacking in
beneficence and
competence
-30% reported
discrimination
-of the 414 people
reporting
discrimination: 50%
discriminated by
healthcare workers

-stigma effects
not providerspecific
-limited stigma
assessment
-patient reports of
perceived stigma
only, with no
observable
measures of
provider stigma
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- discrimination (in
general) associated
with depression,
suicidal thoughts, time -maybe unable to
since diagnosis and
separate out racial
body signs of AIDS
or sexual
orientation stigma
from HIV stigma

Gardezi
(2008)

Kinsler
(2007)

qualitative:
individual
interviews

quantitative:
survey at
baseline and
6 month
follow-up

1. better
understand
HIVrelated
stigma and
its potential
effects to
prevention
practices,
access to
treatment,
and disease
response

HIV+ (N=223)
-gender: 80% male
-sex or.: 54%
infected through
homo. contact
-race: 46% black
-M age: not
provided

-interviews
with HIV+:
impact of
diagnosis,
disclosure,
experiences
accessing
health and
support services

- HIV+ positive
participants spoke
highly of healthcare
they receive, but they
also encountered
discriminatory
attitudes from some
healthcare and service
providers

-focus groups
with HIV-: HIV
in community,
stigma, and
associated
issues

-general distrust of
medical system and
official institutions
and tendencies to
avoid seeking medical
care and social
services.

Perceived
Stigma:
-HCSUS
measure
- 4 items
- health care
provider
specific
(discomfort,
treated as

-provider stigma
reported by ¼
(baseline) and 1/5
(follow up) of
participants
-more than half
reported low access to
healthcare

-provider stigma
not distinctly
separated from
general
community
stigma
in discussion
-HIV-related
stigma not
separated from
racial stigma
creating possible
confounds
- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma
-small number of
stigma items
(may lack
sensitivity)
- patient reports
of perceived
stigma only, with
no observable
measures of
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1. evaluate
the
relationship
between
perceived
stigma
from a
healthcare
provider
and access

HIV+ (N=30)
HIV- (N=74)
-gender: 50%
female
-sex or.: not
provided
-race: East African
and Caribbean
indiv. in Canada
- age range: 17-54

to care
among
HIV+
patients
Lindau
(2005)

qualitative:
semistructured
individual
interviews

1. better
understand
the
healthcare
experiences
of HIV+
pregnant
women

inferior,
preferred to
avoid, refusal
of care)
HIV+ mothers
(N=15)
-gender: 100%
female
-race: mostly black
-M age: 28
-income: most
below poverty line

-interview
items regarding
experiences
with healthcare,
pregnancy,
contraception,
and perinatal
prevention of
HIV

-those with more
perceived stigma had
more than twice the
odds of reporting low
access to care
-10 women received
no or extremely
intermittent prenatal
care, with 4 receiving
limited and late-onset
care
-reported poor
attendance due to
previously negative
and dehumanizing
interactions with
health and child
welfare systems
-reported disrespect
(judgmentalism,
reluctance to provide
care for), lack of
regard for privacy and
confidentiality, refusal
of touch, refusal of
treatment

provider stigma

-small sample
size
-stigma
experienced by
HIV+ women in
study may be
higher than
normal because
had added stigma
of being HIV+
and pregnant
- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma
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Marcenko
(1999)

qualitative:
six focus
groups

1. better
understand
the
healthcare
experiences
of HIV+
pregnant
women

HIV+ mothers
(N=40)
-gender: 100%
female
-race: 70% black
-time since dx:
50% between 4 and
5 years
-M age: 34

-interviews
about
experiences
with healthcare,
family
planning,
parenting

-many described
experiences in which
providers were
disrespectful,
insensitive, and
unhelpful
-reported abrupt visits,
being ignored for long
periods of time, and
instances in which
they were judged and
confronted about their
lifestyles

-small,
nonrandom
sample of women
- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma

-many women
reported that their
providers did not
make efforts to
educate them about
medication regimens
and side effects,
leading to decreased
adherence
Rintamaki
(2007)

qualitative:
individual
and group
interviews

HIV+ veterans
(N=50)
-gender: 100%
male
-sex or.: 68%
hetero.

Perceived
Stigma
-3 provider
specific
interview items
as part of

-subtle (nonverbal
communication,
nervousness) and
extreme (abuse, denial
of services) examples
of stigma noted by

- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma
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1. examine
the
healthcare
experiences
of HIV+
men in the

military
and their
perceptions
of stigma
in
healthcare
contexts

Schuster
(2005)

quantitative:
self-report
surveys

1. to
determine
whether
HIVinfected
people
perceived
that
physicians
and other
health care
providers
have
discriminat
ed against
them.

-race: 46% black
-M age: 50

overall stigma
discussion
-open ended
interview
questions about
forms and
effects of HIV
stigmatization

HIV+ (N=2466)
-gender: 77% male
-sex or.: 56% msm
activity
-race: 49% white
-M age: not
provided

Perceived
Stigma
-HCSUS
measure
- 4 items
- health care
provider
specific
(discomfort,
treated as
inferior,
preferred to
avoid, refusal
of care)

most participants
-sensing dislike
associated with loss of
trust and willingness
to return to treatment

-small sample
may not be
generalizable
(male, vets, older,
had HIV long
time)

- certain provider
behaviors can be
perceived as
stigmatizing even if
they are not intended
as such
-26% reported at least
1 type of stigma in
clinical settings

-limited
assessment of
stigma

-provider stigma
linked to lower access
to care, lower quality
of care, and lower
trust in doctors

-only included
persons who had
disclosed their
status to their
providers
-may be difficult
for some patients
to separate
experiences of
other stigma from
their HIV stigma
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Surlis
(2001)

qualitative:
individual
interviews

1. explore
HIV+
patients’
experiences
during
hospitalizat
ion and
perceptions
of stigma
from
nursing
staff in
Ireland

HIV+ (N=10)
-gender: 70% men
-sex or.: not
provided
-race: not provided
-M age: not
provided, with
range between 2950

Interview (open
style) with
focus on
patient’s
positive and
negative
experiences of
nursing care

-patients reported both
positive and negative
interactions with
nurses

-extremely small
sample limits
generalizability

-stigma displayed by
nurses in their speech
by blaming the
patients and/or
treating them
differently

- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma

-effects of stigma
included: patient
shame and discomfort,
delays in receiving
treatment, lesser
quality of treatment
compared to other
patients, unwanted
disclosure of status
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Thrasher
(2008)

quantitative:
interview at
baseline, 6
month, and
12 month
follow-up

1. assess
relationship
between
discriminatory
healthcare
experience,
provider
distrust,
race, and
adherence

HIV+ (N=1911)
-minority: over
50%
-gender: 33%
female
-sex or.: 28%
homosexual.
-age: 35% < 35
-yrs since dx: 3
-non-minority: <
50%
-gender: 12%
female
-sex or.: 69%
homosexual.
-age: 30% < 35
-yrs since dx: 3

Interview
(structured)
-discriminatory
healthcare
experiences
- HCSUS
measure:
-6 dich. items
(3 at
baseline, 3 at
follow-up)
-hostility and
disrespect,
lessened
attention,
refused service,
discomfort,
treated as
inferior,
preferred to
avoid

-41% reported at least
1 of 6 discriminatory
experiences
-minorities less likely
to report
discriminatory
experiences
-no direct relationship
between provider
discrimination and
HAART adherence
-indirect relationship
found with effects of
provider
discrimination to
adherence found
through decreased
trust in providers and
weakened beliefs in
worth of HAART

-newer study
using older
sample (1996)
may not reflect
more current
discriminatory
experiences
-discrimination
reported “since
had HIV” may
bias results as
some participants
could have
reported on
incidents early on
in epidemic
- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma
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Wingwood
(2007)

quantitative:
survey read
by
interviewers

1. examine
the
relationship
between
discriminat
ory
experiences
and health
outcomes
among
HIV+
women

HIV+ women
(N=366)
-gender: 100%
female
-sex or.: not
provided
-race: 84% black
-M age: 35

Discrimination
-3 items
(yes/no)
-denied medical
care, lost job,
had to move
because of
status

-16% reported
experiencing
discrimination
-4.4% denied medical
care
-HIV discrimination
linked with poorer
health outcomes in
black women
including: greater
stress, lower selfesteem, more
depression, more
unprotected sex, less
likely to seek care

-medical
discrimination
not singled out
from other stigma
items in analyses
-limited
assessment of
stigma (3 items)
-unable to
separate racial
discrimination
from HIV
discrimination
- patient reports
of perceived
stigma only, with
no observable
measures of
provider stigma
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Table 2. Summary of Patient Reported Provider Stigmatization Studies
Stigmatizing Behavior related to Demeanor

First
Author
(Year)

Discomfort
or Negative
Affect
(Irritation,
Fear,
Nervousness)

Avoidance/
Ignoring/
Delayed
Treatment

Lack of
Touch

Inadequate
or
Differential

Refused
Treatment

X
X

X

X

X

X
X

X

X
X

X
X
X

X

X
X

X

X
X

X

X
X

X

X

X

X

X
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Agne
(2000)
Blake
(2008)
Bodenlos
(2007)
Buseh
(2006)
Elford
(2008)
Gardezi
(2008)
Kinsler
(2007)
Lindau
(2006)
Marcenko
(1999)
Rintamaki
(2007)

Nonverbal
Judgmental
Behaviors
Extra
Speech or other (Proximity, Precautions
Communication
Eye
Taken
Issues
Contact)

Stigmatizing Behavior related to Provision of Care

Stigmatizing Behavior related to Demeanor

First
Author
(Year)

Schuster
(2005)
Surlis
(2001)
Thrasher
(2008)
Wingwood
(2007)
Total

Nonverbal
Judgmental
Behaviors
Extra
Speech or other (Proximity, Precautions
Communication
Eye
Taken
Issues
Contact)

Stigmatizing Behavior related to Provision of Care

Discomfort
or Negative
Affect
(Irritation,
Fear,
Nervousness)

Avoidance/
Ignoring/
Delayed
Treatment

X

X

X
X

Lack of
Touch

Inadequate
or
Differential

Refused
Treatment

X

X

X

X

X

X
X

7

3

2

4

8

2

6

6
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Table 3. Frequency of Provider Stigmatization Instances-Qualitative Focus Groups
Stigmatizing Behavior
Judgmental Language (blame, assumptions about
transmission, condescension)
Avoidance or Distancing
Body Language (discomfort)
Demeanor Shifts
Extra Precautions (gloves, masks, etc.)
Non-competence in Treating HIV
Provided Differential Care because HIV+
Problems ignored because HIV+
Confidentiality Issues
Rushing Appointments or not Listening to Patient
Lack of Physical Contact
Refusal of Care

% of Participants (n=18)

56%
44%
28%
22%
22%
22%
22%
22%
17%
17%
11%
11%
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Table 4. Validity Sub-study: Vignette Comparisons
T
Perceptions of Stigma
Stigma vs. No Stigma (long form)
Stigma vs. No Stigma (short form)
Long Form vs. Short Form (stigma vignette)
Long Form vs. Short Form (no stigma vignette)

3.26**
7.16***
-1.70
.18

Comfort Ratings
Stigma vs. No Stigma (long form)
Stigma vs. No Stigma (short form)
Long Form vs. Short Form (stigma vignette)
Long Form vs. Short Form (no stigma vignette)

-3.78**
-7.19***
2.09
-2.50

Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001
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Table 5. Demographic Characteristics of Experimental Phase Sample
Full Sample
Stigma Condition
No-Stigma
(N=90)
(N=45)
Condition (N=45)
M (SD)
%
M (SD)
%
M (SD)
%
Age
45.2 (11.1)
45.7 (11.5)
44.6 (10.9)
Gender
Male
Female
Transgendered
Hispanic/Latino
Race
African
American
Caucasian
Employed
Paid Hours of
Work/Week

64%
33%
2%

64%
36%
2%

9%

7%

11%

52%
40%

53%
40%

51%
40%

29%

38%

20%

33 (14.6)

Have Primary
Relationship
Partner
High School
Education or
Less
Years since
HIV Diagnosis

64%
34%
1%

37.2 (13.7)*

25.4 (13.8)*

63%

67%

60%

31%

60%

53%

11.5 (7.6)

11 (7.5)

12 (7.2)

22%

22%

22%

HIV-related
Hospitalizations

29%

24%

33%

Taking HAART
Medications

83%

80%

87%

AIDS Diagnosis

Previous
3.61
Experience with
(6.56)
HIV Stigma
Note: * p < .05, ** p < .01, *** p < .001

4.29 (8.43)

2.93 (4.26)

Table 6.1. Correlation Table: Association of Mediators and Intention Outcome Variables

1
2
3
4
5
6
7
8
9
10

1
1
-.88***
-.84***
-.82***
-.89***
.10
-.71***
-.68***
-.57***
-.87***

2

3

4

5

6

7

8

9

10

1
.93***
.86***
.92***
-.17
.72***
.67***
.55***
.87***

1
.89***
.91***
-.20
.67***
.63***
.48***
.81***

1
.88***
-.17
.70***
.70***
.57***
.75***

1
-.18
.66***
.63***
.52***
.85***

1
-.172
-.128
-.103
-.096

1
.85***
.74***
.65***

1
.80
.63***

1
.52***

1

Legend:
1 (Perceptions of Stigma)
2 (Comfort-general)
3 (Comfort-sexual behavior)
4 (Comfort-substance use)
5 (Comfort-med adherence)
6 (Previous Experiences of Stigma)
7 (Intention to Disclose Sexual Risk Behaviors)
8 (Intention to Disclose Substance Use Risk Behaviors)
9 (Intentions to Disclose Medication Adherence Difficulties
10 (Intention to Remain in Care)
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Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001

Table 6.2. Correlation Table: Association of Mediators and Disclosure Outcome Variables

Perceptions
of Stigma
Comfortgeneral
Comfortsexual
behavior
Comfortsubstance
use
Comfortmed
adherence
Previous
Experiences
of Stigma

Lifetime
Sexual
Partners
(log)

Recent
Sexual
Partners
(log)

Recent
Condom
Use
Neglect

Recent
Drinking
Frequency
(log)

Recent
Drinking
Quantity
(log)

Recent
Illegal
Drug Use
Frequency
(log)
-.048

Recency of
Last
Skipped
Medication
Dose (log)
-.160

Overall HAART
Non-adherence
(log)

.010

Extent
of
Lifetime
Drug
Use
.046

.061

.138

-.082

-.025

-.127

-.211*

.111

.034

-.007

-.162

-.071

.134

.039

-.228*

-.203

.128

.098

.016

-.149

.031

.132

.041

-.122

-.149

.108

-.022

-.085

-.109

.000

.137

.042

-.067

-.163

.105

.044

.026

-.096

-.024

.160

-.030

.134

.173

.095

.081

.024

-.067

-.029

-.111

.060
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Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001

.016
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Table 7. Summary Statistics for Mediator and Dependent Variables
No-Stigma
Condition
(N=45)
M (SD)
Mediators
Perceptions of Stigma
Comfort-general
Comfort-sexual behavior
Comfort-substance use
Comfort-adherence
Intentions Outcome Variables
Intention to Remain in Care
Intention to Disclose Sexual Risk
Behaviors
Intention to Disclose Substance Use
Risk Behaviors
Intentions to Disclose Medication
Adherence Difficulties
Disclosure Outcome Variables
Number of Lifetime Sexual Partnersa
Number of Recent Sexual Partnersa
Recent Condom Use Neglect
Recent Alcohol Use Frequencya
Recent Alcohol Use Quantitya
Extent of Lifetime Drug Use
Frequency of Recent Drug Usea
Recency of Missed HAART Dosesa
Overall HAART Non-Adherencea

Stigma
Condition
(N=45)
M (SD)

T

2.00 (.82)
5.55 (1.11)
5.42 (1.11)
5.64 (1.43)
6.00 (1.33)

5.23 (1.52)
2.44 (1.69)
2.11 (1.77)
2.69 (1.82)
2.33 (1.72)

-12.54***
10.33***
9.64***
8.56***
11.31***

5.96 (1.45)

2.44 (1.69)

9.29***

4.89 (1.45)

2.90 (1.88)

5.70***

5.05 (1.50)

2.97 (1.88)

5.82***

5.33 (1.43)

3.72 (1.87)

4.50***

76.18 (296.82)
1.49 (2.90)
3.333 (1.78)
1.53 (.79)
1.53 (.97)
2.36 (1.23)
1.69 (1.13)
1.76 (1.50)
2.78 (3.40)

101.89 (244.99)
1.73 (2.90)
2.67 (1.65)
1.49 (.94)
1.51 (.843)
2.40 (1.20
1.53(1.06)
1.29 (.90)
2.93 (3.72)

.28
.55
1.84 Ɨ
.62
-.09
-.17
.76
1.90 Ɨ
.05

Note: a Means and standard deviations presented are based on non-transformed variables
for ease of viewing potential differences between groups. However, T-tests were
performed on Log transformed versions of these variables. Ɨ trend at p < .1, * p < .05, **
p < .01, *** p < .001
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Table 8. Summary Table of Mediational Model Fits
Dependent Variables
Adjusted R

2

Model Summary
df

F

Intention DVs
Intention to Remain in Care
Intention to Disclose Sexual Risk Behaviors
Intention to Disclose Substance Use Risk
Behaviors
Intentions to Disclose Medication
Adherence Difficulties

.804
.536

(3, 86)
(4, 85)

122.90***
26.69***

.505

(4, 85)

23.69***

.308

(4,85)

10.90***

.071
.012
.014
.029
.020
.027
.030

(4, 72)
(4, 84)
(4, 85)
(4, 85)
(4, 85)
(4, 85)
(4, 85)

2.46Ɨ
1.26
1.31
.37
.56
1.62
1.69

.003

(4, 85)

.93

.013

(4, 85)

.71

Disclosure DVs
Disclosure of Lifetime Sexual Partnersa
Disclosure of Recent Sexual Partnersa
Disclosure of Recent Condom Use
Disclosure of Alcohol Use Frequencya
Disclosure of Alcohol Use Quantity a
Disclosure of Lifetime Drug Use
Disclosure of Recent Drug Use a
Disclosure of Recency of Missed HAART
Dosesa
Disclosure of Overall HAART Adherencea

Note: a Analyses performed on Log transformations of these outcome measures.
p < .1, * p < .05, ** p < .01, *** p < .001

Ɨ

trend at

Table 9.1. Mediation Model: The Effect of HIV Stigma on Intentions to Remain in Care through Patients’ Feelings of Comfort and
their Perceptions of Stigmatization within the Patient Provider Relationship.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition
Indirect
Stigma Perceptions
Patient Comfort: Gen.
Total Indirect Effects

Point
Estimate

SE

Z

p

.16

.38

.42 (t)

.674

-1.86
-1.71
-3.56

.45
.38
.42

-4.16
-4.45
-8.54

<.001
<.001
<.001

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-2.81
-2.62
-4.38

-1.00
-.89
-2.84

-2.80
-2.61
-4.23

-1.09
-.90
-2.78
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Table 9.2. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose Sexual Risk Behavior through Patients’ Feelings of
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition
Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Sex
Total Indirect Effects

Point
Estimate

SE

Z

p

.69

.47

1.48 (t)

.143

-1.41
-1.46
.18
-2.69

.53
.62
.52
.43

-2.66
-2.36
.34
-6.28

.008
.018
.734
<.001

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-2.59
-2.86
-1.06
-3.91

-.10
-.16
1.41
-1.79

-2.41
-2.82
-1.00
-3.78

-.09
-.23
1.50
-1.64
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Table 9.3. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose Substance Use Related Risk Behavior through
Patients’ Feelings of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition
Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Subs.
Total Indirect Effects

Point
Estimate

SE

Z

p

.28

.50

.56 (t)

.575

-.98
-.27
-1.11
-2.36

.56
.53
.52
.44

-1.74
-.52
-2.68
-5.34

.083
.61
.007
<.001

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-2.24
-1.82
-2.01
-3.92

.53
.99
-.30
-1.09

-2.35
-1.73
-1.93
-3.71

.50
1.19
-.23
-1.00
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Table 9.4. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose HAART Non-adherence through Patients’ Feelings
of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition
Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Med
Total Indirect Effects

Point
Estimate

SE

Z

p

.19

.55

.34

.74

-1.31
-.92
.43
-1.80

.64
.64
.70
.46

-2.03
-1.45
.62
-3.90

.042
.148
.54
<.001

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-2.72
-2.52
-1.52
-3.28

.26
.37
1.83
-.79

-2.82
-2.49
-1.34
-2.97

.04
.47
2.00
-.72
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Table 10.1. Mediation Model: The Effect of HIV Stigma on Disclosure of Lifetime Sexual Partners through Patients’ Feelings of
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.11

.24

-.47 (t)

.64

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Sex
Total Indirect Effects

-.28
-.28
.70
.15

.26
.29
.26
.19

-1.05
-.97
2.66
.76

.292
.33
.008
.45

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.83
-.95
.26
-.23

.30
.33
1.32
.52

-.88
-1.00
.26
-.20

.26
.32
1.38
.58
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Table 10.2. Mediation Model: The Effect of HIV Stigma on Disclosure of Sexual Partners in Past Three Months through Patients’
Feelings of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.03

.10

-.33 (t)

.74

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Sex
Total Indirect Effects

-.08
.12
.04
.09

.11
.12
.10
.08

-.72
1.00
.40
1.15

.469
.319
.692
.248

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.34
-.16
-.20
-.04

.26
.42
.26
.25

-.35
-.15
-.24
-.04

.31
.47
.24
.27
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Table 10.3. Mediation Model: The Effect of HIV Stigma on Disclosure of Recent Condom Use Neglect through Patients’ Feelings of
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.67

.36

-1.84 (t)

.069

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Sex
Total Indirect Effects

.86
.06
-.42
.50

.68
.79
.69
.49

1.25
.08
-.61
1.01

.210
.940
.540
.309

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.53
-1.58
-1.88
-.60

2.37
1.67
1.08
1.79

-.58
-1.77
-1.88
-.65

2.16
1.79
.98
1.67
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Table 10.4. Mediation Model: The Effect of HIV Stigma Disclosure of Frequency of Alcohol Use through Patients’ Feelings of
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.05

.07

-.68 (t)

.500

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Subs.
Total Indirect Effects

.01
-.05
.05
.02

.08
.07
.05
.05

.19
-.63
.96
.40

.848
.531
.338
.689

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.18
-.18
-.05
-.10

.19
.10
.16
.16

-.15
-.20
-.07
-.10

.21
.09
.16
.14
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Table 10.5. Mediation Model: The Effect of HIV Stigma Disclosure of Quantity of Alcohol Use through Patients’ Feelings of Comfort
and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

.004

.04

.09 (t)

.962

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Subs.
Total Indirect Effects

-.02
-.06
.09
.001

.08
.08
.06
.06

-.29
-.83
1.50
.01

.774
.409
.134
.993

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.17
-.23
-.07
-.13

.12
.12
.24
.16

-.16
-.24
-.06
-.15

.13
.10
.23
.12
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Table 10.6. Mediation Model: The Effect of HIV Stigma Disclosure of Lifetime Drug Use through Patients’ Feelings of Comfort and
their Perceptions of Stigmatization within the Patient Provider Relationship.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.26

.42

-.62 (t)

.537

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Subs.
Total Indirect Effects

-.65
1.00
-.05
.31

.48
.46
.34
.34

-1.36
2.19
-.14
.90

.174
.028
.893
.366

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-1.71
.01
-.71
-.38

.35
2.23
.66
.98

-1.65
-.12
-.76
-.45

.36
2.09
.63
.96
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Table 10.7. Mediation Model: The Effect of HIV Stigma Disclosure of Drug Use in Past Three Months through Patients’ Feelings of
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.08

.08

-.99 (t)

.323

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Subs.
Total Indirect Effects

-.12
.20
-.04
.04

.09
.08
.06
.06

-1.33
2.36
-.67
.67

.184
.018
.502
.506

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.28
.05
-.06
-.06

.04
.39
.14
.14

-.31
.05
-.19
-.06

.05
.38
.11
.14
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Table 10.8. Mediation Model: The Effect of HIV Stigma Disclosure of Recency of Missed HAART Doses through Patients’ Feelings
of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.08

.08

-1.06 (t)

.293

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Med
Total Indirect Effects

-.01
.04
-.04
-.003

.09
.09
.10
.06

-.06
.47
-.40
-.05

.949
.639
.693
.960

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.14
-.14
-.21
-.10

.13
.25
.20
.10

-.13
-.13
-.23
-.11

.13
.25
.18
.10
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Table 10.9. Mediation Model: The Effect of HIV Stigma Disclosure of HAART Non-Adherence through Patients’ Feelings of
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Point
Estimate

SE

Z

p

Direct
Stigma Condition

-.05

.14

-.35 (t)

.731

Indirect
Stigma Perceptions
Patient Comfort: Gen.
Patient Comfort: Med
Total Indirect Effects

.07
-.26
.24
.04

.16
.16
.18
.11

.42
-1.62
1.34
.40

.677
.105
.180
.689

Path

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

-.23
-.58
-.27
-.21

.39
.06
.59
.25

-.24
-.63
-.15
-.15

.36
0.00
.62
.26
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Table 11.1 Alternate Single Mediator Models for Disclosure Outcomes-Model Fit Summary
Model Summary

Dependent Variables

Adjusted R2
df
Disclosure of Lifetime Sexual Partners
.058
(2, 74)
Disclosure of Lifetime Drug Use
.027
(2, 87)
a
Disclosure of Recent Drug Use
.030
(2, 85)
Note: a Analyses performed on Log transformations of these outcome measures.

F
3.32*
2.25
1.69

a

Table 11.2 Alternate Single Mediator Model: The Effect of HIV Stigma on Disclosure of Lifetime Sexual Partners through Patients’
Feelings of Disclosure-Specific Comfort. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition

Point
Estimate

SE

Z

p

-.32

.20

-1.57 (t)

.12

Lower

Indirect
Patient Comfort: Sex
.35
.14
2.47
.01
.14
a
Note: Analyses performed on Log transformations of these outcome measures.

Bias Corr. & Accel. 95% CI

Upper

Lower

Upper

.6

.12

.61
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Table 11.3 Alternate Single Mediator Model: The Effect of HIV Stigma Disclosure of Lifetime Drug Use through Patients’ Feelin gs
of General Comfort.
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition
Indirect
Patient Comfort: Gen.

Point
Estimate

SE

Z

p

-.54

.37

-1.44 (t)

.15

.58

.28

2.09

.04

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

.09

1.12

-.03

1.08
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Table 11.4 Alternate Single Mediator Model: The Effect of HIV Stigma Disclosure of Recent Drug Use through Patients’ Feelings of
General Comfort. (LOG)
Bootstrapping
Percentile
95% CI

Product of Coefficients
Path
Direct
Stigma Condition
Indirect
Patient Comfort: Gen.

Point
Estimate

SE

Z

p

-.13

.07

-1.90 (t)

.06

.09

.05

1.86

.06

Bias Corr. & Accel. 95% CI

Lower

Upper

Lower

Upper

.01

.19

.01

.19
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Figure Captions
Figure 1. Interactional Model of Client Health Behavior
Figure 2. Mediation Model of Provider Stigma’s Effects to HIV+ Patients’ Engagement
in Care
Figure 3. Characterization of the “Non-Stigma” Treatment Vignette-Long Version
Figure 4. Characterization of the “Stigma” Treatment Vignette-Long Version
Figure 5. Characterization of the “Non-Stigma” Treatment Vignette-Short Version
Figure 6. Characterization of the “Stigma” Treatment Vignette-Short Version
Figures 7.1-7.4. Intention-Based Mediation Models
Figures 8.1-8.9. Disclosure-Based Mediation Models

128

Figure 1. Interaction Model of Client Health Behavior (Cox, 1982)

*Note: Specific diagram representation from Mathews, Secrest, & Muirhead (2008).
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Figure 2. Mediation Model of Provider Stigma’s Effects to HIV+ Patients’ Engagement
in Care

Predictor Variable
Stigma Manipulation

Mediation Variables
Dependent Variables
Comfort and Perception of Stigmatization Engagement in Care

Patient Comfort:
1. general feeling of
psychological comfort
with the provider

(1) Future
Intentions to:
Remain in Care

2. feelings of comfort
regarding having
conversations related
to sexual behavior,
substance use, and
adherence
Provider
Stigmatization
Perceptions of
Stigmatization:
1. perceptions of being
devalued by provider
2. perceptions of the
future state of the
patient-provider
relationship

Discuss Sexual
Risk Behaviors
Discuss Alcohol
and Substance
Use
Discuss
Medication
(2) Actual
Adherence
Disclosure of:
Difficulties
Sexual Risk
Behaviors
Alcohol and
Substance Use
Lapses in
Medication
Adherence

Figure 3. Characterization of the “Non-Stigma” Treatment Vignette-Long Version

Comfort
Measure

1.

Comfort
Measure

2.

Comfort
Measure

*3.

Comfort
Measure

*4.

Order of Computerized Protocol:
1. “non-stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She approached Mr.
Johnson and shook his hand while introducing herself. Looking him in the eye, she asked, “How are you doing today?” (Actor)
Manipulated Independent Variables: touch (handshake), eye contact (maintained)
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry
2. “non-stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair a few feet away from the exam table where Mr. Johnson
is sitting and begins reviewing his chart. She says (Actor: calm, pleasant tone), “Mr. Johnson I would like to confirm a few
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for
HIV five years ago, most likely from sexual activity with men.” Mr. Johnson replied, “Yeah, that’s the story.” Dr. Smith
(Actor: same calm, pleasant tone): “Ok, and it says that you began taking anti-retroviral medications pretty soon after the
diagnosis.” Mr. Johnson replied: “Yeah it was within a few months.”
Manipulated Independent Variables: proximity in room (close), language and tone (non-judgmental)
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .
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* Segments 3 and 4 proceed in similar fashion with comfort ratings following each segment.
Note: Pictures shown above are not exact representations. They are intended only to demonstrate the basic layout of the protocol.

Figure 4. Characterization of the “Stigma” Treatment Vignette-Long Version
Comfort
Measure

1.

Comfort
Measure

2.

Comfort
Measure

*3.

Comfort
Measure

*4.

Order of Computerized Protocol:
1. “stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She took a few steps into the
room while introducing herself. While looking at the medical chart, she asked, “How are you doing today? (Actor)”.
Manipulated Independent Variables: touch (no handshake), eye contact (lacking)
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .
2. “stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair across the room from the exam table where Mr. Johnson is
sitting and begins reviewing his chart. She says (Actor: calm, unpleasant tone), “Mr. Johnson I would like to confirm a few
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for
HIV five years ago, having gotten infected because you were sleeping with other men.” Mr. Johnson replied, “Yeah, that’s the
story.” Dr. Smith (Actor: sarcastic tone): “Not surprising. It also says that you began taking anti-retroviral medications pretty
soon after the diagnosis.” Mr. Johnson replied: “Yeah, it was within a few months.”
Manipulated Independent Variables: proximity in room (far), language and tone (judgmental)
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .
* Segments 3 and 4 proceed in similar fashion with comfort ratings following each segment.
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Figure 5. Characterization of the “Non-Stigma” Treatment Vignette-Short Version

Comfort
Measure

1.

2.

*3.

*4.

Order of Computerized Protocol:
1. “non-stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She approached Mr.
Johnson and shook his hand while introducing herself. Looking him in the eye, she asked, “How are you doing today?” (Actor)
Manipulated Independent Variables: touch (handshake), eye contact (maintained)
2. “non-stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair a few feet away from the exam table where Mr. Johnson
is sitting and begins reviewing his chart. She says (Actor: calm, pleasant tone), “Mr. Johnson I would like to confirm a few
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for
HIV five years ago, most likely from sexual activity with men.” Mr. Johnson replied, “Yeah, that’s the story.” Dr. Smith
(Actor: same calm, pleasant tone): “Ok, and it says that you began taking anti-retroviral medications pretty soon after the
diagnosis.” Mr. Johnson replied: “Yeah it was within a few months.”
Manipulated Independent Variables: proximity in room (close), language and tone (non-judgmental)
* Segments 3 and 4 proceed in similar fashion.
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .
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Note: Pictures and narratives shown above are not exact representations. They are intended only to demonstrate the basic layout of the
protocol.
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Figure 6. Characterization of the “Stigma” Treatment Vignette-Short Version

Comfort
Measure

1.

2.

*3.

*4.

Order of Computerized Protocol:
1. “stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She took a few steps int o the
room while introducing herself. While looking at the medical chart, she asked, “How are you doing today? (Actor)”.
Manipulated Independent Variables: touch (no handshake), eye contact (lacking)
2. “stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair across the room from the exam table where Mr. Johnson is
sitting and begins reviewing his chart. She says (Actor: calm, unpleasant tone), “Mr. Johnson I would like to confirm a few
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for
HIV five years ago, having gotten infected because you were sleeping with other men.” Mr. Johnson replied, “Yeah, that’s the
story.” Dr. Smith (Actor: sarcastic tone): “Not surprising. It also says that you began taking anti-retroviral medications pretty
soon after the diagnosis.” Mr. Johnson replied: “Yeah, it was within a few months.”
Manipulated Independent Variables: proximity in room (far), language and tone (judgmental)

* Segments 3 and 4 proceed in similar fashion.
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry
Note: Pictures and narratives shown above are not exact representations. They are intended only to demonstrate the basic layout of the
protocol.
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Figure 7.1. Mediation Model: The Effect of HIV Stigma on Intentions to Remain in Care
through Patients’ Feelings of Comfort and their Perceptions of Stigmatization within the
Patient Provider Relationship.

A. Direct Path
Stigma:
Experimental
Condition

Path c:
B = -3.40***

Intentions to
Remain in Care

B. Multiple Mediation Model: Indirect Paths

Path a1:
B = 3.23***

Stigma:
Experimental
Condition

Perceptions of
Provider Stigma

Path b1:
B = -.57***

Path c’:
B = .16
Intentions to
Remain in Care

Path a2:
B = -3.12***

Path b2:
B = .55***
Patient Comfort:
Overall

Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001
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Figure 7.2. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose Sexual
Risk Behavior through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship.

C. Direct Path
Path c:
B = -2.00***

Stigma:
Experimental
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Disclose Sexual
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D. Multiple Mediation Model: Indirect Paths
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Path a2:
B = -3.12***

Path a3:
B = -3.31***

Path b2:
B = .47*
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Overall

Patient Comfort:
Sexual Behavior
Specific

Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001

Path b1:
B = -.44**

Intentions to
Disclose Sexual
Risk Behaviors

Path b3:
B = -.05
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Figure 7.3. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose
Substance Use Related Risk Behavior through Patients’ Feelings of Comfort and their
Perceptions of Stigmatization within the Patient Provider Relationship.

A. Direct Path
Path c:
B = -2.08***

Stigma:
Experimental
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Intentions to
Disclose Substance
Use Risk
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B. Multiple Mediation Model: Indirect Paths

Perceptions of
Provider Stigma

Path a1:
B = 3.23***

Stigma:
Experimental
Condition

Path c’:
B = .28
Path a2:
B = -3.12***

Path a3:
B = -2.96***

Path b2:
B = .09

Patient Comfort:
Overall

Patient Comfort:
Substance Use
Behavior
Specific

Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001

Path b1:
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B = -.30

Intentions to
Disclose
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Path b3:
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Figure 7.4. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose
HAART Non-Adherence through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship.

A. Direct Path
Path c:
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Experimental
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B. Multiple Mediation Model: Indirect Paths
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Path a3:
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Note: Ɨ trend at p < .1, * p < .05, ** p < .01, *** p < .001

Path b1:
B = -.41*
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Disclose HAART
Non-Adherence

Path b3:
B = -.12
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Figure 8.1. Mediation Model: The Effect of HIV Stigma on Disclosure of Lifetime
Sexual Partners through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship. (LOG)

A. Direct Path
Path c:
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Disclosure of
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Figure 8.2. Mediation Model: The Effect of HIV Stigma on Disclosure of Sexual Partners
in Past Three Months through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship. (LOG)
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Figure 8.3. Mediation Model: The Effect of HIV Stigma on Disclosure of Recent
Condom Use Neglect through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship.
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Figure 8.4. Mediation Model: The Effect of HIV Stigma Disclosure of Frequency of
Alcohol Use through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship. (LOG)
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Figure 8.5. Mediation Model: The Effect of HIV Stigma Disclosure of Quantity of
Alcohol Use through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship. (LOG)
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Figure 8.6. Mediation Model: The Effect of HIV Stigma Disclosure of Lifetime Drug Use
through Patients’ Feelings of Comfort and their Perceptions of Stigmatization within the
Patient Provider Relationship.
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Figure 8.7. Mediation Model: The Effect of HIV Stigma Disclosure of Drug Use in Past
Three Months through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship. (LOG)
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Figure 8.8. Mediation Model: The Effect of HIV Stigma Disclosure of Recency of
Missed HAART Doses through Patients’ Feelings of Comfort and their Perceptions of
Stigmatization within the Patient Provider Relationship. (LOG)
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Figure 8.9. Mediation Model: The Effect of HIV Stigma Disclosure of HAART NonAdherence through Patients’ Feelings of Comfort and their Perceptions of Stigmatization
within the Patient Provider Relationship. (LOG)
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Background
These questions ask about your background. Please remember that all information
you provide is completely confidential. Do no put your name on this form.
1. What is the highest grade in school that you have ever completed? (circle correct
number below)
1 2 3 4 5 6 7 8 9 10 11 12 (12 = high school degree)
13 14 15 16(= bachelors’ degree) 17 18(= masters’ degree) 19
20(=doctoral degree)
2. What is your current age? ______
3. What is your Date of Birth ____ / ____ / ____
4. Do you consider yourself to be Hispanic/Latina/Latino? No

Yes

5. Which of the following best describes your racial/ethnic background? Is it…
1  African-American or Black
4  American Indian or Alaska Native
2  White or Caucasian

5  Mixed or Multiracial

3  Asian or Pacific Islander

6  Other

6. Do you identify as:
1
2
female
male

3
transgender

7. Do you identify as
1  gay/homosexual
3  bisexual

2  heterosexual/straight
4  other

8. Based on your past behavior, which of the following statements applies best to you?
1  I have sex with men only.
2  I have sex mostly with men.
3  I have sex with men and women equally.
4  I have sex mostly with women.
5  I have sex with women only.
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9. Are you currently employed?
no
yes

10. How many hours per week do you work? _______

11. Which best describes your current relationship status?
1  I have a main or primary partner, and we live together
2  I have a main or primary partner, but we live separately
3  I don’t currently have a primary partner
12. Is English your first language?

No

Yes

13. Where do you live?
1  My own apartment
2  My own home
3  My family’s house or apartment
4  Someone else’s house or apartment(not family)
5  A rooming house or single room hotel
6  A shelter
7  A group home or halfway house
8  Other: please specify other: _______________

14. Approximately how much money do you have to live off of in an average month?
This includes money that goes toward paying your rent, utilities, and other
monthly bills.
$ ________
15. How old were you when you first learned that you were HIV+? ______ years old.
16. When were you first diagnosed? ______
month

_______
year

17. Have you ever been hospitalized for an HIV-related illness?
no
yes
17a. How many times? __________
(go to next question)
18. Have you been diagnosed with AIDS?
no
yes
18a. What was the approximate date?______
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19. What was your CD4 or helper t-cell count in your MOST RECENT test report? (If
you are unsure of the exact number, please make as close an approximation as you
can.)
CD4 count ______

I don’t know

20. What was your MOST RECENT HIV viral load?
1
2
Undetectable Don’t know

3
Number:___________

21. Are you currently taking HIV medication(s)?
no
yes
21a. When did you start taking HIV meds? _______
22. Approximately how many medical appointments at the Infectious Disease Clinic have
you missed in the past year? _________

23. What is the most likely way that you became infected with HIV?
1  Sex with a man who was HIV+
2  Sex with a woman who was HIV+
3  Blood Transfusion
4  Sharing Needles
5  Other
6  I don’t know
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Qualitative Focus Group
Interview Guide
Introduction and Consent
Facilitator will introduce herself and review the major points of the consent form with the
group as mentioned in the protocol:
WHO: The project directors for this study are Jessie Heath, M.S., a clinical
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an
associate professor of psychology at Syracuse University and an adjunct assistant
professor of medicine at SUNY Upstate Medical University.
PURPOSE & PROCEDURE: You are being asked to participate in a research
study designed to learn more about effects of positive and negative treatment
experiences of persons living with HIV. Our goal is to identify what medical
provider behaviors are viewed as stigmatizing by HIV+ patients and gain a better
understanding of how stigmatizing behaviors of medical care providers can affect
the HIV+ patients they treat. We will use the information obtained in this study to
inform the development of strategies to reduce the stigmatization of HIV+
patients in medical care settings.
TIME & COMPENSATION: Your participation involves a group discussion and
filling out a short questionnaire, a total of 2 hours. You will receive $20 for you
time.
RISKS/BENEFITS:
o Embarrassment or discomfort: Some of the things we will talk about in
the group discussion involved sensitive, private information. You are
invited to share as much or as little information as you desire, you can
refuse to answer any question you feel is too personal.
o Breach of confidentiality: Because we will be meeting in a group, there is
the potential for other group members to tell other people what you say
during the discussion. We will try to prevent this from happening by
asking group members to keep everything that is said in the group
discussion confidential.
o Benefits: You may learn more about your feelings and become aware of
how your medical treatment experiences have affected you. In addition,
because the information you provide assists in the development of stigma
reducing strategies, your participation could benefit others living with
HIV.
o Questions?
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Warm-Up
To start out, I’d like you to tell me a little about yourself.
 What was your experience like learning your have HIV? When were you
diagnosed?
 Have you participated in research before? What do you think about research?
What do you think about involving people with HIV?
I. Negative Experiences in Medical Care
I’d like to start by asking you a few questions about your experiences with in medical
care.
 In thinking specifically about medical care, what have been some of your most
negative experiences with providers like doctors, nurses, med students?
 Can you tell me about those experiences (what the provider specifically did or
said, how you felt, when it occurred)?
 Why do you think they behaved that way towards you?

II. Stigmatization in Medical Care
Now I would like to talk to you about a specific kind of negative experience in medical
care that HIV+ patients like yourself have reported in the past, namely stigmatization or
stigma.
 When I say the word “stigma” or “stigmatization”, what comes to mind? How
would you explain it to someone?
 If not reported: Other HIV+ patients have reported these stigmatizing experiences
in medical care (e.g. poor eye contact, increased distance, etc.). Have you?
 How did you know that those experiences were related to being HIV+ vs. an
alternative explanation like having a bad doctor or being treated poorly based on
racial identity?
 What would you say are the biggest signs that you are being treated by a
stigmatizing provider?

III. Effects of Provider Stigmatization
We’ve talked about your experiences with stigmatization in medical care. I’d now like to
ask you about how you think those experiences have affected you.
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 How do you think provider stigmatization affects you (physical health, mental
health, relationships, etc.)?
 Do you think stigmatization affects your HIV disease progression?
 Do you think stigmatization affects your relationship with the provider? How?
 How does stigmatization affect your perceptions of your provider and your care?
 Have your experiences of provider stigmatization had any lasting effects in your
life?
 If it weren’t for my experiences of provider stigmatization, I would have . . .?
IV. Positive Treatment Experiences and Suggestions for Improved Care
Given that we’ve talked about your negative experiences with medical care, I would also
like to know about your positive experiences with providers.
 Tell me about some of the most positive experiences you’ve have with medical
providers.
 How did the providers talk to you, behave, and make you feel?
 What are some signs that your provider is not going to treat you in a stigmatizing
way?
 How have providers gotten you to feel comfortable enough to open up about
sensitive information like sexual risk behaviors, substance use, and medication
non-adherence?
 What are some ways your providers could improve your treatment experiences?

V. Feedback
I really appreciate your participation in this study. As we are wrapping up, I would just
like to get your feedback on how it felt to be a part of this group today.
 How did you feel talking with others about your experiences?
 What did you get out of today’s group?
 Would you be interested in participating in future research projects?
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Appendix C
Draft of Qualitative Focus Group Protocol
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QUALITATIVE FOCUS GROUP PROCEDURES
I. INFORMED CONSENT
A. OVERVIEW OF CONSENT INFORMATION
A participant who gives their informed consent to participate in the focus group
discussion should fully understand the nature of the research study, the purpose and
pertinent procedures for the study, potential risks and benefits of participating,
confidentiality and steps taken by research team to ensure confidentiality, and how the
data will be used and stored.
B. FOCUS GROUP CONFIDENTIALITY CONCERNS
Although a number of steps are taken to ensure confidentiality for every
participant, the nature of a discussion group limits our ability to ensure that who attends
and what is said in the focus group remains confidential. Breach of confidentiality may
occur if other group members choose to directly or indirectly disclose information
regarding the identity of group members or the content of what is shared to people
outside of the group. The facilitator of the focus group directly addresses this risk during
the introduction. Specifically, she states that, “What is said here should stay here. Please
respect the privacy of group members by not repeating what is said today outside of the
group.”
C. PARTICIPANT CONSENT
After a brief introduction, the focus group facilitator leads the group through the
informed consent form, highlighting the most important aspects of informed consent.
The following outline illustrates the content that is verbally expressed by the facilitator
during this process:
WHO: The project directors for this study are Jessie Heath, M.S., a clinical
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an
associate professor of psychology at Syracuse University and an adjunct assistant
professor of medicine at SUNY Upstate Medical University.
PURPOSE & PROCEDURE: You are being asked to participate in a research
study designed to learn more about effects of positive and negative treatment
experiences of persons living with HIV. Our goal is to identify what medical
provider behaviors are viewed as stigmatizing by HIV+ patients and gain a better
understanding of how stigmatizing behaviors of medical care providers can affect
the HIV+ patients they treat. We will use the information obtained in this study to
inform the development of strategies to reduce the stigmatization of HIV+
patients in medical care settings.
TIME & COMPENSATION: Your participation involves a group discussion
and filling out a short questionnaire, a total of 2 hours. You will receive $20 for
your time.
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RISKS/BENEFITS:
o Embarrassment or discomfort: Some of the things we will talk about in
the group discussion involved sensitive, private information. You are
invited to share as much or as little information as you desire, you can
refuse to answer any question you feel is too personal.
o Breach of confidentiality: Because we will be meeting in a group, there is
the potential for other group members to tell other people what you say
during the discussion. We will try to prevent this from happening by
asking group members to keep everything that is said in the group
discussion confidential.
o Benefits: You may learn more about your feelings and become aware of
how your medical treatment experiences have affected you. In addition,
because the information you provide assists in the development of stigma
reducing strategies, your participation could benefit others living with
HIV.
CONFIDENTIALITY and HIPPA
o If you decide to participate, any information that you give us is strictly
confidential. We will keep your information private, except under 2
circumstances.
 First, if you tell us that you’re planning to hurt yourself or
someone else we would have to disclose that information.
 Second, if officials were concerned that the research team was
acting inappropriately, the research records might be audited to
make sure the research was being conducted ethically; however,
the auditors would be required to protect your privacy.
PROTECTION OF CONFIDENTIALITY
o All project staff receive extensive training and supervision on
confidentiality procedures.
o Your survey is given an identification number and only authorized
research staff has access to the key that connects your information to your
name. Your identity will not be included on the audiotapes and the tapes
will be erased once we are finished with the project.
o Certificate of Confidentiality from the Department of Health and Human
services, which states that the investigators cannot be forced to release
your information (for example, by subpoena) to any federal, state, or local,
civil, criminal, administrative, legislative, or other proceedings. This
Certificate does NOT prevent you or your family from voluntarily
disclosing information about yourself or your involvement in this research.
PARTICIPATION IS VOLUNTARY: You may refuse to participate or
discontinue your participation at any time without penalty or loss of benefits.
PERMISSION TO BE RECONTACTED: The participants are then asked to
sign and date one copy of the consent form and keep a second copy for their own
records. Participants are also given a copy of University Hospital’s Privacy
Practices Policy and asked to keep it for their records.
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D. STORAGE OF CONSENT FORMS
After pertinent information from the completed consent forms has been entered
into the secure Excel patient database, the completed focus group consent forms will be
stored in a locked filing cabinet in the UPH office.

II. QUANTITATIVE DEMOGRAPHIC SURVEY ADMINISTRATION
A. ASSIGNMENT OF PARTICIPANT NUMBER
After participants consent to and complete the quantitative demographic
questionnaire, they will be assigned a participant ID number.
B. SURVEY ADMINISTRATION
The quantitative demographic survey is administered following the informed
consent. The participants are given clipboards to increase privacy in the group settings
and are asked to complete the survey as accurately and honestly as possible. When
everyone has completed the survey, the surveys are collected and the discussion portion
of the focus group begins.
C. DATA ENTRY
Data from the completed quantitative questionnaire will be entered by the
principle investigator into SPSS. The PI will then verify the accuracy of the initial data
entry by double entering the data.
D. DATA STORAGE
Completed questionnaires will be stored in a locked filing cabinet in the UPH lab
space in the CNY Medical Building. No identifying information will be on the
completed questionnaire.

III. PROTOCOL FOR FOCUS GROUP ADMINISTRATION
A. RECORDING PROCEDURE
During the focus group, two handheld cassette recorders will be used to record the
session. Prior to each focus group, the tape recorders will be tested to ensure that there
are no technical problems.
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B. FOCUS GROUP SCRIPT
The PC/focus group facilitator will follow the focus group script when leading
focus group discussions.

C. PARTICIPANT REIMBURSEMENT
The PI will retrieve reimbursement funds from Sean Kelley prior to the start of
the focus group. Participants will be reimbursed $20 for their two hours of participation
in the focus groups. After participants have received their reimbursement, the PI will
complete a reimbursement receipt including only the participant’s ID number and file it
in the UPH filing cabinet under non-reconciled payment receipts. The original
reimbursement form will then be turned in to Sean Kelley. A photocopy will be stored in
the UPH filing cabinet under reconciled payment receipts.
D. STORAGE OF FOCUS GROUP TAPES
All focus group tapes will be labeled with the tape type (Master vs. Back-up),
focus group date, interviewer’s initials, and focus group number. Back-up tapes for each
group will be stored in a locked filing cabinet in the UPH office.
E. FOCUS GROUP TRANSCRIPTS
The focus group tape will be transcribed, verbatim, by the facilitator. Once the
focus group transcripts are completed, an electronic copy will be stored on the UPH
computer. A paper copy will be stored in the locked UPH filing cabinet in the folder
created specifically for that focus group.
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Appendix D
Draft of Qualitative Focus Group Informed Consent Form

163
SUNY UPSTATE MEDICAL UNIVERSITY AND
SYRACUSE UNIVERSITY
Consent/Authorization Form
Title of Study: Treatment Experiences of HIV+ Patients Focus Group Study
Background/Purpose:
You are invited to participate in a research study designed to gain a better understanding
of how the behaviors of medical care providers can affect the HIV+ patients they treat.
We will use the information obtained in this study to inform the development of
strategies to improve patient-provider relationships and the quality of medical care
received HIV+ patients. The project directors for this study are Jessie Heath, M.S., a
clinical psychology doctoral student at Syracuse University and Dr. Peter Vanable, an
Associate Professor of Psychology at Syracuse University and an adjunct assistant
professor of medicine at SUNY Upstate Medical University. Other trained research staff
will also be involved, and will be supervised by Dr. Peter Vanable of Syracuse
University. We are asking approximately 20 patients from this clinic to participate in the
study.
You will be given enough time to read and understand the information provided in this
consent and authorization form. Please ask the study staff to explain any words or
information that you do not understand. You may keep an unsigned copy of this consent
and authorization form to think about your decision or discuss with your family, friends,
or doctors before making your decision to take part in this research study.
Study Procedures:
If you decide to take part, you will be asked to share some of your positive and negative
medical treatment experiences in a small discussion group that includes other individuals
who are HIV+. In the discussion group, we will seek your input about what provider
behaviors are seen as stigmatizing to HIV+ individuals and how the experience of
stigmatization in medical settings may have affected you. The discussion group will also
include questions regarding your suggestions on how HIV care could be improved.
The discussion group will be tape recorded so that we can review all the suggestions and
feedback provided by you and other participants. However, your identity will not be
included on the audiotapes and the tapes will be erased once we are finished with the
project. The discussion group will take approximately 2 hours to complete.
If you agree to participate in the study, you will also be asked to complete a brief survey
with questions about your background and health information, including medical
appointment attendance, hospitalizations, and recent indicators of health status (CD4
count, viral load).
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Risks:
The risks of participating in this study include the possibility of experiencing
uncomfortable feelings or distress when discussing your past treatment experiences.
These risks will be minimized but not eliminated by our providing you with the
opportunity to discuss any concerns that arise after completing the focus group. There is
also a risk that information that you provide during this study could be inadvertently
disclosed to others, or that a breach in confidentially could occur regarding your
involvement in the study. For example, other individuals who participate in the
discussion group may tell other people what you say during the discussion group.
However, we will try to prevent this from happening by asking group members not to
disclose information that is discussed during the group.
Benefits:
The potential benefit to you is that may learn more about your feelings and become aware
of how your medical treatment experiences have affected you. In addition, because the
information you provide may assist in educating health care providers about the best
approaches to interacting with patients, your participation could benefit others living with
HIV.
Voluntary Participation:
Your participation in this study is entirely voluntary and you may refuse to participate or
discontinue participation at any time without penalty or loss of benefits to which you
would be normally entitled. Your decision about whether or not to participate in the
study will not affect the care you receive at SUNY Upstate Medical University.
Alternatives:
If you decide not to participate in this research study, you will continue to receive your
usual care.
Costs/Payments:
There are no costs to you and/or your insurance carrier for participating in this study.
You will receive $20 for your participation.
If you choose to stop participating in the study before all study requirements are
completed, you will be paid $10 for each hour of time you devote to the study.
In addition, by accepting payment for participating in this study, certain identifying
information about you may be made available to professional auditors to satisfy audit and
Federal reporting requirements, but confidentiality will be preserved. Please note that if
you earn $600 or over in a calendar year as a research subject, you may have to pay taxes
on these earnings.
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Questions:
If you have any questions about the research, please contact Ms. Jessie Heath (315) 4431052 or Dr. Peter Vanable at (315) 443-2024. If you have any questions about your
rights as a research subject, please contact the SUNY Upstate Medical University
Institutional Review Board Office at (315) 464-4317 or the Syracuse University
Institutional Review Board Office at (315) 443-3013.
Confidentiality of Records and Authorization to Use/Share Protected Health
Information for Research:
If you agree to participate in this research, identifiable health information about you
will be used and shared with others involved in this research. For you to be in this
research we need your permission to collect and share this information. Federal law
protects your right to privacy concerning this information.
When you sign this consent form at the end, it means that you have read this section and
authorize the use and/or sharing of your protected health information as explained below.
Your signature also means you have received a copy of Upstate’s Notice of Privacy
Practices.
Individually identifiable health information under the federal privacy law is considered to
be any information from your medical record, or obtained from this study, that can be
associated with you, and relates to your past, present, or future physical or mental health
or condition. This is referred to as protected health information.
Your protected health information will be kept confidential. Research staff will not share
the information you provide during the discussion group with your doctor or nurse here in
the clinic. Further, you will not be identified in any publication or presentation resulting
from this study. Several steps have been taken to protect the confidentiality of your
responses and involvement in this research. Project staff has participated in extensive
training and supervision regarding the importance of maintaining participant
confidentiality. In addition, an identification number will be assigned to your focus
group responses, and only the directors of this research (Jessie Heath, M.S., and Dr.
Vanable) will have access to the key that indicates which number belongs to which
participant. The master list linking the participant ID number to the participant’s
identifying information will be maintained in a separate, secure computer database, and
will be destroyed at the conclusion of the study.
To help us further protect your privacy, the investigators have received a Confidentiality
Certificate from the Department of Health and Human Services. With this Certificate,
the investigators cannot be forced (for example by court subpoena) to disclose research
information that may identify you in any Federal, State, or local, civil, criminal,
administrative, legislative, or other proceedings. The researchers will use the Certificate
to resist any demands for information that would identify you, except as explained below.
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The Certificate cannot be used to resist a request for information from personnel of the
United States Department of Health and Human Services that is used for auditing or
evaluation of federally funded projects.
In addition, the Confidentiality Certificate does not prevent you or a member of your
family from voluntarily releasing information about yourself or your involvement in this
research. Note however, that if an insurer or employer learns about your participation,
and obtains your consent to receive research information, then the investigator may not
use the Certificate of Confidentiality to withhold this information. This means that you
and your family must also actively protect your own privacy.
Why is it necessary to use/share your protected health information with
others?
The main reason to use and share your health information is to conduct the research
as described in this consent form. Your information may also be shared with people
and organizations that make sure the research is being done correctly, and to report
unexpected or bad side effects you may have. In addition, we would be required to
release protected health if you tell us of your intent to harm yourself or others.
What protected health information about you will be used or shared with others as
part of this research?
We may use and share the results of the interviews. We will only collect information
that is needed for the research.
Who will be authorized to use and/or share your protected health
information?
The researchers, their staff and the staff of Upstate Medical University participating
in the research will use your protected health information for this research study. In
addition, the Upstate Institutional Review Board (IRB), a committee responsible for
protecting the rights of research subjects, and other Upstate Medical University or
University Hospital staff who supervise the way the research is done, may have
access to your protected health information.
The researchers and their staff will determine if your protected health information
will be used or shared with others outside of Upstate Medical University for
purposes directly related to the conduct of the research.
With whom would the protected health information be shared?
Your protected health information may be shared with:
Federal agencies that supervise the way the research is conducted, such as the
Department of Health and Human Services’ Office for Human Research
Protections, the National Institutes of Health, or other governmental offices as
required by law.
Researchers from Syracuse University assisting in the study.
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The Syracuse University Institutional Review Board (a committee responsible for
protecting the rights of research subjects).
All reasonable efforts will be used to protect the confidentiality of your protected
health information. However, not all individuals or groups have to comply with the
Federal privacy law. Therefore, once your protected health information is disclosed
(leaves Upstate Medical University), the Federal privacy law may not protect it.
For how long will your protected health information be used or shared with
others?
There is no scheduled date at which this information will be destroyed or no longer used.
This is because information that is collected for research purposes continues to be used
and analyzed for many years and it is not possible to determine when this will be
complete.
Can you withdraw your authorization to collect/use/share your protected
health information?
You always have the right to withdraw your permission (revoke authorization) for
us to use and share your health information, by putting your request in writing to
the investigator in charge of the study. This means that no further private health
information will be collected. Once authorization is revoked, you may no longer
participate in this research activity, but standard medical care and any other benefits to
which you are entitled will not be affected. Revoking your authorization only affects
uses and sharing of information obtained after your written request has been
received, but not information obtained prior to that time.
Even after you withdraw your permission, Upstate Medical University may continue
to use and share information needed for the integrity of the study; for example,
information about an unexpected or bad side effect you experienced related to the
study.
Can you have access to your health information?
At the end of the study, you have the right to see and copy health information about
you in accordance with the SUNY Upstate Medical University policies; however, your
access may be limited while the study is in progress.
Permission To Re-contact For Follow-Up Research
We may conduct additional research on this important topic. May we contact you about
participation in future studies? Indicating you are willing to be contacted does not
obligate you to participate in any other study, nor does it affect your participation in this
study.
 No, I prefer not to be contacted about future studies.
 Yes, I am willing to be contacted about future studies.
Phone: _______________

Mailing Address: ________________________________
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Consent To Participate In Research & Authorization To Use And Share Personal
Health Information:
I hereby give my consent to participate in this research study and agree that my personal
health information can be collected, used and shared by the researchers and staff for the
research study described in this form. I will receive a signed copy of this consent form.
______________________________________
Signature of subject

__________________
Date

_______________________________________
Printed Name of Research Participant

__________________________________________
Signature of Person Obtaining Consent/Authorization

_______________________________________________
Printed Name of Person Obtaining Consent/Authorization

__________________
Date
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Receipt: Treatment Experiences of HIV+ Patients Study
Principle Investigator: Jessie Heath, M. S.

Date: ______________
Study:
Focus Group

Validity

ID:_______

Experimental

Money Received:_____________

Participant:

___________________________
Printed Name

___________________________
Signed Name

___________
Date

Research Assistant:

___________________________
Printed Name
___________________________
Signed Name

___________
Date
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Validity Sub-study Questionnaire
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Validity Sub-study Questionnaire
*Please answer the following items after each segment of the medical care visit is
presented to you.
Vignette Segment 1.
a. Please imagine that you are the patient portrayed in this vignette. Now rate how you
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure,
Worried, Distressed, Serene, having Peace of Mind.
1
Extremely
Uncomfortable
1
Extremely
Uneasy
1
Extremely
Tense
1
Extremely
Insecure
1
Extremely
Worried
1
Extremely
Distressed
1
Extremely
Turbulent
1
Extremely
Troubled

2
Moderately
Uncomfortable
2
Moderately
Uneasy
2
Moderately
Tense
2
Moderately
Insecure
2
Moderately
Worried
2
Moderately
Distressed
2
Moderately
Turbulent

3
Somewhat
Uncomfortable
3
Somewhat
Uneasy
3
Somewhat
Tense
3
Somewhat
Insecure
3
Somewhat
Worried
3
Somewhat
Distressed
3
Somewhat
Turbulent

2
Moderately
Troubled

3
Somewhat
Troubled

4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral

4
Neutral

5
Somewhat
Comfortable
5
Somewhat
At Ease
5
Somewhat
Relaxed
5
Somewhat
Secure
5
Somewhat
Worry-Free
5
Somewhat
Calm
5
Somewhat
Serene
5
Have Some
Peace of
Mind

6
Moderately
Comfortable
6
Moderately
At Ease
6
Moderately
Relaxed
6
Moderately
Secure
6
Moderately
Worry-Free
6
Moderately
Calm
6
Moderately
Serene
6
Have
Moderate
Peace of
Mind

7
Extremely
Comfortable
7
Extremely
At Ease
7
Extremely
Relaxed
7
Extremely
Secure
7
Extremely
Worry-Free
7
Extremely
Calm
7
Extremely
Serene
7
Have
Extreme
Peace of
Mind
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b. Please imagine that you are the patient portrayed in this vignette and rate how much
you agree or disagree with the following questions.

1. I felt
devalued by
this provider.
2. I believe
this provider
made
negative
judgments
about me.
3. I believe
this provider
treated me
like an equal.
4. I believe
this provider
would prefer
not to treat
me.
5. I believe
this provider
treated me the
same as he
treats his
other patients.
6. I believe
this provider
thought I was
a bad person.
7. I felt like
this provider
ignored or
avoided me.
8. I believe
this provider
was
comfortable
treating me.
9. I felt like
this provider
looked down
on me.

Strongly
Disagree

Disagree

Slightly
Disagree

Neutral

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

****Thank you! Please click to watch next segment on the computer screen.
________________________________________________________________________
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Vignette Segment 2.
a. Please imagine that you are the patient portrayed in this vignette. Now rate how you
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure,
Worried, Distressed, Serene, having Peace of Mind.
1
Extremely
Uncomfortable
1
Extremely
Uneasy
1
Extremely
Tense
1
Extremely
Insecure
1
Extremely
Worried
1
Extremely
Distressed
1
Extremely
Turbulent
1
Extremely
Troubled

2
Moderately
Uncomfortable
2
Moderately
Uneasy
2
Moderately
Tense
2
Moderately
Insecure
2
Moderately
Worried
2
Moderately
Distressed
2
Moderately
Turbulent

3
Somewhat
Uncomfortable
3
Somewhat
Uneasy
3
Somewhat
Tense
3
Somewhat
Insecure
3
Somewhat
Worried
3
Somewhat
Distressed
3
Somewhat
Turbulent

2
Moderately
Troubled

3
Somewhat
Troubled

4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral

4
Neutral

5
Somewhat
Comfortable
5
Somewhat
At Ease
5
Somewhat
Relaxed
5
Somewhat
Secure
5
Somewhat
Worry-Free
5
Somewhat
Calm
5
Somewhat
Serene
5
Have Some
Peace of
Mind

6
Moderately
Comfortable
6
Moderately
At Ease
6
Moderately
Relaxed
6
Moderately
Secure
6
Moderately
Worry-Free
6
Moderately
Calm
6
Moderately
Serene
6
Have
Moderate
Peace of
Mind

7
Extremely
Comfortable
7
Extremely
At Ease
7
Extremely
Relaxed
7
Extremely
Secure
7
Extremely
Worry-Free
7
Extremely
Calm
7
Extremely
Serene
7
Have
Extreme
Peace of
Mind

b. Please imagine that you are the patient portrayed in this vignette and rate how much
you agree or disagree with the following questions.
Strongly
Disagree
1. I felt
devalued by
this
provider.
2. I believe
this provider
made
negative
judgments
about me.
3. I believe
this provider
treated me

Disagree

Slightly
Disagree

Neutral

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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like an
equal.
4. I believe
this provider
would prefer
not to treat
me.
5. I believe
this provider
treated me
the same as
he treats his
other
patients.
6. I believe
this provider
thought I
was a bad
person.
7. I felt like
this provider
ignored or
avoided me.
8. I believe
this provider
was
comfortable
treating me.
9. I felt like
this provider
looked down
on me.

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

****Thank you! Please click to watch next segment on the computer screen.
________________________________________________________________________
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Vignette Segment 3.
a. Please imagine that you are the patient portrayed in this vignette. Now rate how you
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure,
Worried, Distressed, Serene, having Peace of Mind.
1
Extremely
Uncomfortable
1
Extremely
Uneasy
1
Extremely
Tense
1
Extremely
Insecure
1
Extremely
Worried
1
Extremely
Distressed
1
Extremely
Turbulent
1
Extremely
Troubled

2
Moderately
Uncomfortable
2
Moderately
Uneasy
2
Moderately
Tense
2
Moderately
Insecure
2
Moderately
Worried
2
Moderately
Distressed
2
Moderately
Turbulent

3
Somewhat
Uncomfortable
3
Somewhat
Uneasy
3
Somewhat
Tense
3
Somewhat
Insecure
3
Somewhat
Worried
3
Somewhat
Distressed
3
Somewhat
Turbulent

2
Moderately
Troubled

3
Somewhat
Troubled

4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral

4
Neutral

5
Somewhat
Comfortable
5
Somewhat
At Ease
5
Somewhat
Relaxed
5
Somewhat
Secure
5
Somewhat
Worry-Free
5
Somewhat
Calm
5
Somewhat
Serene
5
Have Some
Peace of
Mind

6
Moderately
Comfortable
6
Moderately
At Ease
6
Moderately
Relaxed
6
Moderately
Secure
6
Moderately
Worry-Free
6
Moderately
Calm
6
Moderately
Serene
6
Have
Moderate
Peace of
Mind

7
Extremely
Comfortable
7
Extremely
At Ease
7
Extremely
Relaxed
7
Extremely
Secure
7
Extremely
Worry-Free
7
Extremely
Calm
7
Extremely
Serene
7
Have
Extreme
Peace of
Mind

b. Please imagine that you are the patient portrayed in this vignette and rate how much
you agree or disagree with the following questions.
Strongly
Disagree
1. I felt
devalued by
this
provider.
2. I believe
this provider
made
negative
judgments
about me.
3. I believe
this provider
treated me

Disagree

Slightly
Disagree

Neutral

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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like an
equal.
4. I believe
this provider
would prefer
not to treat
me.
5. I believe
this provider
treated me
the same as
he treats his
other
patients.
6. I believe
this provider
thought I
was a bad
person.
7. I felt like
this provider
ignored or
avoided me.
8. I believe
this provider
was
comfortable
treating me.
9. I felt like
this provider
looked down
on me.

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

****Thank you! Please click to watch next segment on the computer screen.
________________________________________________________________________
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Part 4.
a. Please imagine that you are the patient portrayed in this vignette. Now rate how
you feel interacting with this provider in terms of feeling: Comfort, At Ease,
Relaxed, Secure, Worried, Distressed, Serene, having Peace of Mind.
1
Extremely
Uncomfortable
1
Extremely
Uneasy
1
Extremely
Tense
1
Extremely
Insecure
1
Extremely
Worried
1
Extremely
Distressed
1
Extremely
Turbulent
1
Extremely
Troubled

2
Moderately
Uncomfortable
2
Moderately
Uneasy
2
Moderately
Tense
2
Moderately
Insecure
2
Moderately
Worried
2
Moderately
Distressed
2
Moderately
Turbulent

3
Somewhat
Uncomfortable
3
Somewhat
Uneasy
3
Somewhat
Tense
3
Somewhat
Insecure
3
Somewhat
Worried
3
Somewhat
Distressed
3
Somewhat
Turbulent

2
Moderately
Troubled

3
Somewhat
Troubled

4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral

4
Neutral

5
Somewhat
Comfortable
5
Somewhat
At Ease
5
Somewhat
Relaxed
5
Somewhat
Secure
5
Somewhat
Worry-Free
5
Somewhat
Calm
5
Somewhat
Serene
5
Have Some
Peace of
Mind

6
Moderately
Comfortable
6
Moderately
At Ease
6
Moderately
Relaxed
6
Moderately
Secure
6
Moderately
Worry-Free
6
Moderately
Calm
6
Moderately
Serene
6
Have
Moderate
Peace of
Mind

7
Extremely
Comfortable
7
Extremely
At Ease
7
Extremely
Relaxed
7
Extremely
Secure
7
Extremely
Worry-Free
7
Extremely
Calm
7
Extremely
Serene
7
Have
Extreme
Peace of
Mind

b. Please imagine that you are the patient portrayed in this vignette and rate how much
you agree or disagree with the following questions.
Strongly
Disagree
1. I felt
devalued by
this
provider.
2. I believe
this provider
made
negative
judgments
about me.
3. I believe
this provider
treated me
like an

Disagree

Slightly
Disagree

Neutral

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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equal.
4. I believe
this provider
would prefer
not to treat
me.
5. I believe
this provider
treated me
the same as
he treats his
other
patients.
6. I believe
this provider
thought I
was a bad
person.
7. I felt like
this provider
ignored or
avoided me.
8. I believe
this provider
was
comfortable
treating me.
9. I felt like
this provider
looked down
on me.

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

c. Taking into consideration this entire treatment experience, how comfortable would you
feel having a conversation about risky sexual behaviors with this provider?
1
Extremely
Uncomfortabl
e

2
Moderately
Uncomfortabl
e

3
Somewhat
Uncomfortabl
e

4
Neutra
l

5
Somewhat
Comfortabl
e

6
Moderately
Comfortabl
e

7
Extremely
Comfortable

d. Taking into consideration this entire treatment experience, how comfortable would you
feel having a conversation about alcohol and substance use with this provider?
1
Extremely
Uncomfortable

2
Moderately
Uncomfortable

3
Somewhat
Uncomfortable

4
Neutral

5
Somewhat
Comfortable

6
Moderately
Comfortable

7
Extremely
Comfortable
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e. Taking into consideration this entire treatment experience, how comfortable would you
feel having a conversation about HIV medication adherence difficulties with this
provider?
1
Extremely
Uncomfortable

2
Moderately
Uncomfortable

3
Somewhat
Uncomfortable

4
Neutral

5
Somewhat
Comfortable

****Thank you! Please ring bell for research assistant.

6
Moderately
Comfortable

7
Extremely
Comfortable
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Appendix G
Draft of Validity Phase Protocol
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VALIDITY STUDY PROCEDURES
I. INFORMED CONSENT
A. OVERVIEW OF CONSENT INFORMATION
A participant who gives their informed consent to participate in the study should
fully understand the nature of the research study, the purpose and pertinent procedures for
the study, potential risks and benefits of participating, confidentiality and steps taken by
research team to ensure confidentiality, and how the data will be used and stored.
B. PARTICIPANT CONSENT
After a brief introduction, the principle investigator (PI) leads the participant
through the informed consent form, highlighting the most important aspects of informed
consent. The following outline illustrates the content that is verbally expressed by the PI
during this process:
WHO: The project directors for this study are Jessie Heath, M.S., a clinical
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an
associate professor of psychology at Syracuse University and an adjunct assistant
professor of medicine at SUNY Upstate Medical University.
PURPOSE & PROCEDURE: You are being asked to participate in a research
study designed to learn more about how aspects of patient-provider relationships
can affect the medical treatment of persons living with HIV. Our goal is to gain a
better understanding of how the behaviors of medical care providers within
medical appointments can affect the HIV+ patients they treat. We will use the
information obtained in this study to inform the development of strategies to
improve patient-provider relationships and the quality of medical care received
HIV+ patients.
TIME & COMPENSATION: Your participation involves viewing two
vignettes of hypothetical medical care visits, responding to questions using an
interactive computer program, and briefly discussing your opinions with a
research assistant. The study takes approximately one half hour, and you will
receive $10 for you time.
RISKS/BENEFITS:
o Risks: There are three risks associated with this study. First, you may feel
uncomfortable answering personal questions. If this occurs, you may
choose not to answer any question. Second, you may find some aspects of
the vignette mildly upsetting. A third risk involves the risk of disclosing
private information to our research team. However, all information that
you share with members of our team is considered strictly confidential,
and we are obligated to protect your privacy.
o Benefits: You may learn more about your feelings and become aware of
how aspects of medical treatment experiences can affect you. In addition,
because the information you provide assists in the development of
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strategies to improve patient-provider relationships, your participation
could benefit others living with HIV.
CONFIDENTIALITY and HIPPA
o If you decide to participate, any information that you give us is strictly
confidential. We will keep your information private, except under 2
circumstances.
 First, if you tell us that you’re planning to hurt yourself or
someone else we would have to disclose that information.
 Second, if officials were concerned that the research team was
acting inappropriately, the research records might be audited to
make sure the research was being conducted ethically; however,
the auditors would be required to protect your privacy.
PROTECTION OF CONFIDENTIALITY
o All project staff receive extensive training and supervision on
confidentiality procedures.
o Your survey is given an identification number and only authorized
research staff has access to the key that connects your information to your
name. Your identity will not be included on the audiotapes and the tapes
will be erased once we are finished with the project.
o Certificate of Confidentiality from the Department of Health and Human
services, which states that the investigators cannot be forced to release
your information (for example, by subpoena) to any federal, state, or local,
civil, criminal, administrative, legislative, or other proceedings. This
Certificate does NOT prevent you or your family from voluntarily
disclosing information about yourself or your involvement in this research.
PARTICIPATION IS VOLUNTARY: You may refuse to participate or
discontinue your participation at any time without penalty or loss of benefits.
PERMISSION TO BE RECONTACTED: The participants are then asked to
sign and date one copy of the consent form and keep a second copy for their own
records. Participants are also given a copy of University Hospital’s Privacy
Practices Policy and asked to keep it for their records.
C. STORAGE OF CONSENT FORMS
After pertinent information from the completed consent forms has been entered
into the Excel patient database, the completed focus group consent forms will be stored in
a locked filing cabinet in the UPH office.
II. VALIDITY STUDY PROTOCOL ADMINISTRATION
A. ASSIGNMENT OF PARTICIPANT NUMBER AND CONDITION
After participants consent, they will be assigned a participant ID number and
randomized to a view either the “high stigma” or “no stigma” study condition first using
a random number generator.
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B. VIGNETTE AND SURVEY ADMINISTRATION
The quantitative survey is administered following the informed consent. The
participants will be seated in front of a computer, where the PI will introduce the
computerized study protocol and briefly describe how the computer program works. The
PI will answer any questions the participant has and ensure the participant’s ability to
successfully interact with the computer program. For participants with limited computer
exposure, the principle investigator will provide additional instruction on the use of the
mouse and keyboard as necessary. Participants will also be instructed that if they have
any difficulties with the computer program to ring a bell on the desk and the principle
investigator will assist them. Participants will then follow the audio instructions on the
ACASI program to complete the small battery of self-report assessments and respond to
the visual and audio treatment vignettes. The ordering of the protocol will be as follows:
(1) reporting of background and health information, (2) step-by-step presentation of
treatment vignettes with ratings of comfort and stigmatization assessed at several points
throughout the presented patient-provider interaction, and (3) a brief discussion with the
research assistant to elicit feedback about the vignettes.
C. DATA ENTRY AND STORAGE
Data from the ACASI program will be automatically stored upon completion of
the protocol and then transformed into an SPSS format for analyses. There will be no
hard copies of data in the experimental phase of the study and no identifying information
will present in the ACASI or SPSS files.
D. PARTICIPANT REIMBURSEMENT
The PI will retrieve reimbursement funds from Sean Kelley prior to the start of
the focus group. Participants will be reimbursed $10 for their one half hour of
participation in the focus groups. After participants have received their reimbursement,
the PI will complete a reimbursement receipt including only the participant’s ID number
and file it in the UPH filing cabinet under non-reconciled payment receipts. The original
reimbursement form will then be turned in to Sean Kelley. A photocopy will be stored in
the UPH filing cabinet under reconciled payment receipts.
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Appendix H
Draft of Validity Phase Informed Consent Form
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SUNY UPSTATE MEDICAL UNIVERSITY AND
SYRACUSE UNIVERSITY
Consent/Authorization Form
Title of Study: Treatment Experiences of HIV+ Patients Validity Sub-Study
Background/Purpose:
You are invited to participate in a research study designed to learn more about how
aspects of patient-provider relationships can affect the medical treatment of persons
living with HIV. Our goal is to gain a better understanding of how the behaviors of
medical care providers can affect the HIV+ patients they treat. We will use the
information obtained in this study to inform the development of strategies to improve
patient-provider relationships and the quality of medical care received HIV+ patients.
The directors of this study are Jessie Heath, M.S., a clinical psychology doctoral student
and Dr. Peter Vanable, an Associate Professor of Psychology at Syracuse University and
an Adjunct Assistant Professor of Medicine at SUNY Upstate Medical University. Other
trained research staff will also be involved, and will be supervised by Drs. Peter Vanable
of Syracuse University. We are asking approximately 20 patients to participate in the
study.
You will be given enough time to read and understand the information provided in this
consent and authorization form. Please ask the study staff to explain any words or
information that you do not understand. You may keep an unsigned copy of this consent
and authorization form to think about your decision or discuss with your family, friends,
or doctors before making your decision to take part in this research study.
Study Procedures:
If you decide to take part in this study, you will listen and respond to information that is
presented individually to you on a computer. You will view two vignettes representing
typical, first-time medical care visits of an HIV+ patient. On the computer, you will hear
audio descriptions of the medical visits, conversations between the hypothetical patient
and provider, and also view pictures of the interaction. Throughout the presentation of the
vignettes, you will answer questions presented on the computer screen regarding your
feelings and opinions about what you are viewing. Following the presentation of the
vignettes, you will give verbal feedback to a research assistant about your experience in
the study and suggestions for improving the vignettes. The study takes approximately one
half hour to complete, and your participation is completely voluntary.
If you agree to participate in the study, you will also be asked to complete a brief survey
with questions about your background and health information, including medical
appointment attendance, hospitalizations, and recent indicators of health status (CD4
count, viral load).
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Risks:
There are three risks associated with this study. First, you may feel uncomfortable
answering personal questions. If this occurs, you may choose not to answer any question.
Second, you may find some aspects of the treatment vignette mildly upsetting. A third
risk involves the risk of disclosing private information to our research team. However, all
information that you share with members of our team is considered strictly confidential,
and we are obligated to protect your privacy.
Benefits:
The potential benefits are that you may learn more about your feelings and become aware
of how aspects of medical treatment experiences can affect you. In addition, because the
information you provide assists in the development of strategies to improve patientprovider relationships, your participation could benefit others living with HIV.
Voluntary Participation:
Your participation in this study is entirely voluntary and you may refuse to participate or
stop participation at any time without penalty or loss of benefits to which you would
normally be entitled. Your decision about whether or not to participate in the study will
not affect the care you receive at SUNY Upstate Medical University.
Alternatives:
If you decide not to participate in this research study, you will continue to receive your
usual care and will not complete the surveys for research purposes.
Costs/Payments:
There are no costs to you and/or your insurance carrier for participating in this study.
After completing the study, you will receive $10 to offset your expenses and to thank you
for your time.
If you choose to stop participating in the study before all study requirements are
completed, you will be paid $5 for each ¼ hour of time you devote to the study.
In addition, by accepting payment for participating in this study, certain identifying
information about you may be made available to professional auditors to satisfy audit and
Federal reporting requirements, but confidentiality will be preserved. Please note that if
you earn $600 or over in a calendar year as a research subject, you may have to pay taxes
on these earnings.
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Questions:
If you have any questions about the research, please contact Ms. Jessie Heath at (315)
443-1052 or Dr. Peter Vanable at (315) 443-2024. If you have any questions about your
rights as a research subject, please contact the SUNY Upstate Medical University
Institutional Review Board Office at (315) 464-4317 or the Syracuse University
Institutional Review Board Office at (315) 443-3013.
Confidentiality of Records and Authorization to Use/Share Protected Health
Information for Research:
If you agree to participate in this research, identifiable health information about you
will be used and shared with others involved in this research. For you to be in this
research we need your permission to collect and share this information. Federal law
protects your right to privacy concerning this information.
When you sign this consent form at the end, it means that you have read this section and
authorize the use and/or sharing of your protected health information as explained below.
Your signature also means you have received a copy of Upstate’s Notice of Privacy
Practices.
Individually identifiable health information under the federal privacy law is considered to
be any information from your medical record, or obtained from this study, that can be
associated with you, and relates to your past, present, or future physical or mental health
or condition. This is referred to as protected health information.
Your protected health information will be kept confidential. Research staff will not share
the information you provide during the discussion group and on the survey with your
doctor or nurse here in the clinic. Further, you will not be identified in any publication or
presentation resulting from this study. Several steps have been taken to protect the
confidentiality of your responses and involvement in this research. Project staff has
participated in extensive training and supervision regarding the importance of
maintaining participant confidentiality. In addition, an identification number will be
assigned to your survey, and only the directors of this research (Jessie Heath, M.S. and
Dr. Vanable) will have access to the key that indicates which number belongs to which
participant. The master list linking the participant ID number to the participant’s
identifying information will be maintained in a separate, secure computer database, and
will be destroyed at the conclusion of the study. Your name or other identifying
information will not be kept with your survey, and your survey information will be stored
in a secure computer database.
To help us further protect your privacy, the investigators have received a Confidentiality
Certificate from the Department of Health and Human Services. With this Certificate,
the investigators cannot be forced (for example by court subpoena) to disclose research
information that may identify you in any Federal, State, or local, civil, criminal,
administrative, legislative, or other proceedings. The researchers will use the Certificate
to resist any demands for information that would identify you, except as explained below.
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The Certificate cannot be used to resist a request for information from personnel of the
United States Department of Health and Human Services that is used for auditing or
evaluation of federally funded projects.
In addition, the Confidentiality Certificate does not prevent you or a member of your
family from voluntarily releasing information about yourself or your involvement in this
research. Note however, that if an insurer or employer learns about your participation,
and obtains your consent to receive research information, then the investigator may not
use the Certificate of Confidentiality to withhold this information. This means that you
and your family must also actively protect your own privacy.
Why is it necessary to use/share your protected health information with
others? The main reason to use and share your health information is to conduct the
research as described in this consent form. Your information may also be shared
with people and organizations that make sure the research is being done correctly,
and to report unexpected or bad side effects you may have. In addition, we will
release protected health information about you if we learn about your intent to harm
yourself or others.
What protected health information about you will be used or shared with others as
part of this research? We may use and share the results of tests, questionnaires, and
interviews. We will only collect information that is needed for the research.
Who will be authorized to use and/or share your protected health
information? The researchers, their staff and the staff of Upstate Medical University
participating in the research will use your protected health information for this
research study. In addition, the Upstate Medical University and Syracuse University
Institutional Review Boards (IRB), committees responsible for protecting the rights
of research subjects, and other Upstate Medical University, Syracuse University, or
University Hospital staff who supervise the way the research is done, may have
access to your protected health information.
The researchers and their staff will determine if your protected health information
will be used or shared with others outside of Upstate Medical University and
Syracuse University for purposes directly related to the conduct of the research.
With whom would the protected health information be shared? Your protected
health information may be shared with:
Federal agencies that supervise the way the research is conducted, such as the
Department of Health and Human Services’ Office for Human Research
Protections or the National Institutes of Health.
Researchers from Syracuse University assisting in the study.
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The Syracuse University Institutional Review Board (a committee responsible for
protecting the rights of research subjects).
All reasonable efforts will be used to protect the confidentiality of your protected
health information. However, not all individuals or groups have to comply with the
Federal privacy law. Therefore, once your protected health information is disclosed
(leaves Upstate Medical University), the Federal privacy law may not protect it.
For how long will your protected health information be used or shared with
others? There is no scheduled date at which this information will be destroyed or no
longer used. This is because information that is collected for research purposes continues
to be used and analyzed for many years and it is not possible to determine when this will
be complete.
Can you withdraw your authorization to collect/use/share your protected
health information? You always have the right to withdraw your permission
(revoke authorization) for us to use and share your health information, by putting
your request in writing to the investigator in charge of the study. This means that
no further private health information will be collected. Once authorization is
revoked, you may no longer participate in this research activity, but standard medical
care and any other benefits to which you are entitled will not be affected. Revoking
your authorization only affects uses and sharing of information obtained after your
written request has been received, but not information obtained prior to that time.
Even after you withdraw your permission, Upstate Medical University may continue
to use and share information needed for the integrity of the study; for example,
information about an unexpected or bad side effect you experienced related to the
study.
Can you have access to your health information? At the end of the study, you have
the right to see and copy health information about you in accordance with the SUNY
Upstate Medical University policies; however, your access may be limited while the
study is in progress.
Permission To Contact For Follow-Up Research
We may conduct additional research on this important topic. May we contact you about
participation in future studies? Indicating you are willing to be contacted does not
obligate you to participate in any other study, nor does it affect your participation in this
study.
 No, I prefer not to be contacted about future studies.
 Yes, I am willing to be contacted about future studies.
Phone: _______________
Mailing Address: _______________________________________
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Consent To Participate In Research & Authorization To Use And Share Personal
Health Information:
I hereby give my consent to participate in this research study and agree that my personal
health information can be collected, used and shared by the researchers and staff for the
research study described in this form. I will receive a signed copy of this consent form.

______________________________________
Signature of subject

__________________
Date

_____________________________________________
Printed Name of Research Participant

___________________________________________
Signature of Person Obtaining Consent/Authorization

___________________________________________
Printed Name of Person Obtaining Consent/Authorization

__________________
Date
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Experiences of HIV-related Stigmatization in Healthcare
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Experiences of HIV-related Stigmatization in Healthcare

Directions: Please indicate the extent to which you have experienced these behaviors
from a healthcare provider (doctor, nurse, intern, medical student) because you
were HIV+.
Item:

Never

Once or
Twice

3-6
Times

7-10
Times

More than
10 Times

1. has refused to treat me because I am
HIV+

0

1

2

3

4

2. has appeared angry or irritated while
treating me

0

1

2

3

4

3. has avoided touching me because I am
HIV+

0

1

2

3

4

4. has rushed me through an
appointment because I am HIV+

0

1

2

3

4

5. has blamed me for my infection
because of my lifestyle

0

1

2

3

4

6. has given me a lower quality of care
because I am HIV+

0

1

2

3

4

7. would not maintain eye contact with
me because I am HIV+

0

1

2

3

4

8. has sat/stood very far away from me
in the treatment room because I am
HIV+

0

1

2

3

4

9. has made me wait longer for care than
other patients because I am HIV+

0

1

2

3

4

A healthcare provider . . .
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10. has appeared nervous or
uncomfortable while treating me

0

1

2

3

4

11. has treated me rudely or
disrespectfully because I am HIV+

0

1

2

3

4

12. has told me that I deserved to
become infected

0

1

2

3

4

13. referred me to another provider
because I am HIV+

0

1

2

3

4

14. has worn extra gloves to examine me
when it was unnecessary

0

1

2

3

4

15. has told me or acted as if I was a
waste of his/her time because I am HIV+

0

1

2

3

4
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Patient Comfort Measure

1. Please imagine that you are the patient portrayed in this vignette. Now rate how you
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure,
Worried, Distressed, Serene, having Peace of Mind.
1
Extremely
Uncomfortable
1
Extremely
Uneasy
1
Extremely
Tense
1
Extremely
Insecure
1
Extremely
Worried
1
Extremely
Distressed
1
Extremely
Turbulent
1
Extremely
Troubled

2
Moderately
Uncomfortable
2
Moderately
Uneasy
2
Moderately
Tense
2
Moderately
Insecure
2
Moderately
Worried
2
Moderately
Distressed
2
Moderately
Turbulent

3
Somewhat
Uncomfortable
3
Somewhat
Uneasy
3
Somewhat
Tense
3
Somewhat
Insecure
3
Somewhat
Worried
3
Somewhat
Distressed
3
Somewhat
Turbulent

2
Moderately
Troubled

3
Somewhat
Troubled

4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral
4
Neutral

4
Neutral

5
Somewhat
Comfortable
5
Somewhat
At Ease
5
Somewhat
Relaxed
5
Somewhat
Secure
5
Somewhat
Worry-Free
5
Somewhat
Calm
5
Somewhat
Serene
5
Have Some
Peace of
Mind

6
Moderately
Comfortable
6
Moderately
At Ease
6
Moderately
Relaxed
6
Moderately
Secure
6
Moderately
Worry-Free
6
Moderately
Calm
6
Moderately
Serene
6
Have
Moderate
Peace of
Mind

7
Extremely
Comfortable
7
Extremely
At Ease
7
Extremely
Relaxed
7
Extremely
Secure
7
Extremely
Worry-Free
7
Extremely
Calm
7
Extremely
Serene
7
Have
Extreme
Peace of
Mind

2. How comfortable would you feel having a conversation about risky sexual behaviors
with the provider shown in the computer program?

1
Extremely
Uncomfortable

2
Moderately
Uncomfortable

3
Somewhat
Uncomfortable

4
Neutral

5
Somewhat
Comfortable

6
Moderately
Comfortable

7
Extremely
Comfortable
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3. How comfortable would you feel having a conversation about alcohol and substance
use with the provider shown in the computer program?

1
Extremely
Uncomfortable

2
Moderately
Uncomfortable

3
Somewhat
Uncomfortable

4
Neutral

5
Somewhat
Comfortable

6
Moderately
Comfortable

7
Extremely
Comfortable

4. How comfortable would you feel having a conversation about HIV medication
adherence difficulties with the provider shown in the computer program?
1
Extremely
Uncomfortable

2
Moderately
Uncomfortable

3
Somewhat
Uncomfortable

4
Neutral

5
Somewhat
Comfortable

6
Moderately
Comfortable

7
Extremely
Comfortable
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Perceptions of Stigmatization within the Patient-Provider Interaction

Directions: Please indicate the extent to which you agree or disagree with each of the
following statements regarding your beliefs about the provider shown in the
computer program.
Strongly
Disagree
1. I felt
devalued by
this
provider.
2. I believe
this provider
made
negative
judgments
about me.
3. I believe
this provider
treated me
like an
equal.
4. I believe
this provider
would prefer
not to treat
me.
5. I believe
this provider
treated me
the same as
he treats his
other
patients.
6. I believe
this provider
thought I
was a bad
person.
7. I felt like
this provider
ignored or
avoided me.
8. I believe
this provider
was
comfortable
treating me.
9. I felt like
this provider
looked down
on me.

Disagree

Slightly
Disagree

Neutral

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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Patient-Provider
Relationship
Items
10. I believe this
provider would
listen to me.
11. I believe this
provider would
care about me.
12. I believe this
provider would
answer my
questions.
13. I believe this
provider would
spend enough
time with me.
14. I believe this
provider would
involve me in
treatment
decisions.
15. I believe this
provider would
respect my
choices.
16. I believe this
provider would
effectively deal
with my
problems.
17. I believe this
provider would
engage me in my
care.
18. I believe this
provider would be
helpful to me.
19. I believe this
provider would
respect me.
20. I believe this
provider would
support my
decisions.
21. I believe this
provider would
see me when I
ask.
22. I believe this
provider would
give me important
information.

Strongly
Disagree

Disagree

Slightly
Disagree

Neutral

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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Appendix L
Engagement in Care Measure
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Engagement in Care Measures

A. Intentions to Remain in HIV Care Measure
1. How likely is it that you would remain in care with the provider shown in the computer
program?

1
Extremely
Unlikely

2
Moderately
Unlikely

3
Somewhat
Unlikely

4
Neutral

5
Somewhat
Likely

6
Moderately
Likely

7
Extremely
Likely
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B. Intentions to Discuss Sexual Risk Behavior Measure
*Please answer the following questions as if you have had unprotected anal or
vaginal sex since becoming HIV+. In other words, even if you have not had
unprotected sex since becoming HIV+, please imagine that you have when you are
answering these next questions.
1. If the provider shown in the computer program asked, how likely is it that you would
tell them you had unprotected anal or vaginal sex with a STEADY PARTNER:

a. who
was HIVor
unknown
status,
and it
happened
more
than 3
months
ago
b. who
was HIVor
unknown
status,
and it
happened
less than
3 months
ago

Extremely
Unlikely
1

Moderately
Unlikely
2

Somewhat
Unlikely
3

Neutral
4

Somewhat
Likely
5

Moderately
Likely
6

Extremely
Likely
7

1

2

3

4

5

6

7

2. If the provider shown in the computer program asked, how likely is it that you would
tell them you had unprotected anal or vaginal sex with a CASUAL PARTNER:

c. who was
HIV- or
unknown
status, and
it happened
more than
3 months
ago
d. who was
HIV- or
unknown
status, and
it happened

Extremely
Unlikely
1

Moderately
Unlikely
2

Somewhat
Unlikely
3

Neutral
4

Somewhat
Likely
5

Moderately
Likely
6

Extremely
Likely
7

1

2

3

4

5

6

7
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less than 3
months ago

3. In the event that you were having difficulties achieving and maintaining safer sex
practices, how likely is it that you would start a conversation about this with the
provider?

1
Extremely
Unlikely

2
Moderately
Unlikely

3
Somewhat
Unlikely

4
Neutral

5
Somewhat
Likely

6
Moderately
Likely

7
Extremely
Likely

C. Intentions to Discuss Substance Use Risk Behavior Measure
*Please answer the following questions as if you have drank alcohol or used drugs
(not prescribed to you) since becoming HIV+. In other words, even if you have not
drank alcohol or used drugs since becoming HIV+, please imagine that you have
when you are answering these next questions.
1. If the provider shown in the computer program asked, how likely is it that you would
tell them you have consumed ALCOHOL:

a. at low
levels more
than 3
months ago
b. at low
levels less
than 3
months ago
c. at high
levels or
problematically more
than 3
months ago
d. at high
levels or
problematically less
than 3
months ago

Extremely
Unlikely

Moderately
Unlikely

Neutr
al

2

Somewhat
Unlikely
3

Moderately
Likely

Extremely
Likely

4

Somewhat
Likely
5

1

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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2. If the provider shown in the computer program asked, how likely is it that you would
tell them you have used ILLEGAL DRUGS or those NOT PRESCRIBED TO YOU:
Extremely
Unlikely

Moderately
Unlikely

Neutr
al

2

Somewhat
Unlikely
3

Moderately
Likely

Extremely
Likely

4

Somewhat
Likely
5

a. at low
levels more
than 3
months ago

1

6

7

b. at low
levels less
than 3
months ago

1

2

3

4

5

6

7

c. at high
levels or
problematically more
than 3
months ago

1

2

3

4

5

6

7

d. at high
levels or
problematically less
than 3
months ago

1

2

3

4

5

6

7

3. In the event that you were SHARING NEEDLES during drug use, and the provider
shown in the computer program asked, how likely is it that you would tell them?

1
Extremely
Unlikely

2
Moderately
Unlikely

3
Somewhat
Unlikely

4
Neutral

5
Somewhat
Likely

6
Moderately
Likely

7
Extremely
Likely
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4. In the event that you were interested in receiving alcohol or substance abuse treatment,
how likely is it that you would start a conversation about this with this provider?

1
Extremely
Unlikely

2
Moderately
Unlikely

3
Somewhat
Unlikely

4
Neutral

5
Somewhat
Likely

6
Moderately
Likely

7
Extremely
Likely
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D. Intentions to Discuss Medication Adherence Difficulties Measure
*Please answer the following questions as if you are taking HIV MEDICATIONS
and HAVE NOT had perfect 100% adherence. In other words, even if you are not
on HIV medications or have never missed a dose, please imagine that you have when
you are answering these next questions.
1. If the provider shown in the computer program asked, how likely is it that you would
tell them that you had UNINTENTIONALLY missed doses of your HIV medications
(examples: forgetting, misplacing medications, sleeping through doses, etc.) if:
Extremely Moderately
Unlikely
Unlikely

Somewhat
Unlikely

Neutral

Some- Moderately Extremely
what
Likely
Likely
Likely

a. it only
happened
a few
times
and
more
than 3
months
ago

1

2

3

4

5

6

7

b. it
happened
many
times
and
more
than 3
months
ago

1

2

3

4

5

6

7

c. it only
happened
a few
times
and less
than 3
months
ago

1

2

3

4

5

6

7

d. it
happened
many
times
and less
than 3
months
ago

1

2

3

4

5

6

7
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2. If the provider shown in the computer program asked, how likely is it that you would
tell them you had INTENTIONALLY missed doses of your HIV medications
(examples: purposely skipping doses, medication vacations, taking meds not as
prescribed, etc.) if:
Extremely Moderately
Unlikely
Unlikely

Somewhat
Unlikely

Neutral

Some- Moderately Extremely
what
Likely
Likely
Likely

a. it only
happened
a few
times
and
more
than 3
months
ago

1

2

3

4

5

6

7

b. it
happened
many
times
and
more
than 3
months
ago

1

2

3

4

5

6

7

c. it only
happened
a few
times
and less
than 3
months
ago

1

2

3

4

5

6

7

d. it
happened
many
times
and less
than 3
months
ago

1

2

3

4

5

6

7
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3. In the event that you were having difficulties with medication adherence (not taking
your meds exactly how you are supposed to), how likely is it that you would start a
conversation about this with the provider?

1
Extremely
Unlikely

2
Moderately
Unlikely

3
Somewhat
Unlikely

4
Neutral

5
Somewhat
Likely

6
Moderately
Likely

7
Extremely
Likely
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E. Disclosure of Personal Risk Behaviors Measure
*For these next questions, please imagine that you are at a clinic appointment with
Dr. XXX, the provider previously shown on the computer. You are sitting on the
exam table when Dr. XXX enters the room and states that he will be asking you a
series of questions regarding sensitive health behaviors such sexual activities,
alcohol and drug use, and HIV medication adherence. Please answer the provider
based on your own actual, real life experiences.

1. How many sexual partners have you had in your lifetime?

2. How many sexual partners have you had in the past 3 months?

3. In the past 3 months, what percentage of time have you used condoms?

0%
Never

25%
Some of the
Time

50%
Half of the
Time

75%
Most of the
Time

100%
Always

4. Thinking of the past 3 months, how many days a week did you drink alcohol?

0 days

1-2 days

3-4 days

5-6 days

7 days

5. Thinking of times when you have drank in the past three months, how many alcoholic
drinks did you typically have at one time?

None

1-2 drinks

3-4 drinks

5-6 drinks

More than 6
drinks
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6. Have you ever used illegal drugs?

No

Yes, but only a
few times.

Yes, I have
used drugs
frequently but
did not have
problems
related to my
use.

Yes, I have
used drugs
frequently and
did have
problems
related to my
use.

7. In the past three months, how often have you used illegal drugs?

Never

Once or Twice

Once or Twice
a Week

Several Times
a Week

Almost
Everyday

8.When was the last time you purposely SKIPPED taking any of your HIV medications?

Never

More than 3
months ago

1-3 months
ago

2-4 weeks ago

1-2 weeks
ago

within the
past week

9. What percentage of your HIV medication doses have you taken in the past week?

0%
I have not
taken any of
my meds.

100%
I have taken all
10% 20% 30% 40% 50% 60% 70% 80% 90%
the doses of my
meds.
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Appendix M
Vignette Scripts
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Non-Stigma Vignette Female
1. Segment 1:
Narrator: Dr. Everheart knocked on the door before entering into the room. He
approached Ms. Johnson and shook her hand while introducing himself.
Actor 1 (provider): Hello Ms. Johnson my name is Dr. Actor 1 (provider) Everheart and
I’ll be your primary physician here at the clinic. I understand that you are new to the area.
I hope you are enjoying our lovely city. How are you doing?
Narrator: Dr. Everheart takes a seat in a chair near the exam table where Ms. Johnson is
sitting and begins reviewing her chart.
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to
start all over at a new clinic with new doctors.
Actor 1 (provider): Well that’s understandable, we’ll try to make the process as easy as
possible for you. Basically all we are going to be doing today is going over your medical
history, completing a physical exam, and discussing any questions or concerns that you
or I might have about your health. I like to be thorough with all my new patients, and
double check some of the information in their files just to be sure it’s up to date and
correct. Your last treatment center sent us your file yesterday, I just have few pieces of
information that I would like to confirm with you.
Actor 2 (patient): ok
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago
in February of 2006.
Actor 2 (patient): Yeah, that’s the story.
Actor 1 (provider): It says that you most likely became infected from sexual activity with
men, and more specifically your boyfriend at the time.
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months
together we weren’t as strict about using condoms all the time. One day he found out one
of his past hook-ups was positive and we both went in and got tested. Both of us found
out that we were positive. We’re still together though and he moved here with me.
Actor 1 (provider): It seems like you have really been there for each other. You know, it’s
so common for people to not know that they are positive. It seems like both of you got
blind-sided in that situation. It’s really good that you both decided to come in and get
tested when you did.
Actor 2 (patient): Thanks.
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2. Segment 2:
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty
soon after you received your diagnosis.
Actor 2 (patient): Yeah it was within a few months.
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty
stable ever since you started taking meds, except for the summer of last year when your
viral load became detectable again and your CD4 count dropped by 30%. Do you
remember what was going on around that time that caused these changes?
Actor 2 (patient): Yeah, my last doctors tried to switch my meds because they were
making me nauseas and tired throughout the day. The new combination didn’t work, so
they put me back on the old meds after a few months. I was actually upset about it
because physically I felt really great on the new meds. I mean is it really that big of deal
if my numbers change a little?
Actor 1 (provider): You know it can often be a fairly complicated process to find the right
combination of meds for patients. We try to balance out the experience of side effects
with the effectiveness of the medications, and every patient responds a bit differently.
Unfortunately, it is a big deal if your viral load and CD4 count change. Those are our best
indicators of how the HIV virus is progressing in your body, and they can even be better
indicators then how your body is physically feeling. I actually have a great brochure
about some of the important information about viral load and CD4 counts. Would you
like me to go over some of it with you?
Actor 2 (patient): That would actually be really helpful.
Narrator: Dr. Everheart stood up from his chair and grabbed a brochure. After walking
over to the exam table, Dr. Everheart pointed out the key points of the brochure to Ms.
Johnson and answered any remaining questions that she had.
Actor 2 (patient): Ok, so I get now why they took me off the new meds, but is there
anything that you can do to help with the side effects. I can’t be feeling sick all day at my
new job. I don’t want to make that type of impression.
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that
haven’t been tried by your last doctors. And after I get some more detailed results from
your blood draw today, I will look into the possibility of other medication regimens that
might be as effective as your current meds but with less side effects. I don’t know if the
new HIV medications on market will turn out to be a good fit for you, but we can
definitely look into the possibility.
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Actor 2 (patient): Ok, fair enough.
3. Segment 3:
Narrator: Dr. Everheart handed the brochure to Ms. Johnson and explained that he would
now be performing a physical examination.
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination
to check your heart rate, blood pressure, breathing, and also check out your throat, ears,
and eyes for normal functioning.
Narrator: Dr. Everheart approached Ms. Johnson, placing the stethoscope in his ears. He
stood close to Ms. Johnson, placed the stethoscope on her chest, and listened to her
breathing for approximately 10 seconds. He then placed the stethoscope on his back and
listened for another 10 seconds. Dr. Everheart removed the stethoscope from her ears,
reached for the blood pressure cuff, and placed it on Ms. Johnson’s arm. After taking Ms.
Johnson’s blood pressure, Dr. Everheart, stood up and walked to the supply cabinet in the
exam room. Dr. Everheart returned with a tongue depressor and asked Ms. Johnson to
open her mouth. Dr. Everheart leaned towards Ms. Johnson and examined the inside of
her throat thoroughly. Dr. Everheart then felt her lymph nodes on the side of her neck for
a few moments before returning to his seat near the exam table.
4. Segment 4:
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate.
And no signs of temperature or cold symptoms. How have you been feeling recently?
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any
changes in medication, diet, activity level?
Actor 2 (patient): Not really.
Actor 1 (provider): Have you been experiencing a lot of stress lately? Everything been
going ok with friends/family?
Actor 2 (patient): You know I have been stressed out a lot due to the move, but I really
don’t think it’s just that. They’re pretty bad. I get shooting pains right behind my eyes,
and it’s happening at least twice a week.
Actor 1 (provider): Ok, well I have some ideas for what might be causing these types
headaches. Those pain symptoms are pretty common for a lot of people especially those
with a family history of migraines. I’ll check to see if we have some medication samples
to for you take home and see if they help. They shouldn’t interact with any of your HIV
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meds, just make sure to take them with food. If after a week you’re still having problems
we can do some more extensive tests to see what’s going on. Sound okay to you?
Actor 2 (patient): Sounds good.
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.
Narrator: Dr. Everheart left the exam room and returned in several minutes with the
medication samples.
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before
you leave, I’d like to chat with you a little about your current sexual practices and also
any previous or current alcohol or drug use. I know these types of topics are sensitive in
nature and can seem a little out of the blue for a regular medical appointment. Basically
new national standards of medical practice have been created, calling for health care
providers to assess these types of things at all medical care visits to improve prevention
of new infections and also to allow for the best care possible for current HIV+ patients.
It’s important to me that you feel comfortable, so is it okay for me to ask you a few
questions?
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Stigma Vignette Female
1. Segment 1:
Narrator: Dr. Everheart knocked on the door before entering into the room. He walked
through door looking at Ms. Johnson’s file and did not look up while introducing himself.
Actor 1 (provider): Hello Ms. Johnson my name is Dr. Everheart and I’ll be your primary
physician here at the clinic. How are you doing?
Narrator: Dr. Everheart takes a seat in a chair on the far side of the room from where Ms.
Johnson is sitting and begins reviewing her chart.
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to
start all over at a new clinic with new doctors.
Narrator: Dr. Everheart continues to look down at Ms. Johnson’s chart as he speaks.
Actor 1 (provider): Well, nothing to worry about. Basically all we are going to be doing
today is going over your medical history and completing a physical exam. I like to be
thorough with all my new patients, and double check some of the information in their
files. Your last treatment center sent us your file yesterday, I just have few pieces of
information that I would like to confirm with you.
Actor 2 (patient): ok
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago
in February of 2006.
Actor 2 (patient): Yeah, that’s the story.
Actor 1 (provider): It says that you most likely became infected from having sex with
HIV+ men. Hopefully becoming positive has motivated you to be more careful with
reducing your number of sexual partners, using condoms, and staying away from drugs.
Oh wait, I see here that you were infected by your boyfriend at the time.
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months
together we weren’t as strict about using condoms all the time. One day he found out one
of his past hook-ups was positive and we both went in and got tested. Both of us found
out that we were positive. We’re still together though and he moved here with me.
Actor 1 (provider): That’s surprising. You really don’t see that nowadays. But, I guess
you learned your lesson, and at least you both decided to come in and get tested when
you did.
Actor 2 (patient): Thanks.
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2. Segment 2:
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty
soon after you received your diagnosis.
Actor 2 (patient): Yeah it was within a few months.
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty
stable ever since you started taking meds. That is except for the summer of last year when
your viral load became detectable again and your CD4 count dropped by 30%. Did you
stop taking your meds?
Actor 2 (patient): No, actually my last doctors tried to switch my meds because they were
making me nauseas and tired throughout the day. The new combination didn’t work, so
they put me back on the old meds after a few months. I was actually upset about it
because physically I felt really great on the new meds. I mean is it really that big of deal
if my numbers change a little?
Actor 1 (provider): Unfortunately, Ms. Johnson it is a big deal if your viral load and CD4
count change. Those are our best indicators of how the HIV virus is progressing in your
body. You’ve been positive a while, I assumed you knew all this. I think I have a
brochure that can explain viral load and CD4 counts to you. Let me grab it.
Narrator: Dr. Everheart rose from his chair and grabbed a brochure. Without approaching
the exam table, he leaned over to hand the brochure to Ms. Johnson.
Actor 1 (provider): I strongly suggest you review this material.
Actor 2 (patient): I’ll check this out later, but is there anything that you can do to help
with the side effects. I can’t be feeling sick all day at my new job. I don’t want to make
that type of impression.
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that
haven’t been tried by your last doctors.
Actor 2 (patient): What about changing my HIV meds? Can we try something new? I’ve
been reading a lot about a one-a-day pill. Could we try that?
Actor 1 (provider): I really don’t think that’s necessary at this point. Your current meds
are working great, other than a few side effects. But if it’s that important to you, after I
get some more detailed results from your blood draw today, I will look into the
possibility of other medication regimens.
Actor 2 (patient): Ok.
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3. Segment 3:
Narrator: Dr. Everheart explained that he would now be performing a physical
examination.
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination
to check your heart rate, blood pressure, breathing, and also check out your throat, ears,
and eyes for normal functioning.
Narrator: Dr. Everheart walked to the supply cabinet and grabbed two pairs of latex
gloves. He put them on his hands and approached Ms. Johnson, placing the stethoscope
in his ears. He maintained an arm’s length distance from Ms. Johnson, having to stretch
his arm to place the stethoscope on her chest. Leaning away from Ms. Johnson, he
listened to his breathing for a few seconds, and then placed the stethoscope on her back
and listened for another couple seconds. Dr. Everheart removed the stethoscope from his
ears, reached for the blood pressure cuff, and asked Ms. Johnson’s to place it on her own
arm. After taking Ms. Johnson’s blood pressure, Dr. Everheart, stood up and again
walked to the supply cabinet in the exam room. Dr. Everheart returned with a tongue
depressor and asked Ms. Johnson to open her mouth. Dr. Everheart again maintained an
arm’s length distance from Ms. Johnson and had a strained look on his face while
examining the inside of her throat. Dr. Everheart then felt her lymph nodes on the side of
her neck for a few moments before returning to his seat on the far side of the exam room.
4. Segment 4:
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate.
And no signs of temperature or cold symptoms. How have you been feeling recently?
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any
changes in medication, diet, activity level?
Actor 2 (patient): Not really.
Actor 1 (provider): Then it’s probably just HIV-related.
Actor 2 (patient): Well maybe. But they’re pretty bad. I get shooting pains right behind
my eyes, and it’s happening at least twice a week.
Actor 1 (provider): Ok, well it sounds like you might be experiencing migraines. I think
we have some med samples here in the clinic that you could try out, but I’m not really
sure if migraine medications with interact negatively with your HIV medications. Let me
check with your nurse practitioner.
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Narrator: Dr. Everheart walked to the door and opened it far enough to stick his head out
into the hall. In a moderately loud voice, he called for Ms. Johnson’s nurse practitioner.
Actor 1 (provider): Christine, will Imitrex interact with Ms. Regina Johnson’s HIV
regimen?
Narrator: After Dr. Everheart talked with Christine, he closed the door and turned to face
Ms. Johnson.
Actor 1 (provider): Ok, well they shouldn’t interact with any of your HIV meds, just
make sure to take them with food. If after a week you’re still having problems we can do
some more extensive tests to see what else might be going on. Sound okay to you?
Actor 2 (patient): Sounds good.
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.
Narrator: Dr. Everheart left the exam room and returned in 15 minutes with the
medication samples.
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before
you leave, I need to ask you a series of questions about your current sexual practices and
also any previous or current alcohol or drug use.
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Non-Stigma Vignette Male
1. Segment 1:
Narrator: Dr. Everheart knocked on the door before entering into the room. He
approached Mr. Johnson and shook his hand while introducing himself.
Actor 1 (provider): Hello Mr. Johnson my name is Dr. Actor 1 (provider) Everheart and
I’ll be your primary physician here at the clinic. I understand that you are new to the area.
I hope you are enjoying our lovely city. How are you doing?
Narrator: Dr. Everheart takes a seat in a chair near the exam table where Mr. Johnson is
sitting and begins reviewing his chart.
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to
start all over at a new clinic with new doctors.
Actor 1 (provider): Well that’s understandable, we’ll try to make the process as easy as
possible for you. Basically all we are going to be doing today is going over your medical
history, completing a physical exam, and discussing any questions or concerns that you
or I might have about your health. I like to be thorough with all my new patients, and
double check some of the information in their files just to be sure it’s up to date and
correct. Your last treatment center sent us your file yesterday, I just have few pieces of
information that I would like to confirm with you.
Actor 2 (patient): ok
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago
in February of 2006.
Actor 2 (patient): Yeah, that’s the story.
Actor 1 (provider): It says that you most likely became infected from sexual activity with
men, and more specifically your partner at the time.
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months
together we weren’t as strict about using condoms all the time. One day he found out one
of his past hook-ups was positive and we both went in and got tested. Both of us found
out that we were positive. We’re still together though and he moved here with me.
Actor 1 (provider): It seems like you have really been there for each other. You know, it’s
so common for people to not know that they are positive. It seems like both of you got
blind-sided in that situation. It’s really good that you both decided to come in and get
tested when you did.
Actor 2 (patient): Thanks.
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2. Segment 2:
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty
soon after you received your diagnosis.
Actor 2 (patient): Yeah it was within a few months.
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty
stable ever since you started taking meds, except for the summer of last year when your
viral load became detectable again and your CD4 count dropped by 30%. Do you
remember what was going on around that time that caused these changes?
Actor 2 (patient): Yeah, my last doctors tried to switch my meds because they were
making me nauseas and tired throughout the day. The new combination didn’t work, so
they put me back on the old meds after a few months. I was actually upset about it
because physically I felt really great on the new meds. I mean is it really that big of deal
if my numbers change a little?
Actor 1 (provider): You know it can often be a fairly complicated process to find the right
combination of meds for patients. We try to balance out the experience of side effects
with the effectiveness of the medications, and every patient responds a bit differently.
Unfortunately, it is a big deal if your viral load and CD4 count change. Those are our best
indicators of how the HIV virus is progressing in your body, and they can even be better
indicators then how your body is physically feeling. I actually have a great brochure
about some of the important information about viral load and CD4 counts. Would you
like me to go over some of it with you?
Actor 2 (patient): That would actually be really helpful.
Narrator: Dr. Everheart stood up from his chair and grabbed a brochure. After walking
over to the exam table, Dr. Everheart pointed out the key points of the brochure to Mr.
Johnson and answered any remaining questions that he had.
Actor 2 (patient): Ok, so I get now why they took me off the new meds, but is there
anything that you can do to help with the side effects. I can’t be feeling sick all day at my
new job. I don’t want to make that type of impression.
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that
haven’t been tried by your last doctors. And after I get some more detailed results from
your blood draw today, I will look into the possibility of other medication regimens that
might be as effective as your current meds but with less side effects. I don’t know if the
new HIV medications on market will turn out to be a good fit for you, but we can
definitely look into the possibility.

223
Actor 2 (patient): Ok, fair enough.
3. Segment 3:
Narrator: Dr. Everheart handed the brochure to Mr. Johnson and explained that he would
now be performing a physical examination.
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination
to check your heart rate, blood pressure, breathing, and also check out your throat, ears,
and eyes for normal functioning.
Narrator: Dr. Everheart approached Mr. Johnson, placing the stethoscope in his ears. He
stood close to Mr. Johnson, placed the stethoscope on his chest, and listened to his
breathing for approximately 10 seconds. He then placed the stethoscope on his back and
listened for another 10 seconds. Dr. Everheart removed the stethoscope from his ears,
reached for the blood pressure cuff, and placed it on Mr. Johnson’s arm. After taking Mr.
Johnson’s blood pressure, Dr. Everheart, stood up and walked to the supply cabinet in the
exam room. Dr. Everheart returned with a tongue depressor and asked Mr. Johnson to
open his mouth. Dr. Everheart leaned towards Mr. Johnson and examined the inside of
his throat thoroughly. Dr. Everheart then felt his lymph nodes on the side of his neck for
a few moments before returning to his seat near the exam table.
4. Segment 4:
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate.
And no signs of temperature or cold symptoms. How have you been feeling recently?
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any
changes in medication, diet, activity level?
Actor 2 (patient): Not really.
Actor 1 (provider): Have you been experiencing a lot of stress lately? Everything been
going ok with friends/family?
Actor 2 (patient): You know I have been stressed out a lot due to the move, but I really
don’t think it’s just that. They’re pretty bad. I get shooting pains right behind my eyes,
and it’s happening at least twice a week.
Actor 1 (provider): Ok, well I have some ideas for what might be causing these types
headaches. Those pain symptoms are pretty common for a lot of people especially those
with a family history of migraines. I’ll check to see if we have some medication samples
to for you take home and see if they help. They shouldn’t interact with any of your HIV
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meds, just make sure to take them with food. If after a week you’re still having problems
we can do some more extensive tests to see what’s going on. Sound okay to you?
Actor 2 (patient): Sounds good.
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.
Narrator: Dr. Everheart left the exam room and returned in several minutes with the
medication samples.
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before
you leave, I’d like to chat with you a little about your current sexual practices and also
any previous or current alcohol or drug use. I know these types of topics are sensitive in
nature and can seem a little out of the blue for a regular medical appointment. Basically
new national standards of medical practice have been created, calling for health care
providers to assess these types of things at all medical care visits to improve prevention
of new infections and also to allow for the best care possible for current HIV+ patients.
It’s important to me that you feel comfortable, so is it okay for me to ask you a few
questions?
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Stigma Vignette Male
1. Segment 1:
Narrator: Dr. Everheart knocked on the door before entering into the room. He walked
through door looking at Mr. Johnson’s file and did not look up while introducing himself.
Actor 1 (provider): Hello Mr. Johnson my name is Dr. Everheart and I’ll be your primary
physician here at the clinic. How are you doing?
Narrator: Dr. Everheart takes a seat in a chair on the far side of the room from where Mr.
Johnson is sitting and begins reviewing his chart.
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to
start all over at a new clinic with new doctors.
Narrator: Dr. Everheart continues to look down at Mr. Johnson’s chart as he speaks.
Actor 1 (provider): Well, nothing to worry about. Basically all we are going to be doing
today is going over your medical history and completing a physical exam. I like to be
thorough with all my new patients, and double check some of the information in their
files. Your last treatment center sent us your file yesterday, I just have few pieces of
information that I would like to confirm with you.
Actor 2 (patient): ok
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago
in February of 2006.
Actor 2 (patient): Yeah, that’s the story.
Actor 1 (provider): It says that you most likely became infected from having sex with
other men. Hopefully becoming positive has motivated you to be more careful with
reducing your number of sexual partners and using condoms. Oh wait, I see here that you
were infected by your partner at the time.
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months
together we weren’t as strict about using condoms all the time. One day he found out one
of his past hook-ups was positive and we both went in and got tested. Both of us found
out that we were positive. We’re still together though and he moved here with me.
Actor 1 (provider): That’s surprising. You really don’t see that nowadays. But, I guess
you learned your lesson, and at least you both decided to come in and get tested when
you did.
Actor 2 (patient): Thanks.
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2. Segment 2:
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty
soon after you received your diagnosis.
Actor 2 (patient): Yeah it was within a few months.
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty
stable ever since you started taking meds. That is except for the summer of last year when
your viral load became detectable again and your CD4 count dropped by 30%. Did you
stop taking your meds?
Actor 2 (patient): No, actually my last doctors tried to switch my meds because they were
making me nauseas and tired throughout the day. The new combination didn’t work, so
they put me back on the old meds after a few months. I was actually upset about it
because physically I felt really great on the new meds. I mean is it really that big of deal
if my numbers change a little?
Actor 1 (provider): Unfortunately, Mr. Johnson it is a big deal if your viral load and CD4
count change. Those are our best indicators of how the HIV virus is progressing in your
body. You’ve been positive a while, I assumed you knew all this. I think I have a
brochure that can explain viral load and CD4 counts to you. Let me grab it.
Narrator: Dr. Everheart rose from his chair and grabbed a brochure. Without approaching
the exam table, he leaned over to hand the brochure to Mr. Johnson.
Actor 1 (provider): I strongly suggest you review this material.
Actor 2 (patient): I’ll check this out later, but is there anything that you can do to help
with the side effects. I can’t be feeling sick all day at my new job. I don’t want to make
that type of impression.
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that
haven’t been tried by your last doctors.
Actor 2 (patient): What about changing my HIV meds? Can we try something new? I’ve
been reading a lot about a one-a-day pill. Could we try that?
Actor 1 (provider): I really don’t think that’s necessary at this point. Your current meds
are working great, other than a few side effects. But if it’s that important to you, after I
get some more detailed results from your blood draw today, I will look into the
possibility of other medication regimens.
Actor 2 (patient): Ok.
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3. Segment 3:
Narrator: Dr. Everheart explained that he would now be performing a physical
examination.
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination
to check your heart rate, blood pressure, breathing, and also check out your throat, ears,
and eyes for normal functioning.
Narrator: Dr. Everheart walked to the supply cabinet and grabbed two pairs of latex
gloves. He put them on his hands and approached Mr. Johnson, placing the stethoscope in
his ears. He maintained an arm’s length distance from Mr. Johnson, having to stretch his
arm to place the stethoscope on his chest. Leaning away from Mr. Johnson, he listened to
his breathing for a few seconds, and then placed the stethoscope on his back and listened
for another couple seconds. Dr. Everheart removed the stethoscope from his ears, reached
for the blood pressure cuff, and asked Mr. Johnson’s to place it on his own arm. After
taking Mr. Johnson’s blood pressure, Dr. Everheart, stood up and again walked to the
supply cabinet in the exam room. Dr. Everheart returned with a tongue depressor and
asked Mr. Johnson to open his mouth. Dr. Everheart again maintained an arm’s length
distance from Mr. Johnson and had a strained look on his face while examining the inside
of his throat. Dr. Everheart then felt his lymph nodes on the side of his neck for a few
moments before returning to his seat on the far side of the exam room.
4. Segment 4:
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate.
And no signs of temperature or cold symptoms. How have you been feeling recently?
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any
changes in medication, diet, activity level?
Actor 2 (patient): Not really.
Actor 1 (provider): Then it’s probably just HIV-related.
Actor 2 (patient): Well maybe. But they’re pretty bad. I get shooting pains right behind
my eyes, and it’s happening at least twice a week.
Actor 1 (provider): Ok, well it sounds like you might be experiencing migraines. I think
we have some med samples here in the clinic that you could try out, but I’m not really
sure if migraine medications with interact negatively with your HIV medications. Let me
check with your nurse practitioner.
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Narrator: Dr. Everheart walked to the door and opened it far enough to stick his head out
into the hall. In a moderately loud voice, he called for Mr. Johnson’s nurse practitioner.
Actor 1 (provider): Christine, will Imitrex interact with Mr. Robert Johnson’s HIV
regimen?
Narrator: After Dr. Everheart talked with Christine, he closed the door and turned to face
Mr. Johnson.
Actor 1 (provider): Ok, well they shouldn’t interact with any of your HIV meds, just
make sure to take them with food. If after a week you’re still having problems we can do
some more extensive tests to see what else might be going on. Sound okay to you?
Actor 2 (patient): Sounds good.
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.
Narrator: Dr. Everheart left the exam room and returned in 15 minutes with the
medication samples.
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before
you leave, I need to ask you a series of questions about your current sexual practices and
also any previous or current alcohol or drug use.

229
Appendix N
Draft of Experimental Phase Protocol
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EXPERIMENTAL PROCEDURES
I. INFORMED CONSENT
A. OVERVIEW OF CONSENT INFORMATION
A participant who gives their informed consent to participate in the study should
fully understand the nature of the research study, the purpose and pertinent procedures for
the study, potential risks and benefits of participating, confidentiality and steps taken by
research team to ensure confidentiality, and how the data will be used and stored.
B. PARTICIPANT CONSENT
After a brief introduction, the principle investigator (PI) leads the participant
through the informed consent form, highlighting the most important aspects of informed
consent. The following outline illustrates the content that is verbally expressed by the PI
during this process:
WHO: The project directors for this study are Jessie Heath, M.S., a clinical
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an
associate professor of psychology at Syracuse University and an adjunct assistant
professor of medicine at SUNY Upstate Medical University.
PURPOSE & PROCEDURE: You are being asked to participate in a research
study designed to learn more about how aspects of patient-provider relationships
can affect the medical treatment of persons living with HIV. Our goal is to gain a
better understanding of how the behaviors of medical care providers within
medical appointments can affect the HIV+ patients they treat. We will use the
information obtained in this study to inform the development of strategies to
improve patient-provider relationships and the quality of medical care received
HIV+ patients.
TIME & COMPENSATION: Your participation involves viewing a vignette of
a hypothetical medical care visit and responding to questions using an interactive
computer program. The study takes approximately one hour, and you will receive
$20 for you time.
RISKS/BENEFITS:
o Risks: There are three risks associated with this study. First, you may feel
uncomfortable answering personal questions. If this occurs, you may
choose not to answer any question. Second, you may find some aspects of
the vignette mildly upsetting. A third risk involves the risk of disclosing
private information to our research team. However, all information that
you share with members of our team is considered strictly confidential,
and we are obligated to protect your privacy.
o Benefits: You may learn more about your feelings and become aware of
how aspects of medical treatment experiences can affect you. In addition,
because the information you provide assists in the development of
strategies to improve patient-provider relationships, your participation
could benefit others living with HIV.
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CONFIDENTIALITY and HIPPA
o If you decide to participate, any information that you give us is strictly
confidential. We will keep your information private, except under 2
circumstances.
 First, if you tell us that you’re planning to hurt yourself or
someone else we would have to disclose that information.
 Second, if officials were concerned that the research team was
acting inappropriately, the research records might be audited to
make sure the research was being conducted ethically; however,
the auditors would be required to protect your privacy.
PROTECTION OF CONFIDENTIALITY
o All project staff receive extensive training and supervision on
confidentiality procedures.
o Your survey is given an identification number and only authorized
research staff has access to the key that connects your information to your
name. Your identity will not be included on the audiotapes and the tapes
will be erased once we are finished with the project.
o Certificate of Confidentiality from the Department of Health and Human
services, which states that the investigators cannot be forced to release
your information (for example, by subpoena) to any federal, state, or local,
civil, criminal, administrative, legislative, or other proceedings. This
Certificate does NOT prevent you or your family from voluntarily
disclosing information about yourself or your involvement in this research.
PARTICIPATION IS VOLUNTARY: You may refuse to participate or
discontinue your participation at any time without penalty or loss of benefits.
PERMISSION TO BE RECONTACTED: The participants are then asked to
sign and date one copy of the consent form and keep a second copy for their own
records. Participants are also given a copy of University Hospital’s Privacy
Practices Policy and asked to keep it for their records.
C. STORAGE OF CONSENT FORMS
After pertinent information from the completed consent forms has been entered
into the Excel patient database, the completed focus group consent forms will be stored in
a locked filing cabinet in the UPH office.
II. EXPERIMENTAL PROTOCOL ADMINISTRATION
A. ASSIGNMENT OF PARTICIPANT NUMBER AND CONDITION
After participants consent, they will be assigned a participant ID number and
randomized to a “high stigma,” “moderate stigma,” or “no stigma” study condition using
a random number generator.
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B. VIGNETTE AND SURVEY ADMINISTRATION
The quantitative survey is administered following the informed consent. The
participants will be seated in front of a computer, where the PI will introduce the
computerized study protocol and briefly describe how the computer program works. The
PI will answer any questions the participant has and ensure the participant’s ability to
successfully interact with the computer program. For participants with limited computer
exposure, the principle investigator will provide additional instruction on the use of the
mouse and keyboard as necessary. Participants will also be instructed that if they have
any difficulties with the computer program to ring a bell on the desk and the principle
investigator will assist them. Participants will then follow the audio instructions on the
ACASI program to complete the small battery of self-report assessments and respond to
the visual and audio treatment vignettes. The ordering of the protocol will be as follows:
(1) reporting of background and health information, (2) step-by-step presentation of
treatment vignette with ratings of comfort assessed at several points throughout the
presented patient-provider interaction, (3) ratings on the Perceptions of Stigmatization
within the Patient-Provider Interaction scale, (4) ratings on measures assessing intentions
to engage in care, and (5) ratings on the Experiences of HIV-related Stigmatization in
Healthcare Settings measure.
C. DATA ENTRY AND STORAGE
Data from the ACASI program will be automatically stored upon completion of
the protocol and then transformed into an SPSS format for analyses. There will be no
hard copies of data in the experimental phase of the study and no identifying information
will present in the ACASI or SPSS files.
D. PARTICIPANT REIMBURSEMENT
The PI will retrieve reimbursement funds from Sean Kelley prior to the start of
the focus group. Participants will be reimbursed $20 for their one hour of participation in
the focus groups. After participants have received their reimbursement, the PI will
complete a reimbursement receipt including only the participant’s ID number and file it
in the UPH filing cabinet under non-reconciled payment receipts. The original
reimbursement form will then be turned in to Sean Kelley. A photocopy will be stored in
the UPH filing cabinet under reconciled payment receipts.
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Appendix O
Draft of Experimental Phase Informed Consent Form
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SUNY UPSTATE MEDICAL UNIVERSITY AND
SYRACUSE UNIVERSITY
Consent/Authorization Form
Title of Study: Treatment Experiences of HIV+ Patients Study
Background/Purpose:
You are invited to participate in a research study designed to learn more about how
aspects of patient-provider relationships can affect the medical treatment of persons
living with HIV. Our goal is to gain a better understanding of how the behaviors of
medical care providers within medical appointments can affect the HIV+ patients they
treat. We will use the information obtained in this study to inform the development of
strategies to improve patient-provider relationships and the quality of medical care
provided to persons living with HIV. The directors of this study are Jessie Heath, M.S., a
clinical psychology doctoral student and Dr. Peter Vanable, an Associate Professor of
Psychology at Syracuse University and an Adjunct Assistant Professor of Medicine at
SUNY Upstate Medical University. Other trained research staff will also be involved,
and will be supervised by Drs. Peter Vanable of Syracuse University. We are asking
approximately 150 patients to participate in the study.
You will be given enough time to read and understand the information provided in this
consent and authorization form. Please ask the study staff to explain any words or
information that you do not understand. You may keep an unsigned copy of this consent
and authorization form to think about your decision or discuss with your family, friends,
or doctors before making your decision to take part in this research study.
Study Procedures:
If you decide to take part in this study, you will listen and respond to information that is
presented individually to you on a computer. You will be randomly assigned to view one
of two vignettes representing a typical, first-time medical care visit of an HIV+ patient.
On the computer, you will hear audio descriptions of the medical visit, conversations
between the hypothetical patient and provider, and also view pictures of the interaction.
Throughout, and following the presentation of the vignette, you will answer questions
presented on the computer screen regarding your feelings and opinions about what you
are viewing. You will then respond to questions related to health, sexual behavior, and
substance use. The study takes approximately one hour to complete, and your
participation is completely voluntary.
If you agree to participate in the study, you will also be asked to complete a brief survey
with questions about your background and health information, including medical
appointment attendance, hospitalizations, and recent indicators of health status (CD4
count, viral load).
Risks:
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There are three risks associated with this study. First, you may feel uncomfortable
answering personal questions. If this occurs, you may choose not to answer any question.
Second, you may find some aspects of the vignette mildly upsetting. A third risk involves
the risk of disclosing private information to our research team. However, all information
that you share with members of our team is considered strictly confidential, and we are
obligated to protect your privacy.
Benefits:
The potential benefits are that you may learn more about your feelings and become aware
of how aspects of medical treatment experiences can affect you. In addition, because the
information you provide assists in the development of strategies to improve patientprovider relationships, your participation could benefit others living with HIV.
Voluntary Participation:
Your participation in this study is entirely voluntary and you may refuse to participate or
stop participation at any time without penalty or loss of benefits to which you would
normally be entitled. Your decision about whether or not to participate in the study will
not affect the care you receive at SUNY Upstate Medical University.
Alternatives:
If you decide not to participate in this research study, you will continue to receive your
usual care and will not complete the surveys for research purposes.
Costs/Payments:
There are no costs to you and/or your insurance carrier for participating in this study.
After completing the study, you will receive $20 to offset your expenses and to thank you
for your time.
If you choose to stop participating in the study before all study requirements are
completed, you will be paid $10 for each ½ hour of time you devote to the study.
In addition, by accepting payment for participating in this study, certain identifying
information about you may be made available to professional auditors to satisfy audit and
Federal reporting requirements, but confidentiality will be preserved. Please note that if
you earn $600 or over in a calendar year as a research subject, you may have to pay taxes
on these earnings.
Questions:
If you have any questions about the research, please contact Ms. Jessie Heath at (315)
443-1052 or Dr. Peter Vanable at (315) 443-2024. If you have any questions about your
rights as a research subject, please contact the SUNY Upstate Medical University
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Institutional Review Board Office at (315) 464-4317 or the Syracuse University
Institutional Review Board Office at (315) 443-3013.
Confidentiality of Records and Authorization to Use/Share Protected Health
Information for Research:
If you agree to participate in this research, identifiable health information about you
will be used and shared with others involved in this research. For you to be in this
research we need your permission to collect and share this information. Federal law
protects your right to privacy concerning this information.
When you sign this consent form at the end, it means that you have read this section and
authorize the use and/or sharing of your protected health information as explained below.
Your signature also means you have received a copy of Upstate’s Notice of Privacy
Practices.
Individually identifiable health information under the federal privacy law is considered to
be any information from your medical record, or obtained from this study, that can be
associated with you, and relates to your past, present, or future physical or mental health
or condition. This is referred to as protected health information.
Your protected health information will be kept confidential. Research staff will not share
the information you provide during the discussion group and on the survey with your
doctor or nurse here in the clinic. Further, you will not be identified in any publication or
presentation resulting from this study. Several steps have been taken to protect the
confidentiality of your responses and involvement in this research. Project staff has
participated in extensive training and supervision regarding the importance of
maintaining participant confidentiality. In addition, an identification number will be
assigned to your survey, and only the directors of this research (Jessie Heath, M.S. and
Dr. Vanable) will have access to the key that indicates which number belongs to which
participant. The master list linking the participant ID number to the participant’s
identifying information will be maintained in a separate, secure computer database, and
will be destroyed at the conclusion of the study. Your name or other identifying
information will not be kept with your survey, and your survey information will be stored
in a secure computer database.
To help us further protect your privacy, the investigators have received a Confidentiality
Certificate from the Department of Health and Human Services. With this Certificate,
the investigators cannot be forced (for example by court subpoena) to disclose research
information that may identify you in any Federal, State, or local, civil, criminal,
administrative, legislative, or other proceedings. The researchers will use the Certificate
to resist any demands for information that would identify you, except as explained below.
The Certificate cannot be used to resist a request for information from personnel of the
United States Department of Health and Human Services that is used for auditing or
evaluation of federally funded projects.
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In addition, the Confidentiality Certificate does not prevent you or a member of your
family from voluntarily releasing information about yourself or your involvement in this
research. Note however, that if an insurer or employer learns about your participation,
and obtains your consent to receive research information, then the investigator may not
use the Certificate of Confidentiality to withhold this information. This means that you
and your family must also actively protect your own privacy.
Why is it necessary to use/share your protected health information with
others? The main reason to use and share your health information is to conduct the
research as described in this consent form. Your information may also be shared
with people and organizations that make sure the research is being done correctly,
and to report unexpected or bad side effects you may have. In addition, we will
release protected health information about you if we learn about your intent to harm
yourself or others.
What protected health information about you will be used or shared with others as
part of this research? We may use and share the results of tests, questionnaires, and
interviews. We will only collect information that is needed for the research.
Who will be authorized to use and/or share your protected health
information? The researchers, their staff and the staff of Upstate Medical University
participating in the research will use your protected health information for this
research study. In addition, the Upstate Medical University and Syracuse University
Institutional Review Boards (IRB), committees responsible for protecting the rights
of research subjects, and other Upstate Medical University, Syracuse University, or
University Hospital staff who supervise the way the research is done, may have
access to your protected health information.
The researchers and their staff will determine if your protected health information
will be used or shared with others outside of Upstate Medical University and
Syracuse University for purposes directly related to the conduct of the research.
With whom would the protected health information be shared? Your protected
health information may be shared with:
Federal agencies that supervise the way the research is conducted, such as the
Department of Health and Human Services’ Office for Human Research
Protections or the National Institutes of Health.
Researchers from Syracuse University assisting in the study.
The Syracuse University Institutional Review Board (a committee responsible for
protecting the rights of research subjects).
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All reasonable efforts will be used to protect the confidentiality of your protected
health information. However, not all individuals or groups have to comply with the
Federal privacy law. Therefore, once your protected health information is disclosed
(leaves Upstate Medical University), the Federal privacy law may not protect it.
For how long will your protected health information be used or shared with
others? There is no scheduled date at which this information will be destroyed or no
longer used. This is because information that is collected for research purposes continues
to be used and analyzed for many years and it is not possible to determine when this will
be complete.
Can you withdraw your authorization to collect/use/share your protected
health information? You always have the right to withdraw your permission
(revoke authorization) for us to use and share your health information, by putting
your request in writing to the investigator in charge of the study. This means that
no further private health information will be collected. Once authorization is
revoked, you may no longer participate in this research activity, but standard medical
care and any other benefits to which you are entitled will not be affected. Revoking
your authorization only affects uses and sharing of information obtained after your
written request has been received, but not information obtained prior to that time.
Even after you withdraw your permission, Upstate Medical University may continue
to use and share information needed for the integrity of the study; for example,
information about an unexpected or bad side effect you experienced related to the
study.
Can you have access to your health information? At the end of the study, you have
the right to see and copy health information about you in accordance with the SUNY
Upstate Medical University policies; however, your access may be limited while the
study is in progress.
Permission To Contact For Follow-Up Research
We may conduct additional research on this important topic. May we contact you about
participation in future studies? Indicating you are willing to be contacted does not
obligate you to participate in any other study, nor does it affect your participation in this
study.
 No, I prefer not to be contacted about future studies.
 Yes, I am willing to be contacted about future studies.
Phone: _______________
Mailing Address: _______________________________________
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Consent To Participate In Research & Authorization To Use And Share Personal
Health Information:
I hereby give my consent to participate in this research study and agree that my personal
health information can be collected, used and shared by the researchers and staff for the
research study described in this form. I will receive a signed copy of this consent form.

______________________________________
Signature of subject

__________________
Date

_____________________________________________
Printed Name of Research Participant

___________________________________________
Signature of Person Obtaining Consent/Authorization

___________________________________________
Printed Name of Person Obtaining Consent/Authorization

__________________
Date
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